<SEC-DOCUMENT>0001493152-22-004649.txt : 20220215
<SEC-HEADER>0001493152-22-004649.hdr.sgml : 20220215
<ACCEPTANCE-DATETIME>20220215110723
ACCESSION NUMBER:		0001493152-22-004649
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		17
CONFORMED PERIOD OF REPORT:	20220211
ITEM INFORMATION:		Entry into a Material Definitive Agreement
ITEM INFORMATION:		Other Events
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20220215
DATE AS OF CHANGE:		20220215

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Enveric Biosciences, Inc.
		CENTRAL INDEX KEY:			0000890821
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				954484725
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-38286
		FILM NUMBER:		22637489

	BUSINESS ADDRESS:	
		STREET 1:		4851 TAMIAMI TRAIL N, SUITE 200
		CITY:			NAPLES
		STATE:			FL
		ZIP:			34103
		BUSINESS PHONE:		239-302-1707

	MAIL ADDRESS:	
		STREET 1:		4851 TAMIAMI TRAIL N, SUITE 200
		CITY:			NAPLES
		STATE:			FL
		ZIP:			34103

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	AMERI Holdings, Inc.
		DATE OF NAME CHANGE:	20150527

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	SPATIALIZER AUDIO LABORATORIES INC
		DATE OF NAME CHANGE:	19950323
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>form8-k.htm
<TEXT>
<XBRL>
<?xml version="1.0" encoding="utf-8"?>
<html xmlns="http://www.w3.org/1999/xhtml" xmlns:xs="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:dei="http://xbrl.sec.gov/dei/2021q4" xmlns:ref="http://www.xbrl.org/2006/ref" xmlns:us-gaap="http://fasb.org/us-gaap/2021-01-31" xmlns:us-roles="http://fasb.org/us-roles/2021-01-31" xmlns:country="http://xbrl.sec.gov/country/2021" xmlns:srt="http://fasb.org/srt/2021-01-31" xmlns:ENVB="http://enveric.com/20220211">
<head>
     <title></title>
<meta http-equiv="Content-Type" content="text/html" />
</head>
<!-- Field: Set; Name: xdx; ID: xdx_02A_US%2DGAAP%2D2021 -->
<!-- Field: Set; Name: xdx; ID: xdx_03E_ENVB_enveric.com_20220211 -->
<!-- Field: Set; Name: xdx; ID: xdx_047_20220211_20220211 -->
<!-- Field: Set; Name: xdx; ID: xdx_05D_edei%2D%2DEntityCentralIndexKey_0000890821 -->
<!-- Field: Set; Name: xdx; ID: xdx_059_edei%2D%2DAmendmentFlag_false -->
<!-- Field: Set; Name: xdx; ID: xdx_06B_USD_1_iso4217%2D%2DUSD -->
<!-- Field: Set; Name: xdx; ID: xdx_062_Shares_2_xbrli%2D%2Dshares -->
<!-- Field: Set; Name: xdx; ID: xdx_06D_USDPShares_3_iso4217%2D%2DUSD_xbrli%2D%2Dshares -->
<body style="font: 10pt Times New Roman, Times, Serif">
<div style="display: none">
<ix:header>
 <ix:hidden>
  <ix:nonNumeric contextRef="From2022-02-11to2022-02-11" name="dei:EntityCentralIndexKey">0000890821</ix:nonNumeric>
  <ix:nonNumeric contextRef="From2022-02-11to2022-02-11" format="ixt:booleanfalse" name="dei:AmendmentFlag">false</ix:nonNumeric>
  </ix:hidden>
 <ix:references>
  <link:schemaRef xlink:href="envb-20220211.xsd" xlink:type="simple" />
  </ix:references>
 <ix:resources>
    <xbrli:context id="From2022-02-11to2022-02-11">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000890821</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-02-11</xbrli:startDate>
        <xbrli:endDate>2022-02-11</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:unit id="USD">
      <xbrli:measure>iso4217:USD</xbrli:measure>
    </xbrli:unit>
    <xbrli:unit id="Shares">
      <xbrli:measure>xbrli:shares</xbrli:measure>
    </xbrli:unit>
    <xbrli:unit id="USDPShares">
      <xbrli:divide>
        <xbrli:unitNumerator>
          <xbrli:measure>iso4217:USD</xbrli:measure>
        </xbrli:unitNumerator>
        <xbrli:unitDenominator>
          <xbrli:measure>xbrli:shares</xbrli:measure>
        </xbrli:unitDenominator>
      </xbrli:divide>
    </xbrli:unit>
  </ix:resources>
 </ix:header>
</div>


<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<!-- Field: Rule-Page --><div style="width: 100%"><div style="border-top: Black 4pt solid; border-bottom: Black 1.5pt solid; font-size: 1pt">&#160;</div></div><!-- Field: /Rule-Page -->

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 18pt"><b>UNITED
STATES</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 18pt"><b>SECURITIES
AND EXCHANGE COMMISSION</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 12pt"><b>Washington,
D.C. 20549</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 18pt"><b>FORM
<span id="xdx_907_edei--DocumentType_c20220211__20220211_zux766SYAgUh"><ix:nonNumeric contextRef="From2022-02-11to2022-02-11" name="dei:DocumentType">8-K</ix:nonNumeric></span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Current
Report</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Pursuant
to Section 13 or 15(d) of the</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Securities
Exchange Act of 1934</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Date
of Report (Date of earliest event reported): <span id="xdx_90C_edei--DocumentPeriodEndDate_c20220211__20220211_zVB70qd1LiYj"><ix:nonNumeric contextRef="From2022-02-11to2022-02-11" format="ixt:datemonthdayyearen" name="dei:DocumentPeriodEndDate">February 11, 2022</ix:nonNumeric></span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 18pt"><b><span id="xdx_90F_edei--EntityRegistrantName_c20220211__20220211_z9RmpoIu8fN1"><ix:nonNumeric contextRef="From2022-02-11to2022-02-11" name="dei:EntityRegistrantName">Enveric
Biosciences, Inc.</ix:nonNumeric></span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(Exact
name of Registrant as specified in its charter)</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 32%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_904_edei--EntityIncorporationStateCountryCode_c20220211__20220211_zt1BHGxvbPcl"><ix:nonNumeric contextRef="From2022-02-11to2022-02-11" format="ixt-sec:stateprovnameen" name="dei:EntityIncorporationStateCountryCode">Delaware</ix:nonNumeric></span></b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 2%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 32%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_903_edei--EntityFileNumber_c20220211__20220211_zNfRfIClzV2k"><ix:nonNumeric contextRef="From2022-02-11to2022-02-11" name="dei:EntityFileNumber">001-38286</ix:nonNumeric></span></b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 2%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 32%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_908_edei--EntityTaxIdentificationNumber_c20220211__20220211_zf6FAlCOxdS5"><ix:nonNumeric contextRef="From2022-02-11to2022-02-11" name="dei:EntityTaxIdentificationNumber">95-4484725</ix:nonNumeric></span></b></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(State
    or other jurisdiction</b></span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>of
    incorporation)</b></span></p></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(Commission</b></span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>File
    No.)</b></span></p></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(IRS
    Employer</b></span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Identification
    No.)</b></span></p></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Enveric
Biosciences, <span>Inc.</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span><span id="xdx_907_edei--EntityAddressAddressLine1_c20220211__20220211_ztbAq4pPlong"><ix:nonNumeric contextRef="From2022-02-11to2022-02-11" name="dei:EntityAddressAddressLine1">4851
Tamiami Trail N</ix:nonNumeric></span></span>, <span id="xdx_90C_edei--EntityAddressAddressLine2_c20220211__20220211_zGbOzpQeilcf"><ix:nonNumeric contextRef="From2022-02-11to2022-02-11" name="dei:EntityAddressAddressLine2">Suite 200</ix:nonNumeric></span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_90E_edei--EntityAddressCityOrTown_c20220211__20220211_zelKWYUko9Wj"><ix:nonNumeric contextRef="From2022-02-11to2022-02-11" name="dei:EntityAddressCityOrTown">Naples</ix:nonNumeric></span>,
<span id="xdx_90B_edei--EntityAddressStateOrProvince_c20220211__20220211_zMmCgww1uYRd"><ix:nonNumeric contextRef="From2022-02-11to2022-02-11" name="dei:EntityAddressStateOrProvince">FL</ix:nonNumeric></span> <span id="xdx_903_edei--EntityAddressPostalZipCode_c20220211__20220211_zlJlSEaEIPde"><ix:nonNumeric contextRef="From2022-02-11to2022-02-11" name="dei:EntityAddressPostalZipCode">34103</ix:nonNumeric></span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(Address
of principal executive offices and zip code)</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Registrant&#8217;s
telephone number, including area code: <span id="xdx_904_edei--CityAreaCode_c20220211__20220211_zf9Jpl2Fah62"><ix:nonNumeric contextRef="From2022-02-11to2022-02-11" name="dei:CityAreaCode">(239)</ix:nonNumeric></span> <span id="xdx_906_edei--LocalPhoneNumber_c20220211__20220211_zHTqwOFPbw9k"><ix:nonNumeric contextRef="From2022-02-11to2022-02-11" name="dei:LocalPhoneNumber">302-1707</ix:nonNumeric></span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>N/A</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(Former
name or former address, if changed since last report.)</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Check
the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under
any of the following provisions:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90B_edei--WrittenCommunications_c20220211__20220211_zS6DvI4y6gy9"><ix:nonNumeric contextRef="From2022-02-11to2022-02-11" format="ixt:booleanfalse" name="dei:WrittenCommunications">&#9744;</ix:nonNumeric></span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Written
    communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90D_edei--SolicitingMaterial_c20220211__20220211_zMznnFmGLdee"><ix:nonNumeric contextRef="From2022-02-11to2022-02-11" format="ixt:booleanfalse" name="dei:SolicitingMaterial">&#9744;</ix:nonNumeric></span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Soliciting
    material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_900_edei--PreCommencementTenderOffer_c20220211__20220211_zED93HMmhm3l"><ix:nonNumeric contextRef="From2022-02-11to2022-02-11" format="ixt:booleanfalse" name="dei:PreCommencementTenderOffer">&#9744;</ix:nonNumeric></span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pre-commencement
    communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_902_edei--PreCommencementIssuerTenderOffer_c20220211__20220211_zcG4j7Ka5HD9"><ix:nonNumeric contextRef="From2022-02-11to2022-02-11" format="ixt:booleanfalse" name="dei:PreCommencementIssuerTenderOffer">&#9744;</ix:nonNumeric></span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pre-commencement
    communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; width: 38%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title
    of each class</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 2%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; width: 18%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Trading
    Symbol(s)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 2%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 40%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name
    of each exchange on which registered</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_905_edei--Security12bTitle_c20220211__20220211_za0O6MIxAvWi"><ix:nonNumeric contextRef="From2022-02-11to2022-02-11" name="dei:Security12bTitle">Common
    stock, par value $0.01 per share</ix:nonNumeric></span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_904_edei--TradingSymbol_c20220211__20220211_zBCxh8kpfHB7"><ix:nonNumeric contextRef="From2022-02-11to2022-02-11" name="dei:TradingSymbol">ENVB</ix:nonNumeric></span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_905_edei--SecurityExchangeName_c20220211__20220211_zByXfUIVEb3d"><ix:nonNumeric contextRef="From2022-02-11to2022-02-11" format="ixt-sec:exchnameen" name="dei:SecurityExchangeName">The
    Nasdaq Stock Market</ix:nonNumeric></span></span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Indicate
by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (&#167;230.405
of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (&#167;240.12b-2 of this chapter).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Emerging
growth company <span id="xdx_90E_edei--EntityEmergingGrowthCompany_c20220211__20220211_zy4kCwuuN86i"><ix:nonNumeric contextRef="From2022-02-11to2022-02-11" format="ixt:booleanfalse" name="dei:EntityEmergingGrowthCompany">&#9744;</ix:nonNumeric></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying
with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. &#9744;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<!-- Field: Rule-Page --><div style="width: 100%"><div style="border-top: Black 1.5pt solid; border-bottom: Black 4pt solid; font-size: 1pt">&#160;</div></div><!-- Field: /Rule-Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.75in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Item
    1.01.</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Entry
    Into a Material Definitive Agreement</b>.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
February 11, 2022, Enveric Biosciences, Inc. (the &#8220;Company&#8221;) entered into an underwriting agreement (the &#8220;Underwriting
Agreement&#8221;) with A.G.P./Alliance Global Partners (the &#8220;Underwriter&#8221;). Pursuant to the Underwriting Agreement, the Company
agreed to sell, in a firm commitment offering, 20,000,000 shares of the Company&#8217;s common stock, $0.01 par value per share, and
accompanying warrants to purchase up to an aggregate of 20,000,000 shares of its common stock, as well as up to 3,000,000 additional
shares of common stock and/or warrants to purchase an aggregate of up to 3,000,000 shares of its common stock that may be purchased by
the Underwriter pursuant to a 45-day option granted to the Underwriter by the Company (the &#8220;Offering&#8221;). Each share of common
stock is being sold together with a common warrant to purchase one share of common stock, at an exercise price of $0.55 per share. Such
common warrants are immediately exercisable and will expire five years from the date of issuance. There is not expected to be any trading
market for the common warrants issued in the Offering. The combined public offering price of each share of common stock and accompanying
common warrant sold in the Offering was $0.50. On February 14, 2022, the Underwriter exercised its option to purchase warrants to purchase
up to 3,000,000 additional shares of the Company&#8217;s common stock.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
net proceeds from the Offering, after deducting underwriting discounts and commissions and other estimated offering expenses payable
by the Company and excluding the net proceeds, if any, from the exercise of the common warrants, are approximately $9.2 million (including
net proceeds received on account of the Underwriter&#8217;s purchase of additional warrants to purchase 3,000,000 shares of the Company&#8217;s
common stock ). The Company intends to use the net proceeds from the Offering for working capital and to fund other general corporate
purposes.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">All
securities offered and sold in the Offering (including the shares of common stock issuable from time to time upon exercise of the common
warrants) will be issued pursuant to the Company&#8217;s shelf registration statement on Form S-3 (Registration Statement No. 333-257690)
previously filed with the Securities and Exchange Commission (the &#8220;Commission&#8221;) and declared effective by the Commission
on July 9, 2021. A preliminary prospectus supplement and prospectus supplement and the accompanying prospectus relating to the Offering
have been filed with the Commission. The Offering, including the purchase of the additional warrants, is expected to close
on or about February 15, 2022, subject to satisfaction of customary closing conditions.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Underwriter acted as the sole book-running manager for the Offering. The Company paid the Underwriter an underwriting discount equal
to 6.5% of the gross proceeds of the Offering, and has agreed to reimburse the Underwriter for accountable expenses of up to $75,000,
including legal fees.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Underwriting Agreement contains customary representations and warranties, agreements and obligations, conditions to closing and termination
provisions. The Underwriting Agreement provides for indemnification by the Underwriter of the Company, its directors and certain of its
executive officers, and by the Company of the Underwriter, for certain liabilities, including liabilities arising under the Securities
Act of 1933, as amended, and affords certain rights of contribution with respect thereto. The legal opinion of Haynes and Boone, LLP
relating to the legality of the issuance and sale of the shares of common stock (including the shares of common stock issuable from time
to time upon exercise of the common warrants) is attached as Exhibit 5.1 to this Current Report on Form 8-K.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
description of terms and conditions of the Underwriting Agreement and the Form of Common Stock Purchase Warrant set forth herein do not
purport to be complete and are qualified in their entirety by the full text of the Underwriting Agreement and the Form of Common Stock
Purchase Warrant, which are attached hereto as Exhibits 1.1 and 4.1, respectively.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.75in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Item
    8.01.</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Other
    Events.</b></span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
February 10, 2022, the Company issued a press release announcing the proposed public offering of its securities. A copy of the press
release is attached as Exhibit 99.1 to this Current Report on Form 8-K and is hereby incorporated by reference herein.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
February 11, 2022, the Company issued a press release announcing the pricing of the public offering of its securities. A copy of the
press release is attached as Exhibit 99.2 to this Current Report on Form 8-K and is hereby incorporated by reference herein.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.75in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Item
    9.01.</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Financial
    Statements and Exhibits</b>.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(d)
Exhibits.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; width: 0.75in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Exhibit
    No.</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.1in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Description</b></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.1</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="ex1-1.htm">Underwriting Agreement, dated February 11, 2022, by and between Enveric Biosciences, Inc. and A.G.P./Alliance Global Partners</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.1</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="ex4-1.htm">Form of Common Stock Purchase Warrant</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.1</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="ex5-1.htm">Legal Opinion of Haynes and Boone, LLP</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">23.1</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="ex5-1.htm">Consent of Haynes and Boone, LLP (contained in Exhibit 5.1)</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">99.1</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="ex99-1.htm">Press Release, issued February 10, 2022 (furnished pursuant to Item 8.01)</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">99.2</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="ex99-2.htm">Press Release, issued February 11, 2022 (furnished pursuant to Item 8.01)</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">104</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Cover
    Page Interactive Data File (embedded within the Inline XBRL document)</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">*
* *</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&#160;</p>


<!-- Field: Page; Sequence: 3 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>SIGNATURES</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by
the undersigned hereunto duly authorized.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><b>ENVERIC
    BIOSCIENCES, INC.</b></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 5%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 45%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 3%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 47%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Date:</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">February
    15, 2022</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</span></td>
    <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>/s/
    Joseph Tucker</i></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Joseph
    Tucker</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief
    Executive Officer</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 4; Options: Last -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

</body>
</html>
<!-- Field: Set; Name: xdx; ID: xdx_08B_extensions -->
<!-- eJxFjd0KgkAQhZ/Adxj2WkwX7cLLpCKyCJHodskplnRHZre/R+otW5VoGBiGc75zhAjFmla6RYbToiqhxq5vlUOo8IKM5ozeUWy2Ofhb4VVbx8q48f2BBXkGPZNFiVReGK0PbbHJIZazJJ1JCfE8z1I47EQw6AWZi27QOK1aUKaBA1PPGp3i95RQqxcZ6t5j1RHZajI5JFE8yR+QcSJhTw/1JL5ZKMtCBOE4gVgz3fuh5m4ddbBssfNddkL/G3wBF4VJSQ== -->
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-1.1
<SEQUENCE>2
<FILENAME>ex1-1.htm
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Exhibit
1.1</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>UNDERWRITING
AGREEMENT</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>between</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><B>ENVERIC
BIOSCIENCES, INC.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>and</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>A</B>.<B>G</B>.<B>P</B>.<B>/ALLIANCE
GLOBAL PARTNERS,</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>as
Representative of the Several Underwriters</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>ENVERIC
BIOSCIENCES, INC.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>UNDERWRITING
AGREEMENT</U></FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">New
York, New York</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">February
11, 2022</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">A.G.P./Alliance
Global Partners</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
Representative of the several Underwriters named on Schedule 1 attached hereto</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">590
Madison Avenue, 28<SUP>th</SUP> Floor</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">New
York, New York 10022</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Ladies
and Gentlemen:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
undersigned, Enveric BioSciences, Inc., a Delaware corporation (the &ldquo;<B>Company</B>&rdquo;), hereby confirms its agreement (this
&ldquo;<B>Agreement</B>&rdquo;) with A.G.P./Alliance Global Partners (hereinafter referred to as &ldquo;<B>you</B>&rdquo; (including
its correlatives) or the &ldquo;<B>Representative</B>&rdquo;) and with the other underwriters named on <U>Schedule 1</U> hereto for which
the Representative is acting as representative (the Representative and such other underwriters being collectively called the &ldquo;<B>Underwriters</B>&rdquo;
or, individually, an &ldquo;<B>Underwriter</B>&rdquo;) as follows:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal">1.
</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Purchase and Sale of Securities</U><FONT STYLE="font-weight: normal">.</FONT></FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-weight: normal">1.1
</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal"><U>Firm Securities</U><FONT STYLE="font-weight: normal">.</FONT></FONT></P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal">1.1.1.
</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Nature and Purchase of Securities</U><FONT STYLE="font-weight: normal">.</FONT></FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal">(i)
On the basis of the representations and warranties herein contained, but subject to the terms and conditions herein set forth, the Company
agrees to issue and sell to the several Underwriters, an aggregate of 20,000,000 shares (the &ldquo;</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Firm
Shares<FONT STYLE="font-weight: normal">&rdquo;) of the Company&rsquo;s common stock, par value $0.01 per share (the &ldquo;</FONT>Common
Stock<FONT STYLE="font-weight: normal">&rdquo;), together with Common Stock purchase warrants (the &ldquo;</FONT>Firm Warrants<FONT STYLE="font-weight: normal">&rdquo;)
to purchase up to an aggregate of 20,000,000 shares of Common Stock, which shall have an exercise price of $0.55 per share, subject to
adjustment as provided for in the form of warrant. The Firm Shares and the Firm Warrants are referred to herein as the &ldquo;</FONT>Firm
Securities<FONT STYLE="font-weight: normal">.&rdquo; The Firm Shares and the Firm Warrants shall be issued separately and shall be immediately
transferable separately upon issuance.</FONT></FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal">(ii)
The Underwriters, severally and not jointly, agree to purchase from the Company the number of Firm Securities set forth opposite their
respective names on <U>Schedule 1</U> attached hereto and made a part hereof at a purchase price of $0.4675 per share of Common Stock
(93.5% of the per Firm Share public offering price) and accompanying Firm Warrant. The Securities are to be offered initially to the
public at the combined offering prices set forth on the cover page of the Prospectus (as defined in <U>Section 2.1.1</U>).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal">1.1.2.
</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Firm Securities Payment and Delivery</U><FONT STYLE="font-weight: normal">.</FONT></FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal">(i)
Delivery and payment for the Firm Securities shall be made at 10:00 a.m., Eastern time, on the second (2nd) Business Day following the
date of this Agreement (or the third (3rd) Business Day following the date of this Agreement if the pricing for the Offering (as defined
in <U>Section 2.1.1</U>) occurs after 4:01 p.m., Eastern time on the date of this Agreement) or at such earlier time as shall be agreed
upon by the Representative and the Company, at the offices of McGuireWoods LLP, 1251 Avenue of the Americas, 20<SUP>th</SUP> Floor, New
York, New York 10020 (&ldquo;</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Representative Counsel<FONT STYLE="font-weight: normal">&rdquo;),
or at such other place (or remotely by electronic transmission) as shall be agreed upon by the Representative and the Company. The hour
and date of delivery and payment for the Securities is called the &ldquo;</FONT>Closing Date<FONT STYLE="font-weight: normal">.&rdquo;</FONT></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal">(ii)
Payment for the Firm Securities shall be made on the Closing Date by wire transfer in Federal (same day) funds, payable to the order
of the Company upon delivery of the Firm Shares via the Depository Trust Company (&ldquo;</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">DTC<FONT STYLE="font-weight: normal">&rdquo;)
for the account of the Underwriters and certificates (in form and substance satisfactory to the Underwriters) representing the Firm Warrants.
The Firm Securities shall be registered in such name or names and in such authorized denominations as the Representative may request
in writing at least two (2) full Business Days prior to the Closing Date. The Company shall not be obligated to sell or deliver the Firm
Securities except upon tender of payment by the Representative for all of the Firm Securities. The term &ldquo;</FONT>Business Day<FONT STYLE="font-weight: normal">&rdquo;
means any day other than a Saturday, a Sunday or a legal holiday or a day on which banking institutions are authorized or obligated by
law to close in New York, New York.</FONT></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-weight: normal">1.2
</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal"><U>Over-allotment Option</U><FONT STYLE="font-weight: normal">.</FONT></FONT></P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal">1.2.1.
</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Option Securities</U><FONT STYLE="font-weight: normal">.
For the purposes of covering any over-allotments in connection with the distribution and sale of the Firm Securities, the Company hereby
grants to the Underwriters an option (the &ldquo;</FONT>Over-allotment Option<FONT STYLE="font-weight: normal">&rdquo;) to purchase up
to an additional 3,000,000 shares of Common Stock from the Company (the &ldquo;</FONT>Option Shares<FONT STYLE="font-weight: normal">&rdquo;),
and/or (b) warrants to purchase up to 3,000,000 shares of Common Stock (the &ldquo;</FONT>Option Warrants<FONT STYLE="font-weight: normal">&rdquo;
and collectively with the Option Shares, the &ldquo;</FONT>Option Securities<FONT STYLE="font-weight: normal">&rdquo;), in any combination
thereof. The purchase price to be paid per Option Security shall be equal to the price per applicable Firm Security set forth in <U>Section
1.1.1</U>. The Option Shares and the Option Warrants shall be issued separately and shall be immediately transferable separately upon
issuance. The shares of Common Stock underlying the Firm Warrants and the Option Warrants are hereinafter referred to as the &ldquo;</FONT>Warrant
Shares<FONT STYLE="font-weight: normal">.&rdquo; The Firm Securities and the Option Securities are hereinafter referred to together as
the &ldquo;</FONT>Securities<FONT STYLE="font-weight: normal">.&rdquo; The offering and sale of the Securities is hereinafter referred
to as the &ldquo;</FONT>Offering<FONT STYLE="font-weight: normal">.&rdquo;</FONT></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal">1.2.2.
</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Exercise of Option</U><FONT STYLE="font-weight: normal">.
The Over-allotment Option granted pursuant to <U>Section 1.2.1</U> hereof may be exercised by the Representative as to all (at any time)
or any part (from time to time) of the Option Securities within forty-five (45) days after the date of the Prospectus (as defined below).
The Underwriters shall not be under any obligation to purchase any Option Securities prior to the exercise of the Over-allotment Option.
The Over-allotment Option granted hereby may be exercised by the giving of oral notice to the Company from the Representative, which
must be confirmed in writing by overnight mail or facsimile or other electronic transmission setting forth the number of Option Securities
to be purchased and the date and time for delivery of and payment for the Option Securities (each, an &ldquo;</FONT>Option Closing Date<FONT STYLE="font-weight: normal">&rdquo;),
which shall not be later than five (5) full Business Days after the date of the notice or such other time as shall be agreed upon by
the Company and the Representative, at the offices of Representative Counsel, or at such other place (including remotely by facsimile
or other electronic transmission) as shall be agreed upon by the Company and the Representative. If such delivery and payment for the
Option Securities does not occur on the Closing Date, the Option Closing Date will be as set forth in the notice. Upon exercise of the
Over-allotment Option with respect to all or any portion of the Option Securities, subject to the terms and conditions set forth herein,
(i) the Company shall become obligated to sell to the Underwriters the number of Option Securities specified in such notice and (ii)
each of the Underwriters, acting severally and not jointly, shall purchase that portion of the total number of Option Securities then
being purchased as set forth in <U>Schedule 1</U> opposite the name of such Underwriter.</FONT></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 3; Options: NewSection; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --> -</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal">1.2.3.
</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Payment and Delivery</U><FONT STYLE="font-weight: normal">.
Payment for the Option Securities shall be made on the Option Closing Date by wire transfer in Federal (same day) funds, payable to the
order of the Company upon delivery to you of certificates (in form and substance satisfactory to the Underwriters) representing the Option
Shares (or through the facilities of DTC) for the account of the Underwriters and certificates (in form and substance satisfactory to
the Underwriters) representing the Option Warrants. The Option Securities shall be registered in such name or names and in such authorized
denominations as the Representative may request in writing at least two (2) full Business Days prior to the Option Closing Date. The
Company shall not be obligated to sell or deliver the Option Securities except upon tender of payment by the Representative for the applicable
Option Securities.</FONT></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal">2.
</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Representations and Warranties of the Company</U><FONT STYLE="font-weight: normal">.
The Company represents and warrants to the Underwriters as of the Applicable Time (as defined below), as of the Closing Date and as of
each Option Closing Date (if any) as follows:</FONT></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-weight: normal">2.1
</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal"><U>Filing of Registration Statement</U><FONT STYLE="font-weight: normal">.</FONT></FONT></P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal">2.1.1.
</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Pursuant to the Securities Act</U><FONT STYLE="font-weight: normal">.
The Company has filed with the U.S. Securities and Exchange Commission (the &ldquo;</FONT>Commission<FONT STYLE="font-weight: normal">&rdquo;)
a &ldquo;shelf&rdquo; registration statement on Form S-3 (File No. 333-257690), including any related prospectus or prospectuses, which
registration statement was declared effective on July 9, 2021, for the registration of the sale of certain securities of the Company,
including the Securities, under the Securities Act of 1933, as amended (the &ldquo;</FONT>Securities Act<FONT STYLE="font-weight: normal">&rdquo;),
which registration statement was prepared by the Company and is in all material respects in conformity with the requirements of the Securities
Act and the rules and regulations of the Commission promulgated thereunder (the &ldquo;</FONT>Securities Act Regulations<FONT STYLE="font-weight: normal">&rdquo;).
Except as the context may otherwise require, such registration statement on file with the Commission at the time the registration statement
became effective (including the prospectus included in the registration statement, financial statements, schedules, exhibits and all
other documents filed as a part thereof or incorporated pursuant to Form S-3 under the Securities Act at such time and the documents
and information otherwise deemed to be a part thereof or included therein pursuant to Rule 430B of the Securities Act Regulations (the
&ldquo;</FONT>Rule 430B Information<FONT STYLE="font-weight: normal">&rdquo;) or otherwise pursuant to the Securities Act Regulations
at such time, is referred to herein as the &ldquo;</FONT>Registration Statement<FONT STYLE="font-weight: normal">.&rdquo; If the Company
files any registration statement with the Commission pursuant to Rule 462(b) of the Securities Act Regulations relating to the Securities,
then, after such filing, any reference herein to the Registration Statement shall also be deemed to include such registration statement
filed pursuant to Rule 462(b).</FONT></FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal">The
prospectus in the form in which it was filed with the Commission in connection with the initial filing of the Registration Statement
is herein called the &ldquo;</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Base Prospectus<FONT STYLE="font-weight: normal">.&rdquo;
Each preliminary prospectus supplement to the Base Prospectus (including the Base Prospectus as so supplemented) that describes the Securities
and the Offering and omitted Rule 430B Information and that was used prior to the filing of the final prospectus supplement referred
to in the following paragraph is herein called a &ldquo;</FONT>Preliminary Prospectus<FONT STYLE="font-weight: normal">.&rdquo;</FONT></FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal">Promptly
after the execution and delivery of this Agreement, the Company will prepare and file with the Commission a final prospectus supplement
to the Base Prospectus relating to the Securities and the Offering in accordance with the provisions of Rule 430B (&ldquo;</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Rule
430B<FONT STYLE="font-weight: normal">&rdquo;) and Rule 424(b) (&ldquo;</FONT>Rule 424(b)<FONT STYLE="font-weight: normal">&rdquo;) of
the Securities Act Regulations. Such final prospectus supplement (including the Base Prospectus as so supplemented), in the form filed
with the Commission pursuant to Rule 424(b) under the Securities Act is herein called the &ldquo;</FONT>Prospectus<FONT STYLE="font-weight: normal">.&rdquo;</FONT></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 4; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --> -</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal">Any
reference in this Agreement to the Registration Statement, the Base Prospectus, any Preliminary Prospectus or the Prospectus shall be
deemed to refer to and include the documents incorporated or deemed incorporated by reference therein pursuant to Form S-3 which were
filed under the Securities Exchange Act of 1934, as amended (the &ldquo;</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Exchange
Act<FONT STYLE="font-weight: normal">&rdquo;), and the rules and regulations of the Commission promulgated thereunder (the &ldquo;</FONT>Exchange
Act Regulations<FONT STYLE="font-weight: normal">&rdquo;), on or before the date of this Agreement, or the issue date of the Base Prospectus,
any Preliminary Prospectus or the Prospectus, as the case may be; and any reference in this Agreement to the terms &ldquo;amend,&rdquo;
&ldquo;amendment&rdquo; or &ldquo;supplement&rdquo; with respect to the Registration Statement, the Base Prospectus, any Preliminary
Prospectus or the Prospectus shall be deemed to refer to and include the filing of any document under the Exchange Act after the date
of this Agreement, or the issue date of the Base Prospectus, any Preliminary Prospectus or the Prospectus, as the case may be, deemed
to be incorporated therein by reference. All references in this Agreement to financial statements and schedules and any other information
which is &ldquo;contained, &ldquo;included,&rdquo; &ldquo;described,&rdquo; &ldquo;referenced,&rdquo; &ldquo;set forth&rdquo; or &ldquo;stated&rdquo;
in the Registration Statement, the Base Prospectus, any Preliminary Prospectus or the Prospectus (and all other references of like import)
mean and include all such financial statements and schedules and any other information which is or is deemed to be incorporated by reference
in the Registration Statement, the Base Prospectus, any Preliminary Prospectus or the Prospectus, as the case may be.</FONT></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<B>Applicable
Time</B>&rdquo; means 8:30 a.m., Eastern Time, on the date of this Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<B>Issuer
Free Writing Prospectus</B>&rdquo; means any &ldquo;issuer free writing prospectus,&rdquo; as defined in Rule 433 of the Securities Act
Regulations (&ldquo;<B>Rule 433</B>&rdquo;), including without limitation any &ldquo;free writing prospectus&rdquo; (as defined in Rule
405 of the Securities Act Regulations) relating to the Securities that is (i) required to be filed with the Commission by the Company,
(ii) a &ldquo;road show that is a written communication&rdquo; within the meaning of Rule 433(d)(8)(i), whether or not required to be
filed with the Commission, or (iii) exempt from filing with the Commission pursuant to Rule 433(d)(5)(i) because it contains a description
of the Securities or of the Offering that does not reflect the final terms, in each case in the form filed or required to be filed with
the Commission or, if not required to be filed, in the form retained in the Company&rsquo;s records pursuant to Rule 433(g).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<B>Issuer
General Use Free Writing Prospectus</B>&rdquo; means any Issuer Free Writing Prospectus that is intended for general distribution to
prospective investors (other than a &ldquo;<I>bona fide</I> electronic road show,&rdquo; as defined in Rule 433), as evidenced by its
being specified in <U>Schedule 2-B</U> hereto.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<B>Issuer
Limited Use Free Writing Prospectus</B>&rdquo; means any Issuer Free Writing Prospectus that is not an Issuer General Use Free Writing
Prospectus.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<B>Pricing
Disclosure Package</B>&rdquo; means any Issuer General Use Free Writing Prospectus issued at or prior to the Applicable Time, the Preliminary
Prospectus dated February 11, 2022 and the information included on <U>Schedule 2-A</U> hereto, all considered together.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal">2.1.2.
<U>Pursuant to the Exchange Act</U>. The shares of Common Stock are registered pursuant to Section 12(b) under the Exchange Act. The
Company has taken no action designed to, or likely to have the effect of, terminating the registration of the shares of Common Stock
under the Exchange Act, nor has the Company received any notification that the Commission is contemplating terminating such registration.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-weight: normal">2.2
</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal"><U>S-3 Eligibility</U><FONT STYLE="font-weight: normal">.
The Company was at the time of the filing of the Registration Statement eligible to use Form S-3. The Company is eligible to use Form
S-3 under the Securities Act and it meets the transaction requirements as set forth in General Instruction I.B.1. of Form S-3. The Company
is not currently a shell company (as defined in Rule 405 of Regulations) and has not been a shell company for at least 12 calendar months
previously and, if applicable, has filed current Form 10 information (as defined in 5 of Form S-3) with the Commission at least 12 calendar
months previously reflecting its status as an entity that is not a shell company.</FONT></FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-weight: normal">2.3
</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal"><U>No Stop Orders, etc</U><FONT STYLE="font-weight: normal">.
Neither the Commission nor, to the Company&rsquo;s knowledge, any state regulatory authority has issued any order preventing or suspending
the use of the Registration Statement, any Preliminary Prospectus or the Prospectus or has instituted or, to the Company&rsquo;s knowledge,
threatened to institute, any proceedings with respect to such an order. The Company has complied with each request (if any) from the
Commission for additional information.</FONT></FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-weight: normal">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 5; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --> -</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-weight: normal">2.4
</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal"><U>Stock Exchange Listing</U><FONT STYLE="font-weight: normal">.
The shares of Common Stock are listed on The Nasdaq Capital Market (&ldquo;</FONT>Nasdaq<FONT STYLE="font-weight: normal">&rdquo; or
the &ldquo;</FONT>Exchange<FONT STYLE="font-weight: normal">&rdquo;), and the Company has taken no action designed to, or likely to have
the effect of delisting the shares of Common Stock from Nasdaq, nor has the Company received any notification that Nasdaq is contemplating
terminating such listing. The Company is, and has no reason to believe that it will not in the foreseeable future continue to be, in
compliance with all such listing and maintenance requirements other than the minimum bid price requirement for continued listing on the
Nasdaq Capital Market. The Company has submitted the Listing of Additional Shares Notification Form with the Exchange with respect to
the Offering of the Securities.</FONT></FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-weight: normal">2.5
</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal"><U>Disclosures in Registration Statement</U><FONT STYLE="font-weight: normal">.</FONT></FONT></P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal">2.5.1.
</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Compliance with Securities Act and 10b-5 Representation</U><FONT STYLE="font-weight: normal">.</FONT></FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal">(i)
Each of the Registration Statement and any post-effective amendment thereto, at the time it became effective, complied in all material
respects with the requirements of the Securities Act and the Securities Act Regulations. Each Preliminary Prospectus, including the Base
Prospectus filed as part of the Registration Statement as originally filed or as part of any amendment or supplement thereto, and the
Prospectus, at the time it was filed with the Commission, complied in all material respects with the requirements of the Securities Act
and the Securities Act Regulations. Each Preliminary Prospectus delivered to the Underwriters for use in connection with this Offering
and the Prospectus was or will be identical to the electronically transmitted copies thereof filed with the Commission pursuant to EDGAR,
except to the extent permitted by Regulation S-T.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal">(ii)
Neither the Registration Statement nor any amendment thereto, at its effective time, as of the Applicable Time or at the Closing Date,
contained, contains or will contain an untrue statement of a material fact or omitted, omits or will omit to state a material fact required
to be stated therein or necessary to make the statements therein not misleading; <U>provided</U>, <U>however</U>, that the Company makes
no representation or warranty with respect to any statements or omissions made in reliance upon and in conformity with the Underwriters&rsquo;
Information (as defined below)</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">.</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal">(iii)
The Pricing Disclosure Package, as of the Applicable Time, as of the date of this Agreement or at the Closing Date, did not, does not
and will not include an untrue statement of a material fact or omit to state a material fact necessary in order to make the statements
therein, in the light of the circumstances under which they were made, not misleading; and each Issuer Limited Use Free Writing Prospectus
hereto does not conflict with the information contained in the Registration Statement, any Preliminary Prospectus or the Prospectus,
and each such Issuer Limited Use Free Writing Prospectus, as supplemented by and taken together with the Prospectus as of the Applicable
Time, did not include an untrue statement of a material fact or omit to state a material fact necessary in order to make the statements
therein, in the light of the circumstances under which they were made, not misleading; <U>provided</U>, <U>however</U>, that this representation
and warranty shall not apply to statements made or statements omitted in reliance upon and in conformity with written information furnished
to the Company with respect to the Underwriters by the Representative expressly for use in the Registration Statement, the Pricing Disclosure
Package, any Preliminary Prospectus or the Prospectus or any amendment thereof or supplement thereto. The parties acknowledge and agree
that such information provided by or on behalf of any Underwriter consists solely of the following disclosure contained in the &ldquo;Underwriting&rdquo;
section of the Prospectus: the first three sentences under the subheading titled &ldquo;Discounts and Commissions,&rdquo; the disclosure
under the subheading titled &ldquo;Stabilization,&rdquo; and the disclosure under subheadings titled &ldquo;Passive Market Making,&rdquo;
&ldquo;Electronic Distribution,&rdquo; and &ldquo;Other&rdquo; (the &ldquo;</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Underwriters&rsquo;
Information<FONT STYLE="font-weight: normal">&rdquo;).</FONT></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal">(iv)
Neither the Prospectus nor any amendment or supplement thereto (including any prospectus wrapper), as of its issue date, at the time
of any filing with the Commission pursuant to Rule 424(b) or at the Closing Date, included, includes or will include an untrue statement
of a material fact or omitted, omits or will omit to state a material fact necessary in order to make the statements therein, in the
light of the circumstances under which they were made, not misleading; <U>provided</U>, <U>however</U>, that this representation and
warranty shall not apply to the Underwriters&rsquo; Information.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 6; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --> -</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal">(v)
The documents incorporated by reference in the Registration Statement, the Pricing Disclosure Package and the Prospectus, conform in
all material respects to the descriptions thereof contained or incorporated by reference therein, conformed in all material respects
to the requirements of the Securities Act or the Exchange Act, as applicable at the time filed, and were filed on a timely basis with
the Commission and none of such documents contained an untrue statement of a material fact or omitted to state a material fact necessary
to make the statements therein, in the light of the circumstances under which they were made, not misleading; and there are no agreements
or other documents required by the Securities Act and the rules and regulations thereunder to be described in the Registration Statement,
the Pricing Disclosure Package or Prospectus or to be filed with the Commission as exhibits to the Registration Statement or to be incorporated
by reference in the Registration Statement, the Pricing Disclosure Package or Prospectus, that have not been so described or filed or
incorporated by reference.</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal">2.5.2.
</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Disclosure of Agreements</U><FONT STYLE="font-weight: normal">.
The agreements and documents described in the Registration Statement, the Pricing Disclosure Package and the Prospectus conform in all
material respects to the descriptions thereof contained or incorporated by reference therein, and there are no agreements or other documents
required by the Securities Act and the Securities Act Regulations to be described in the Registration Statement, the Pricing Disclosure
Package and the Prospectus or to be filed with the Commission as exhibits to the Registration Statement or to be incorporated by reference
in the Registration Statement and the Prospectus, that have not been so described or filed or incorporated by reference. Each agreement
or other instrument (however characterized or described) to which the Company is a party or by which it is or may be bound or affected
and (i) that is referred to or incorporated by reference in the Registration Statement, the Pricing Disclosure Package or the Prospectus,
or (ii) is material to the Company&rsquo;s business, has been duly authorized and validly executed by the Company, is in full force and
effect in all material respects and is enforceable against the Company and, to the Company&rsquo;s knowledge, the other parties thereto,
in accordance with its terms, except (x) as such enforceability may be limited by bankruptcy, insolvency, reorganization or similar laws
affecting creditors&rsquo; rights generally, (y) as enforceability of any indemnification or contribution provision may be limited under
the federal and state securities laws, and (z) that the remedy of specific performance and injunctive and other forms of equitable relief
may be subject to the equitable defenses and to the discretion of the court before which any proceeding therefor may be brought. None
of such agreements or instruments has been assigned by the Company, and neither the Company nor, to the Company&rsquo;s knowledge, any
other party is in default thereunder and, to the Company&rsquo;s knowledge, no event has occurred that, with the lapse of time or the
giving of notice, or both, would constitute a default thereunder except for a default or event which would not reasonably be expected
to result in a Material Adverse Effect (as such term is defined in <U>Section 2.5.4</U>). To the best of the Company&rsquo;s knowledge,
performance by the Company of the material provisions of such agreements or instruments will not result in a violation of any existing
applicable law, rule, regulation, judgment, order or decree of any governmental agency or court, domestic or foreign, having jurisdiction
over the Company or any of its assets or businesses, including, without limitation, those relating to environmental laws and regulations.</FONT></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal">2.5.3.
</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Subsidiaries</U><FONT STYLE="font-weight: normal">.
All of the direct and indirect subsidiaries of the Company (each, a &ldquo;</FONT>Subsidiary<FONT STYLE="font-weight: normal">&rdquo;,
and collectively, the &ldquo;</FONT>Subsidiaries<FONT STYLE="font-weight: normal">&rdquo;) are set forth in the SEC Reports (as defined
below). The Company owns, directly or indirectly, all of the capital stock or other equity interests of each Subsidiary free and clear
of any lien, charge, mortgage, pledge, security interest, claim, right of first refusal, pre-emptive right, or other encumbrance of any
kind whatsoever (any of the foregoing, a &ldquo;</FONT>Lien<FONT STYLE="font-weight: normal">&rdquo;), and all of the issued and outstanding
shares of capital stock of each Subsidiary are validly issued and are fully paid, non-assessable and free of preemptive and similar rights
to subscribe for or purchase securities. Except as disclosed in the SEC Reports, there are no outstanding options, warrants, scrip rights
to subscribe to, calls or commitments of any character whatsoever relating to, or securities, rights or obligations convertible into
or exercisable or exchangeable for, or giving any Person any right to subscribe for or acquire, any capital stock of any Subsidiary,
or contracts, commitments, understandings or arrangements by which any Subsidiary is or may become bound to issue capital stock.</FONT></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 7; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --> -</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal">2.5.4.
</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Organization and Qualification</U><FONT STYLE="font-weight: normal">.
The Company and each of the Subsidiaries has been duly organized and validly exists as a corporation, limited partnership or company
in good standing (or the foreign equivalent thereof, if any) under the laws of its jurisdiction of organization. The Company and each
of the Subsidiaries is duly qualified to do business and is in good standing as a foreign or extra-provincial corporation, partnership,
company or limited liability company in each jurisdiction in which the character or location of its properties (owned, leased or licensed)
or the nature or conduct of its business makes such qualification necessary, except for those failures to be so qualified or in good
standing which (individually and in the aggregate) would not have a Material Adverse Effect. No action, claim, suit, investigation or
proceeding (including, without limitation, an investigation or partial proceeding, such as a deposition) has been instituted in any such
jurisdiction revoking, limiting or curtailing or seeking to revoke, limit or curtail such power and authority or qualification. Neither
the Company nor any Subsidiary is in violation or default of any of the provisions of its respective certificate or articles of incorporation,
bylaws or other organizational or charter documents. The term &ldquo;</FONT>Material Adverse Effect<FONT STYLE="font-weight: normal">&rdquo;
means an effect, change, event or occurrence that, alone or in conjunction with any other or others: (i) has or would reasonably be expected
to have a material adverse effect on: (A) the business, general affairs, management, condition (financial or otherwise), results of operations,
stockholders&rsquo; equity, properties or prospects of the Company and the Subsidiaries, taken as a whole, or (B) the legality, validity
or enforceability of any of this Agreement, the Firm Warrants, the Option Warrants, the Lock-up Agreements, all exhibits and schedules
thereto and hereto and any other documents or agreements executed in connection with the transactions contemplated hereunder or thereunder
(each, a &ldquo;</FONT>Transaction Document<FONT STYLE="font-weight: normal">&rdquo;), (ii) a material adverse effect on the Company&rsquo;s
ability to perform in any material respect on a timely basis its obligations, including the conducting of the Offering, under any Transaction
Document or (iii) would result in the Prospectus or any amendment thereto containing a misrepresentation within the meaning of applicable
securities laws; provided that a change in the market price or trading volume of the Common Stock alone shall not be deemed, in and of
itself, to constitute a Material Adverse Effect.</FONT></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal">2.5.5.
</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Authorization; Enforcement</U><FONT STYLE="font-weight: normal">.
The Company has the requisite corporate power and authority to enter into and to consummate the transactions contemplated by this Agreement
and each of the other Transaction Documents and otherwise to carry out its obligations hereunder and thereunder. The execution and delivery
of this Agreement and each of the other Transaction Documents by the Company and the consummation by it of the transactions contemplated
hereby and thereby have been duly authorized by all necessary action on the part of the Company and no further action is required by
the Company, the Board of Directors or the Company&rsquo;s stockholders in connection herewith or therewith other than in connection
with the Required Approvals. This Agreement and each other Transaction Document to which the Company is a party has been (or upon delivery
will have been) duly executed by the Company and, when delivered in accordance with the terms hereof and thereof, will constitute the
valid and binding obligation of the Company enforceable against the Company in accordance with its terms, except (i) as limited by general
equitable principles and applicable bankruptcy, insolvency, reorganization, moratorium and other laws of general application affecting
enforcement of creditors&rsquo; rights generally, (ii) as limited by laws relating to the availability of specific performance, injunctive
relief or other equitable remedies and (iii) insofar as indemnification and contribution provisions may be limited by applicable law.</FONT></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 8; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --> -</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal">2.5.6.
</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>No Conflicts</U><FONT STYLE="font-weight: normal">.
The execution, delivery and performance by the Company of this Agreement and the other Transaction Documents to which it is a party,
the issuance and sale of the Securities and the consummation by it of the transactions contemplated hereby and thereby do not and will
not (i) conflict with or violate any provision of the Company&rsquo;s or any Subsidiary&rsquo;s certificate or articles of incorporation,
bylaws or other organizational or charter documents, or (ii) conflict with, or constitute a default (or an event that with notice or
lapse of time or both would become a default) under, result in the creation of any Lien upon any of the properties or assets of the Company
or any Subsidiary, or give to others any rights of termination, amendment, anti-dilution or similar adjustments, acceleration or cancellation
(with or without notice, lapse of time or both) of, any agreement, credit facility, debt or other instrument (evidencing a Company or
Subsidiary debt or otherwise) or other understanding to which the Company or any Subsidiary is a party or by which any property or asset
of the Company or any Subsidiary is bound or affected, or (iii) subject to the Required Approvals, conflict with or result in a violation
of any law, rule, regulation, order, judgment, injunction, decree or other restriction of any court or governmental authority, to which
the Company or a Subsidiary is subject (including federal and state securities laws and regulations), or by which any property or asset
of the Company or a Subsidiary is bound or affected; except in the case of each of clauses (ii) and (iii), such as could not have or
reasonably be expected to result in a Material Adverse Effect.</FONT></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal">2.5.7.
</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Filings, Consents and Approvals</U><FONT STYLE="font-weight: normal">.
The Company is not required to obtain any consent, waiver, authorization or order of, give any notice to, or make any filing or registration
with, any court or other federal, state (including state blue sky laws), local or other governmental authority or other Person in connection
with the execution, delivery and performance by the Company of this Agreement and the other Transaction Documents, including with respect
to the sale and issuance of the Securities, other than: (i) the filing with the Commission of the Prospectus, (ii) application(s) to
the Nasdaq for the listing of the Firm Shares, the Option Shares and the Warrant Shares for trading thereon in the time and manner required
thereby, and (iii) such filings as are required to be made under applicable state securities laws (collectively, the &ldquo;</FONT>Required
Approvals<FONT STYLE="font-weight: normal">&rdquo;).</FONT></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal">2.5.8.
</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Issuance of the Shares and Warrant Shares; Qualification;
Registration</U><FONT STYLE="font-weight: normal">.</FONT></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 2in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal">2.5.8.1.
The Firm Shares and the Option Shares are duly authorized and, when issued and paid for in accordance with the applicable Transaction
Documents, will be duly and validly issued, fully paid and non-assessable, free and clear of all Liens imposed by the Company. The Firm
Warrants and the Option Warrants, when issued and paid for in accordance with the applicable Transaction Documents, will be valid and
binding obligations of the Company, enforceable against the Company in accordance with their terms. The Warrant Shares are duly authorized
and, when issued in accordance with the terms of the Firm Warrants and/or the Option Warrants, will be validly issued, fully paid and
non-assessable. The Company has reserved from its duly authorized capital stock the maximum number of shares of Common Stock issuable
pursuant to this Agreement including with respect to issuance of the Warrant Shares upon exercise of the Firm Warrants and the Option
Warrants (without taking into account any limitations on the exercise of the Firm Warrants or the Option Warrants set forth therein).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 2in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 9; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --> -</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal">2.5.9.
</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Capitalization</U><FONT STYLE="font-weight: normal">.
The equity capitalization of the Company is as set forth in the SEC Reports, other than changes pursuant to the exercise of employee
stock options under the Company&rsquo;s stock option plans, the issuance of shares of Common Stock to employees pursuant to the Company&rsquo;s
employee stock purchase plans and pursuant to the conversion and/or exercise of Common Stock Equivalents outstanding as of the date of
the most recently filed periodic report under the Exchange Act. All of the issued and outstanding shares of Common Stock are duly authorized,
validly issued, fully paid and non-assessable, have been issued in compliance with all federal and state securities laws, and none of
such outstanding shares was issued in violation of or subject to any preemptive or similar right that entitles any person to acquire
from the Company any Common Stock or other security of the Company or any security convertible into, or exercisable or exchangeable for,
Common Stock or any other such security, except for such rights as may have been fully satisfied or waived prior to the date hereof.
Except as a result of the purchase and sale of the Securities and as described in the Registration Statement, the Pricing Disclosure
Package and the Prospectus, the Company has no outstanding options, warrants, scrip rights to subscribe to, calls or commitments of any
character whatsoever relating to, or securities, rights or obligations convertible into or exercisable or exchangeable for, or giving
any Person any right to subscribe for or acquire, any Common Stock, or contracts, commitments, understandings or arrangements by which
the Company is or may become bound to issue additional Common Stock or Common Stock Equivalents. No Person has any right of first refusal,
pre-emptive right, right of participation, or any similar right to participate in the transactions contemplated by the Transaction Documents.
The issuance and sale of the Securities will not obligate the Company to issue Common Stock or other securities to any Person (other
than the Underwriters) and will not result in a right of any holder of Company securities to adjust the exercise, conversion, exchange
or reset price under any of such securities. There are no outstanding securities or instruments of the Company with any provision that
adjusts the exercise, conversion, exchange or reset price of such security or instrument upon an issuance of securities by the Company.
There are no outstanding securities or instruments of the Company that contain any redemption or similar provisions, and there are no
contracts, commitments, understandings or arrangements by which the Company is or may become bound to redeem a security of the Company.
Except for the Required Approvals, no further approval or authorization of any stockholder of the Company, the Board of Directors or
others is required for the issuance and sale of the Securities. There are no stockholders agreements, voting agreements or other similar
agreements with respect to the Company&rsquo;s capital stock to which the Company is a party or, to the knowledge of the Company, between
or among any of the Company&rsquo;s stockholders.</FONT></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal">2.5.10.
</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>SEC Reports</U><FONT STYLE="font-weight: normal">.
The Company has filed all reports, schedules, forms, statements and other &lrm;documents required to be filed by the Company under the
Securities Act and Exchange &lrm;Act, including pursuant to Section 13(a) or 15(d) thereof, for the two years preceding the date hereof
(or such shorter period as the Company was required by law or regulation to file such material) (the foregoing materials, &lrm;including
the exhibits thereto and documents incorporated by reference therein, together &lrm;with the Prospectus, the Pricing Disclosure Package
and the Prospectus, being collectively referred to &lrm;herein as the &ldquo;</FONT>SEC Reports<FONT STYLE="font-weight: normal">&rdquo;)
on a timely basis or has received a valid extension of such &lrm;time of filing and has filed any such SEC Reports prior to the expiration
of any such &lrm;extension. As of their respective dates, the SEC Reports complied in all material respects &lrm;with the requirements
of the Securities Act and the Exchange Act, as applicable, and none of the SEC Reports, when filed, contained any untrue statement of
a material fact or omitted to state a material fact required to be stated therein or necessary in order to make the statements therein,
in the light of the circumstances under which they were made, not misleading. The Company is not, and has never been, an issuer subject
to Rule 144(i)(1) of the Securities Act.</FONT></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal">2.5.11.
</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Financial Statements</U><FONT STYLE="font-weight: normal">.
The consolidated financial statements, including the notes thereto, included or incorporated by reference in the Registration Statement,
the Pricing Disclosure Package and the Prospectus comply in all material respects with applicable accounting requirements and the rules
and regulations of the Commission with respect thereto as in effect at the time of filing. Such financial statements have been prepared
in accordance with United States generally accepted accounting principles applied on a consistent basis during the periods involved (&ldquo;</FONT>GAAP<FONT STYLE="font-weight: normal">&rdquo;),
except as may be otherwise specified in such financial statements or the notes thereto and except that unaudited financial statements
may not contain all footnotes required by GAAP, and fairly present in all material respects the financial position of the Company and
its consolidated Subsidiaries as of and for the dates thereof and the results of operations and cash flows for the periods then ended,
subject, in the case of unaudited statements, to normal, immaterial, year-end audit adjustments.</FONT></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 10; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --> -</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal">2.5.12.
</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Material Changes; Undisclosed Events, Liabilities
or Developments</U><FONT STYLE="font-weight: normal">. Since the date of the latest consolidated financial statements included in or
incorporated by reference into the Registration Statement, the Pricing Disclosure Package and the Prospectus, except as set forth in
the Registration Statement, the Pricing Disclosure Package and the Prospectus, (i) there has been no event, occurrence or development
that has had or that could reasonably be expected to result in a Material Adverse Effect, (ii) neither the Company nor any Subsidiary
has incurred any liabilities (contingent or otherwise) other than (A) trade payables and accrued expenses incurred in the ordinary course
of business consistent with past practice and (B) liabilities not required to be reflected in the Company&rsquo;s financial statements
pursuant to GAAP or disclosed in filings made with the Commission, (iii) the Company has not altered its method of accounting, (iv) the
Company has not declared or made any dividend or distribution of cash or other property to its stockholders or purchased, redeemed or
made any agreements to purchase or redeem any shares of its capital stock and (v) the Company has not issued any equity securities to
any officer, director or Affiliate, except pursuant to existing Company stock option or other omnibus incentive plans or as a condition
of entering into an employment agreement. The Company does not have pending before the Commission any request for confidential treatment
of information. Except for the issuance of the Securities contemplated by this Agreement or as set forth in the SEC Reports, no event,
liability, fact, circumstance, occurrence or development has occurred or exists or is reasonably expected to occur or exist with respect
to the Company or its Subsidiaries or their respective businesses, prospects, properties, operations, assets or financial condition that
would be required to be disclosed by the Company under applicable securities laws at the time this representation is made or deemed made
that has not been publicly disclosed at least one (1) Business Day prior to the date that this representation is made.</FONT></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal">2.5.13.
</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Litigation</U><FONT STYLE="font-weight: normal">.
There is no action, suit, inquiry, notice of violation, proceeding or investigation pending or, to the knowledge of the Company, threatened
against or affecting the Company, any Subsidiary or any of their respective properties before or by any court, arbitrator, governmental
or administrative agency or regulatory authority (federal, state, county, local or foreign) (collectively, an &ldquo;</FONT>Action<FONT STYLE="font-weight: normal">&rdquo;)
which (i) adversely affects or challenges the legality, validity or enforceability of any of the Transaction Documents or the Securities
or (ii) could, if there were an unfavorable decision, have or reasonably be expected to result in a Material Adverse Effect. Neither
the Company nor any Subsidiary, nor any director or officer thereof, is or has been the subject of any Action involving a claim of violation
of or liability under federal or state securities laws or a claim of breach of fiduciary duty, which could result in a Material Adverse
Effect. The Company has disclosed in its SEC Reports all information that it is required to disclose in respect of any Action pursuant
to the requirements of the Securities Act and the Exchange Act, as applicable. There has not been, and to the knowledge of the Company,
there is not pending or contemplated, any material investigation by the Commission involving the Company or any current or former director
or officer of the Company which is required to be disclosed in the SEC Reports. The Commission has not issued any stop order or other
order suspending the effectiveness of any registration statement filed by the Company or any Subsidiary under the Exchange Act or the
Securities Act.</FONT></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal">2.5.14.
</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Labor Relations</U><FONT STYLE="font-weight: normal">.
No labor dispute exists or, to the knowledge of the Company, is imminent with respect to any of the employees of the Company or any Subsidiary,
which could reasonably be expected to result in a Material Adverse Effect. None of the Company&rsquo;s or its Subsidiaries&rsquo; employees
is a member of a union that relates to such employee&rsquo;s relationship with the Company or such Subsidiary, and neither the Company
nor any of its Subsidiaries is a party to a collective bargaining agreement, and the Company and its Subsidiaries believe that their
relationships with their employees are good. To the knowledge of the Company, no executive officer of the Company or any Subsidiary,
is, or is now expected to be, in violation of any material term of any employment contract, confidentiality, disclosure or proprietary
information agreement or non-competition agreement, or any other contract or agreement or any restrictive covenant in favor of any third
party, and the continued employment of each such executive officer does not subject the Company or any of its Subsidiaries to any liability
with respect to any of the foregoing matters. The Company and its Subsidiaries are in compliance with all U.S. federal, state, local
and foreign laws and regulations relating to employment and employment practices, terms and conditions of employment and wages and hours,
except where the failure to be in compliance could not, individually or in the aggregate, reasonably be expected to have a Material Adverse
Effect.</FONT></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 11; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --> -</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal">2.5.15.
</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Compliance</U><FONT STYLE="font-weight: normal">.
Neither the Company nor any Subsidiary: (i) is in default under or in violation of (and no event has occurred that has not been waived
that, with notice or lapse of time or both, would result in a default by the Company or any Subsidiary under), nor has the Company or
any Subsidiary received notice of a claim that it is in default under or that it is in violation of, any indenture, loan or credit agreement
or any other agreement or instrument to which it is a party or by which it or any of its properties is bound (whether or not such default
or violation has been waived), (ii) is in violation of any judgment, decree or order of any court, arbitrator or other governmental authority
or (iii) is in violation of any statute, rule, ordinance or regulation of any governmental authority, including without limitation all
foreign, federal, state and local laws relating to taxes, environmental protection, occupational health and safety, product quality and
safety and employment and labor matters, except in each case of <U>clauses (i)</U>, <U>(ii)</U> and <U>(iii)</U> as could not have or
reasonably be expected to result in a Material Adverse Effect.</FONT></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal">2.5.16.
</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Environmental Law</U><FONT STYLE="font-weight: normal">.
There has been no storage, generation, transportation, handling, use, treatment, disposal, discharge, emission, contamination, release
or other activity involving any kind of hazardous, toxic or other wastes, pollutants, contaminants, petroleum products or other hazardous
or toxic substances, chemicals or materials (&ldquo;</FONT>Hazardous Substances<FONT STYLE="font-weight: normal">&rdquo;) by, due to,
on behalf of, or caused by the Company or any Subsidiary (or, to the Company&rsquo;s knowledge, any other entity for whose acts or omissions
the Company is or may be liable) upon any property now or previously owned, operated, used or leased by the Company or any Subsidiary,
or upon any other property, which would be a violation of or give rise to any liability under any applicable law, rule, regulation, order,
judgment, decree or permit, common law provision or other legally binding standard relating to pollution or protection of human health
and the environment (&ldquo;</FONT>Environmental Law<FONT STYLE="font-weight: normal">&rdquo;), except for violations and liabilities
which, individually or in the aggregate, would not have a Material Adverse Effect. There has been no disposal, discharge, emission contamination
or other release of any kind at, onto or from any such property or into the environment surrounding any such property of any Hazardous
Substances with respect to which the Company or any Subsidiary has knowledge, except as would not, individually or in the aggregate,
have a Material Adverse Effect. There is no pending or, to the best of the Company&rsquo;s knowledge, threatened administrative, regulatory
or judicial action, claim or notice of noncompliance or violation, investigation or proceedings relating to any Environmental Law against
the Company or any Subsidiary, except as would not, individually or in the aggregate, have a Material Adverse Effect. No property of
the Company or any Subsidiary is subject to any Lien under any Environmental Law. Except as disclosed in the Registration Statement,
the Pricing Disclosure Package and the Prospectus, neither the Company nor any Subsidiary is subject to any order, decree, agreement
or other individualized legal requirement related to any Environmental Law, which, in any case (individually or in the aggregate), could
be reasonably expected to have a Material Adverse Effect. The Company and each Subsidiary are in compliance in all material respects
with all applicable federal, state, local and Environmental Laws and each has all permits, authorizations and approvals required under
any applicable Environmental Laws and are each in compliance with their requirements, except where the failure to so comply could be
reasonably expected to have, individually or in the aggregate, a Material Adverse Effect. In the ordinary course of its business, the
Company periodically reviews the effect of Environmental Laws on the business, operations and properties of the Company and the Subsidiaries,
in the course of which it identifies and evaluates associated costs and liabilities (including, without limitation, any capital or operating
expenditures required for clean-up, closure or remediation of properties or compliance with Environmental Laws, or any permit, license
or approval, any related constraints on operating activities and any potential liabilities to third parties). On the basis of such review,
the Company has reasonably concluded that such associated costs and liabilities would not, individually or in the aggregate, have a Material
Adverse Effect.</FONT></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal">2.5.17.
</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Title to Assets</U><FONT STYLE="font-weight: normal">.
The Company and the Subsidiaries have good and marketable title in fee simple to all real property owned by them and good and marketable
title in all personal property owned by them that is material to the business of the Company and the Subsidiaries, in each case free
and clear of all Liens, except for (i) Liens as do not materially affect the value of such property and do not materially interfere with
the use made and proposed to be made of such property by the Company and the Subsidiaries and (ii) Liens for the payment of federal,
state or other taxes, for which appropriate reserves have been made therefor in accordance with GAAP and, the payment of which is neither
delinquent nor subject to penalties. Any real property and facilities held under lease by the Company and the Subsidiaries are held by
them under valid, subsisting and enforceable leases with which the Company and the Subsidiaries are in compliance in all material respects.</FONT></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 12; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --> -</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal">2.5.18.
</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Regulatory Permits</U><FONT STYLE="font-weight: normal">.
The Company and the Subsidiaries possess all certificates, authorizations and permits issued by the appropriate federal, state, local
or foreign regulatory authorities necessary to conduct their respective businesses as described in the Registration Statement, the Pricing
Disclosure Package and the Prospectus, except where the failure to possess such permits could not reasonably be expected to result in
a Material Adverse Effect (&ldquo;</FONT>Material Permits<FONT STYLE="font-weight: normal">&rdquo;), and neither the Company nor any
Subsidiary has received any notice of proceedings relating to the revocation or modification of any Material Permit.</FONT></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal">2.5.19.
</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Intellectual Property</U><FONT STYLE="font-weight: normal"><I>.
</I>The Company and the Subsidiaries have, or have rights to use, all patents, patent applications, trademarks, trademark applications,
service marks, trade names, trade secrets, inventions, copyrights, licenses and other intellectual property rights and similar rights
necessary or required for use in connection with their respective businesses as described in the Registration Statement, the Pricing
Disclosure Package and the Prospectus and which the failure to so have could have a Material Adverse Effect (collectively, the &ldquo;</FONT>Intellectual
Property Rights<FONT STYLE="font-weight: normal">&rdquo;). None of, and neither the Company nor any Subsidiary has received a notice
(written or otherwise) that any of, the Intellectual Property Rights has expired, terminated or been abandoned, or is expected to expire
or terminate or be abandoned, within two (2) years from the date of this Agreement except as would not reasonably be expected to have
a Material Adverse Effect. Neither the Company nor any Subsidiary has received, since the date of the latest audited financial statements
included within the SEC Reports, a written notice of a claim or otherwise has any knowledge that the Intellectual Property Rights violate
or infringe upon the rights of any Person and neither is aware of any facts which would form a reasonable basis for any such claim, except
as could not have or reasonably be expected to not have a Material Adverse Effect. To the knowledge of the Company, all such Intellectual
Property Rights are enforceable and there is no existing infringement by another Person of any of the Intellectual Property Rights. The
Company and its Subsidiaries have taken reasonable security measures to protect the secrecy, confidentiality and value of all of their
intellectual properties, except where failure to do so could not, individually or in the aggregate, reasonably be expected to have a
Material Adverse Effect. None of the Intellectual Property Rights used by the Company or any of its Subsidiaries in their respective
businesses has been obtained or is being used by the Company or such Subsidiary in violation of any contractual obligation binding on
the Company or any of its subsidiaries in violation of the rights of any person. The Company and its subsidiaries have taken all reasonable
steps in accordance with normal industry practice to protect and maintain the Intellectual Property Rights including, without limitation,
the execution of appropriate nondisclosure and invention assignment agreements. The consummation of the transactions contemplated by
this Agreement will not result in the loss or impairment of, or payment of, and additional amounts with respect to, nor require the consent
of, any other person regarding the Company&rsquo;s or any of its subsidiaries&rsquo; right to own or use any of the Intellectual Property
Rights as owned or used in the conduct of such party&rsquo;s business as currently conducted. To the knowledge of the Company and its
Subsidiaries, no employee of any of the Company or its subsidiaries is the subject of any pending claim or proceeding involving a violation
of any term of any employment contract, invention disclosure agreement, patent disclosure agreement, noncompetition agreement, non-solicitation
agreement, nondisclosure agreement or restrictive covenant to or with a former employer, where the basis of such violation relates to
such employee&rsquo;s employment with the Company or its subsidiaries or actions undertaken by the employee while employed with the Company
or its Subsidiaries.</FONT></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal">2.5.20.
</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Insurance</U><FONT STYLE="font-weight: normal">.
The Company and the Subsidiaries are insured by insurers of recognized financial responsibility against such losses and risks and in
such amounts as are prudent and customary in the businesses in which the Company and the Subsidiaries are engaged, including, but not
limited to, directors and officers insurance coverage. Neither the Company nor any Subsidiary has any reason to believe that it will
not be able to renew its existing insurance coverage as and when such coverage expires or to obtain similar coverage from similar insurers
as may be necessary to continue its business without a significant increase in cost.</FONT></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 13; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --> -</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal">2.5.21.
</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Transactions With Affiliates and Employees</U><FONT STYLE="font-weight: normal">.
Except as disclosed in the SEC Reports, none of the officers or directors of the Company or any Subsidiary and, to the knowledge of the
Company, none of the employees of the Company or any Subsidiary is presently a party to any transaction with the Company or any Subsidiary
(other than for services as employees, officers and directors), including any contract, agreement or other arrangement providing for
the furnishing of services to or by, providing for rental of real or personal property to or from, providing for the borrowing of money
from or lending of money to or otherwise requiring payments to or from any officer, director or such employee or, to the knowledge of
the Company, any entity in which any officer, director, or any such employee has a substantial interest or is an officer, director, trustee,
stockholder, member or partner, in each case in excess of $120,000 other than for (i) payment of salary or consulting fees for services
rendered, (ii) reimbursement for expenses incurred on behalf of the Company and (iii) other employee benefits, including stock option
agreements under any stock option plan of the Company.</FONT></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal">2.5.22.
</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Sarbanes-Oxley; Internal Accounting Controls</U><FONT STYLE="font-weight: normal">.
Except as disclosed in the SEC Reports, the Company and the Subsidiaries and their respective officers and directors are in compliance
with the applicable provisions of the Sarbanes-Oxley Act of 2002, as amended. The Company and the Subsidiaries maintain a system of internal
accounting controls sufficient to provide reasonable assurance that: (i) transactions are executed in accordance with management&rsquo;s
general or specific authorizations, (ii) transactions are recorded as necessary to permit preparation of financial statements in conformity
with GAAP and to maintain asset accountability, (iii) access to assets is permitted only in accordance with management&rsquo;s general
or specific authorization, and (iv) the recorded accountability for assets is compared with the existing assets at reasonable intervals
and appropriate action is taken with respect to any differences. The Company and the Subsidiaries have established disclosure controls
and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) for the Company and the Subsidiaries and designed such disclosure
controls and procedures to ensure that information required to be disclosed by the Company in the reports it files or submits under the
Exchange Act is recorded, processed, summarized and reported, within the time periods specified in the Commission&rsquo;s rules and forms.
The Company&rsquo;s certifying officers have evaluated the effectiveness of the disclosure controls and procedures of the Company and
the Subsidiaries as of the applicable dates specified under the Exchange Act (such date, the &ldquo;</FONT>Evaluation Date<FONT STYLE="font-weight: normal">&rdquo;).
The Company presented in its most recently filed annual report on Form 10-K the conclusions of the certifying officers about the effectiveness
of the disclosure controls and procedures based on their evaluations as of the Evaluation Date. Except as set forth in the Registration
Statement, the Pricing Disclosure Package and the Prospectus, since the Evaluation Date, there have been no changes in the internal control
over financial reporting (as such term is defined in the Exchange Act) of the Company and the Subsidiaries that have materially affected,
or is reasonably likely to materially affect, the internal control over financial reporting of the Company and the Subsidiaries.</FONT></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal">2.5.23.
</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Certain Fees</U><FONT STYLE="font-weight: normal">.
Except for fees payable to A.G.P. as will be as set forth in the Prospectus, no brokerage or finder&rsquo;s fees or commissions are or
will be payable by the Company or any Subsidiary to any broker, financial advisor or consultant, finder, placement agent, investment
banker, bank or other Person with respect to the transactions contemplated by the Transaction Documents. The Underwriters shall have
no obligation with respect to any fees or with respect to any claims made by or on behalf of other Persons for fees of a type contemplated
in this Section that may be due in connection with the transactions contemplated by the Transaction Documents.</FONT></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal">2.5.24.
</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Investment Company</U><FONT STYLE="font-weight: normal">.
The Company is not, and is not an Affiliate of, and immediately after receipt of payment for the Securities, will not be or be an Affiliate
of, an &ldquo;investment company&rdquo; within the meaning of the Investment Company Act of 1940, as amended. The Company shall conduct
its business in a manner so that it will not become an &ldquo;investment company&rdquo; subject to registration under the Investment
Company Act of 1940, as amended.</FONT></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 14; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --> -</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal">2.5.25.
</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Registration Rights</U><FONT STYLE="font-weight: normal">.
No Person has any right to cause the Company or any Subsidiary &lrm;to effect the registration under the Securities Act of any &lrm;securities
of the Company or any Subsidiary.</FONT></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal">2.5.26.
</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Listing and Maintenance Requirements</U><FONT STYLE="font-weight: normal">.
The Company is subject to the reporting requirements of Section 13 of the Exchange Act and files periodic reports with the SEC; the Common
Stock is registered pursuant to Section 12(b) of the Exchange Act and the Company is not in breach of any filing or other requirements
under the Exchange Act. The Company has taken no action designed to or which is likely to have the effect of terminating the registration
of its Common Stock under the Exchange Act nor has it received any notice that the Commission is contemplating terminating such registration.
The Company has not, in the 12 months preceding the date hereof, received notice from the Nasdaq to the effect that the Company is not
in compliance with the listing or maintenance requirements of the Nasdaq. The Company is, and has no reason to believe that it will not
in the foreseeable future continue to be, in compliance with all such listing and maintenance requirements, other than the minimum bid
price requirement, for continued listing on the Nasdaq. The Common Stock is currently eligible for electronic transfer through the Depository
Trust Company or another established clearing corporation and the Company is current in payment of the fees to the Depository Trust Company
(or such other established clearing corporation) in connection with such electronic transfer.</FONT></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal">2.5.27.
</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>No Integrated Offering</U><FONT STYLE="font-weight: normal">.
Neither the Company, nor any of its Affiliates, nor any Person acting on its or their behalf has, directly or indirectly, made any offers
or sales of any security or solicited any offers to buy any security, under circumstances that would cause this offering of the Securities
to be integrated with prior offerings by the Company for purposes of (i) the Securities Act, or (ii) any applicable shareholder approval
provisions of the Nasdaq.</FONT></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal">2.5.28.
</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Solvency</U><FONT STYLE="font-weight: normal">. Based
on the consolidated financial condition of the Company as of the Closing Date and each Option Closing Date (if any), after giving effect
to the receipt by the Company of the proceeds from the sale of the Securities hereunder, (i) the fair saleable value of the Company&rsquo;s
assets exceeds the amount that will be required to be paid on or in respect of the Company&rsquo;s existing debts and other liabilities
(including known contingent liabilities) as they mature, (ii) the Company&rsquo;s assets do not constitute unreasonably small capital
to carry on its business as now conducted and as proposed to be conducted including its capital needs taking into account the particular
capital requirements of the business conducted by the Company, consolidated and projected capital requirements and capital availability
thereof, and (iii) the current cash flow of the Company, together with the proceeds the Company would receive, were it to liquidate all
of its assets, after taking into account all anticipated uses of the cash, would be sufficient to pay all amounts on or in respect of
its liabilities when such amounts are required to be paid. The Company does not intend to incur debts beyond its ability to pay such
debts as they mature (taking into account the timing and amounts of cash to be payable on or in respect of its debt). The Company has
no knowledge of any facts or circumstances which lead it to believe that it will file for reorganization or liquidation under the bankruptcy
or reorganization laws of any jurisdiction within one year from the Closing Date. Neither the Company nor any Subsidiary is in default
with respect to any Indebtedness. For the purposes of this Agreement, &ldquo;</FONT>Indebtedness<FONT STYLE="font-weight: normal">&rdquo;
means (x) any liabilities for borrowed money or amounts owed by the Company in excess of $50,000 (other than trade accounts payable incurred
in the ordinary course of business), (y) all guaranties, endorsements and other contingent obligations in respect of indebtedness of
others to third parties, whether or not the same are or should be reflected in the Company&rsquo;s consolidated balance sheet (or the
notes thereto), except guaranties by endorsement of negotiable instruments for deposit or collection or similar transactions in the ordinary
course of business; and (z) the present value of any lease payments in excess of $50,000 due under leases required to be capitalized
in accordance with GAAP.</FONT></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 15; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence --> -</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal">2.5.29.
</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Tax Status</U><FONT STYLE="font-weight: normal">.
Except for matters that would not, individually or in the aggregate, have or reasonably be expected to result in a Material Adverse Effect,
the Company and its Subsidiaries each (i) has made or filed all United States federal, state and local income and all foreign tax returns,
reports and declarations required by any jurisdiction to which it is subject, (ii) has paid all taxes and other governmental assessments
and charges that are material in amount, shown or determined to be due on such returns, reports and declarations and (iii) has set aside
on its books provision reasonably adequate for the payment of all material taxes for periods subsequent to the periods to which such
returns, reports or declarations apply. There are no unpaid taxes in any material amount claimed to be due by the taxing authority of
any jurisdiction, and the officers of the Company or of any Subsidiary know of no basis for any such claim.</FONT></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal">2.5.30.
</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Foreign Corrupt Practices</U><FONT STYLE="font-weight: normal">.
Neither the Company nor any Subsidiary, nor to the knowledge of the Company or any Subsidiary, any agent or other person acting on behalf
of the Company or any Subsidiary, has (i) directly or indirectly, used any funds for unlawful contributions, gifts, entertainment or
other unlawful expenses related to foreign or domestic political activity, (ii) made any unlawful payment to foreign or domestic government
officials or employees or to any foreign or domestic political parties or campaigns from corporate funds, (iii) failed to disclose fully
any contribution made by the Company or any Subsidiary (or made by any person acting on its behalf of which the Company is aware) which
is in violation of law, or (iv) violated in any material respect any provision of FCPA.</FONT></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal">2.5.31.
</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Accountants</U><FONT STYLE="font-weight: normal">.
The Company&rsquo;s independent registered public accounting firm is as set forth in the Prospectus. To the knowledge and belief of the
Company, such accounting firm (i) is a registered public accounting firm as required by the Exchange Act and (ii) will express its opinion
with respect to the financial statements to be included in the Company&rsquo;s Annual Report on Form 10-K for the fiscal year ended December
31, 2021.</FONT></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal">2.5.32.
</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Acknowledgment Regarding Underwriters&rsquo; Purchase
of Securities</U><FONT STYLE="font-weight: normal">. The Company acknowledges and agrees that each of the Underwriters is acting solely
in the capacity of an arm&rsquo;s length purchaser with respect to the Transaction Documents and the transactions contemplated thereby.
The Company further acknowledges that no Underwriter is acting as a financial advisor or fiduciary of the Company (or in any similar
capacity) with respect to the Transaction Documents and the transactions contemplated thereby and any advice given by any Underwriter
or any of their respective representatives or agents in connection with the Transaction Documents and the transactions contemplated thereby
is merely incidental to the Underwriters&rsquo; purchase of the Securities. The Company further represents to each Underwriter that the
Company&rsquo;s decision to enter into this Agreement and the other Transaction Documents has been based solely on the independent evaluation
of the transactions contemplated hereby by the Company and its representatives.</FONT></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal">2.5.33.
</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Acknowledgment Regarding Underwriters&rsquo; Trading
Activity</U><FONT STYLE="font-weight: normal">. Anything in this Agreement or elsewhere herein to the contrary notwithstanding, it is
understood and acknowledged by the Company that: (i) none of the Underwriters has been asked by the Company to agree, nor has any Underwriter
agreed, to desist from purchasing or selling, long and/or short, securities of the Company, or &ldquo;derivative&rdquo; securities based
on securities issued by the Company or to hold the Securities for any specified term; (ii) past or future open market or other transactions
by any Underwriter, specifically including, without limitation, Short Sales or &ldquo;derivative&rdquo; transactions, before or after
the closing of this or future private placement transactions, may negatively impact the market price of the Company&rsquo;s publicly-traded
securities; (iii) any Underwriter, and counter-parties in &ldquo;derivative&rdquo; transactions to which any such Underwriter is a party,
directly or indirectly, presently may have a &ldquo;short&rdquo; position in the Common Stock, and (iv) each Underwriter shall not be
deemed to have any affiliation with or control over any arm&rsquo;s length counter-party in any &ldquo;derivative&rdquo; transaction.
The Company further understands and acknowledges that (y) one or more Underwriters may engage in hedging activities (in material compliance
with applicable laws) at various times during the period that the Securities are outstanding, and (z) such hedging activities (if any)
could reduce the value of the existing stockholders&rsquo; equity interests in the Company at and after the time that the hedging activities
are being conducted. The Company acknowledges that such aforementioned hedging activities do not constitute a breach of any of the Transaction
Documents.</FONT></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 16; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence --> -</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal">2.5.34.
</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Regulation M Compliance</U><FONT STYLE="font-weight: normal">.
The Company has not, and to its knowledge no one acting on its behalf has, (i) taken, directly or indirectly, any action designed to
cause or to result in the stabilization or manipulation of the price of any security of the Company to facilitate the sale or resale
of any of the Securities, (ii) sold, bid for, purchased, or, paid any compensation for soliciting purchases of, any of the Securities,
or (iii) paid or agreed to pay to any Person any compensation for soliciting another to purchase any other securities of the Company,
other than, in the case of <U>clauses (ii)</U> and <U>(iii)</U>, compensation paid to A.G.P.</FONT></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal">2.5.35.
</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Office of Foreign Assets Control</U><FONT STYLE="font-weight: normal">.
Neither the Company nor any Subsidiary nor, to the Company&rsquo;s knowledge, any director, officer, agent, employee or affiliate of
the Company or any Subsidiary is currently subject to any &ldquo;Sanctions,&rdquo; which shall include but are not limited to any U.S.
sanctions administered by the Office of Foreign Assets Control of the U.S. Treasury Department (&ldquo;</FONT>OFAC<FONT STYLE="font-weight: normal">&rdquo;)
and the Company will not, directly or indirectly, use the proceeds of this offering, or lend, contribute or otherwise make available
such proceeds to any subsidiary, joint venture partner or other person or entity, for the purpose of financing the activities of any
person currently subject to any Sanctions, including but not limited to U.S. sanctions administered by OFAC.</FONT></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal">2.5.36.
</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Stock Option Plans</U><FONT STYLE="font-weight: normal">.
Each stock option granted by the Company under the Company&rsquo;s stock option plan or omnibus long-term incentive plan was granted
(i) in accordance with the terms of such plan and (ii) with an exercise price at least equal to the fair market value of the Common Stock
on the date such stock option would be considered granted under GAAP and applicable law. No stock option granted under the Company&rsquo;s
stock option plan or omnibus long-term incentive plan has been backdated. The Company has not knowingly granted, and there is no and
has been no Company policy or practice to knowingly grant, stock options prior to, or otherwise knowingly coordinate the grant of stock
options with, the release or other public announcement of material information regarding the Company or the Subsidiaries or their financial
results or prospects.</FONT></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal">2.5.37.
</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>U.S. Real Property Holding Corporation</U><FONT STYLE="font-weight: normal">.
The Company is not and has never been a United States real property holding corporation within the meaning of Section 897 of the Code,
and the Company shall so certify upon any Underwriter&rsquo;s request.</FONT></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal">2.5.38.
</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Bank Holding Company Act</U><FONT STYLE="font-weight: normal">.
Neither the Company nor any of its Subsidiaries or Affiliates is subject to the Bank Holding Company Act of 1956, as amended (the &ldquo;BHCA&rdquo;)
and to regulation by the Board of Governors of the Federal Reserve System (the &ldquo;</FONT>Federal Reserve<FONT STYLE="font-weight: normal">&rdquo;).
Neither the Company nor any of its Subsidiaries or Affiliates owns or controls, directly or indirectly, five percent (5%) or more of
the outstanding shares of any class of voting securities or twenty-five percent (25%) or more of the total equity of a bank or any entity
that is subject to the BHCA and to regulation by the Federal Reserve. Neither the Company nor any of its Subsidiaries or Affiliates exercises
a controlling influence over the management or policies of a bank or any entity that is subject to the BHCA and to regulation by the
Federal Reserve.</FONT></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal">2.5.39.
</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Money Laundering</U><FONT STYLE="font-weight: normal">.
The operations of the Company and its Subsidiaries are and have been conducted at all times in compliance with applicable financial record-keeping
and reporting requirements of the Currency and Foreign Transactions Reporting Act of 1970, as amended, applicable money laundering statutes
and applicable rules and regulations thereunder (collectively, the &ldquo;Money Laundering Laws&rdquo;), and no action, suit or proceeding
by or before any court or governmental agency, authority or body or any arbitrator involving the Company or any Subsidiary with respect
to the Money Laundering Laws is pending or, to the knowledge of the Company or any Subsidiary, threatened.</FONT></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 17; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->16<!-- Field: /Sequence --> -</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal">2.5.40.
</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Information Technology</U><FONT STYLE="font-weight: normal">.
The Company&rsquo;s and the Subsidiaries&rsquo; information technology assets and equipment, computers, systems, networks, hardware,
software, websites, applications, and databases (collectively, &ldquo;</FONT>IT Systems<FONT STYLE="font-weight: normal">&rdquo;) operate
and perform in all material respects as required in connection with the operation of the business of the Company and the Subsidiaries
as currently conducted. The Company and the Subsidiaries maintain commercially reasonable controls, policies, procedures, and safeguards
to maintain and protect their material confidential information and the integrity, continuous operation, redundancy and security of all
IT Systems and all personal, personally identifiable, sensitive, confidential or regulated data (&ldquo;</FONT>Personal Data<FONT STYLE="font-weight: normal">&rdquo;)
processed and stored thereon, and to the knowledge of the Company, there have been no breaches, incidents, violations, outages, compromises
or unauthorized uses of or accesses to same, except for those that have been remedied without material cost or liability or the duty
to notify any other person, nor any incidents under internal review or investigations relating to the same. The Company and the Subsidiaries
are presently in compliance in all material respects with all applicable laws or statutes and all applicable judgments, orders, rules
and regulations of any court or arbitrator or governmental or regulatory authority, internal policies and contractual obligations relating
to the privacy and security of IT Systems and Personal Data and to the protection of such IT Systems and Personal Data from unauthorized
use, access, misappropriation or modification, except for any such noncompliance that would not have a Material Adverse Effect.</FONT></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal">2.5.41.
</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Other Covered Persons</U><FONT STYLE="font-weight: normal">.
Other than A.G.P., the Company is not aware of any person that has been or will be paid (directly or indirectly) remuneration for solicitation
of purchasers in connection with the sale of any Securities.</FONT></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal">2.5.42.
</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Regulatory</U><FONT STYLE="font-weight: normal">.
Except as described in the Registration Statement, the Pricing Disclosure Package and the Prospectus, as applicable, the Company and
its Subsidiaries (i) have not received any notice from any court or arbitrator or governmental or regulatory authority or third party
alleging or asserting noncompliance with any laws or any licenses, exemptions, certificates, approvals, clearances, authorizations, permits,
registrations and supplements or amendments thereto required to conduct the Company&rsquo;s business as presently conducted (&ldquo;</FONT>Authorizations<FONT STYLE="font-weight: normal">&rdquo;);
(ii) possess all material Authorizations and such Authorizations are valid and in full force and effect and are not in violation of any
term of any such Authorizations; (iii) have not received any written notice that any court or arbitrator or governmental or regulatory
authority has taken, is taking or intends to take, action to limit, suspend, materially modify or revoke any Authorizations nor is any
such limitation, suspension, modification or revocation threatened; (iv) have filed, obtained, maintained or submitted all material reports,
documents, forms, notices, applications, records, claims, submissions and supplements or amendments as required by any Authorizations
and that all such reports, documents, forms, notices, applications, records, claims, submissions and supplements or amendments were complete
and accurate on the date filed (or were corrected or supplemented by a subsequent submission); and (v) are not a party to any corporate
integrity agreements, monitoring agreements, consent decrees, settlement orders, or similar agreements with or imposed by any governmental
or regulatory authority, except in the case of each of <U>clauses (i)</U> through <U>(v)</U>, such as could not have or reasonably be
expected to result in a Material Adverse Effect.</FONT></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal">2.5.43.
</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Health Care Authorizations</U><FONT STYLE="font-weight: normal">.
The Company has submitted and possesses, or qualifies for applicable exemptions to, such valid and current registrations, listings, approvals,
licenses, certificates, authorizations or permits and supplements or amendments thereto (collectively, &ldquo;</FONT>Health Care Authorizations<FONT STYLE="font-weight: normal">&rdquo;)
issued or required by the appropriate local, state, federal, national, supranational or other foreign regulatory agencies or bodies (collectively,
&ldquo;</FONT>Health Regulatory Agencies<FONT STYLE="font-weight: normal">&rdquo;) necessary to conduct its business as described in
the SEC Reports, including, without limitation, all such Health Care Authorizations required by the FDA, the Drug Enforcement Administration
as required for research involving Schedule 1 controlled substances, the Department of Health and Human Services, the European Commission,
the EMA or any other Health Regulatory Agencies as may be required. The information and data submitted on any Health Care Authorization
application or submission was true and complete in all material respects as of the date of submission. The Company has not received any
notice of proceedings, or have any knowledge of any threatened proceedings, relating to the revocation or modification of, or non-compliance
with, any such Health Care Authorization, except where such revocation, modification or non-compliance would not result in a Material
Adverse Effect.</FONT></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 18; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->17<!-- Field: /Sequence --> -</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal">2.5.44.
</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Compliance with Health Care Laws</U><FONT STYLE="font-weight: normal">.
The Company is, and has been, in compliance with all applicable Health Care Laws, and has not engaged in activities which are, as applicable,
cause for false claims liability or civil penalties, except where such noncompliance, false claims liability or civil penalties would
not reasonably be expected to, singly or in the aggregate, result in a Material Adverse Effect. For purposes of this Agreement, &ldquo;</FONT>Health
Care Laws<FONT STYLE="font-weight: normal">&rdquo; means all health care laws applicable to the Company, including, but not limited to:
the Federal Food, Drug, and Cosmetic Act (21 U.S.C. Section 301 et seq.), the Anti-Kickback Statute (42 U.S.C. Section 1320a-7b(b)),
the Civil Monetary Penalties Law (42 U.S.C. &sect; 1320a-7a), the Civil False Claims Act (31 U.S.C. Section 3729 et seq.), the criminal
False Claims Law (42 U.S.C. &sect; 1320a-7b(a)), all criminal laws relating to health care fraud and abuse, including but not limited
to 18 U.S.C. Sections 286 and 287, and the health care fraud criminal provisions under the U.S. Health Insurance Portability and Accountability
Act of 1996 (&ldquo;</FONT>HIPAA<FONT STYLE="font-weight: normal">&rdquo;) (42 U.S.C. Section 1320d et seq.), the exclusion laws (42
U.S.C. &sect; 1320a-7), Basic Health and Human Services Policy for Protection of Human Research Subjects &ldquo;Common Rule&rdquo; as
codified and enforced by the Department of Health and Human Services in 45 C.F.R. part 46 and enforced by FDA under 21 C.F.R. part 50,
Laboratory Animal Welfare Act of 1966, HIPAA, as amended by the Health Information Technology for Economic and Clinical Health Act (42
U.S.C. Section 17921 et seq.) any and all other applicable comparable local, state, federal, national, supranational and foreign health
care laws and the regulations promulgated pursuant to such laws, each as amended from time to time; for the avoidance of doubt Health
Care Laws excludes any U.S. federal laws, statutes, codes, ordinances, decrees, rules or regulations which apply to the production, trafficking,
distribution, processing, extraction, sale and/or possession of cannabis, marijuana, psilocybin or related substances, products or synthetic
compounds containing or related to same, including, but not limited to, the prohibition on drug trafficking under 21 U.S.C. &sect;841(a).
The Company has not received written notice of any claim, action, suit, proceeding, hearing, enforcement, investigation, arbitration
or other action from any court or arbitrator or governmental or regulatory authority or third party alleging that any product operation
or activity is in material violation of any Health Care Laws, and, to the knowledge of the Company, no such claim, action, suit, proceeding,
hearing, enforcement, investigation, arbitration or other action is threatened. The Company has not received any written notice of adverse
filing, warning letter, untitled letter or other correspondence or notice from the FDA, the European Commission, the EMA or any other
Health Regulatory Agencies, or any other court or arbitrator, alleging or asserting material noncompliance with the Health Care Laws.
The Company is not a party to and has no ongoing reporting obligations pursuant to any corporate integrity agreements, deferred prosecution
agreements, monitoring agreements, consent decrees, settlement orders, plans of correction or similar agreements with or imposed by any
governmental or regulatory authority. Additionally, neither the Company, nor, to the knowledge of the Company, any of its employees,
officers or directors has been excluded, suspended or debarred from participation in any U.S. federal health care program or human research
study or trial or, to the knowledge of the Company, is subject to a governmental inquiry, investigation, proceeding, or other similar
action that could reasonably be expected to result in debarment, suspension or exclusion.</FONT></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 19; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->18<!-- Field: /Sequence --> -</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal">2.5.45.
</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Research Studies and Trials</U><FONT STYLE="font-weight: normal">.
(A) The research studies and trials conducted by or, to the Company&rsquo;s knowledge, on behalf of, or sponsored by, the Company, or
in which the Company has participated, that are described in the Registration Statement, the Pricing Disclosure Package or the Prospectus,
or the results of which are referred to in the Registration Statement, the Pricing Disclosure Package or the Prospectus, as applicable,
were and, if still pending, are being, conducted in all material respects in accordance with applicable Health Care Authorizations, experimental
protocols, procedures and controls pursuant to, where applicable, accepted professional and scientific standards for products or product
candidates comparable to those being developed by the Company and all applicable statutes, rules and regulations of the FDA, National
Institute of Health Department of Health and Human Services, the European Commission, the EMA and any other Health Regulatory Agencies
to which it is subject; (B) the descriptions of the results of such studies and trials contained in the Registration Statement, the Pricing
Disclosure Package and the Prospectus do not contain any misstatement of a material fact or omit to state a material fact necessary to
make such statements not misleading; (C) the Company has no knowledge of any research studies or trials not described in the Registration
Statement, the Pricing Disclosure Package and the Prospectus the results of which reasonably call into question in any material respect
the results of the research studies and trials described in the Registration Statement, the Pricing Disclosure Package and the Prospectus;
(D) the Company has not received any notices or correspondence from the FDA, the European Commission, the EMA or any Health Regulatory
Agency or any institutional review board or comparable authority requiring or threatening the premature termination, suspension, material
modification or clinical hold of any research studies or trials conducted by or on behalf of, or sponsored by, the Company or in which
the Company has participated that are described in the Registration Statement, the Pricing Disclosure Package or the Prospectus, and,
to the Company&rsquo;s knowledge, there are no reasonable grounds for the same; (E) there has not been any violation of applicable law
or regulation by the Company in any of its product development efforts, submissions or reports to the FDA, the European Commission, the
EMA or any other Health Regulatory Agency that could reasonably be expected to require investigation, corrective action or result in
enforcement action, except where such violation would not, singly or in the aggregate, result in a Material Adverse Effect; and (F) the
research studies and clinical trials of Company are being conducted in an ethical and humane manner under state, national or supra-national
applicable laws that are either equal or more stringent than applicable laws and regulations enforced by the Department of Health and
Human Services and FDA governing human, animal or non-human primate research participants and test subjects and such studies and the
clinical trials are conducted under the auspices of a neutral and independent Institutional Animal Care and Use Committee or Institutional
Review Board and applicable state, national, or supra national agencies responsible for oversight.</FONT></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal">2.5.46.
</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Health Care Products Purchase, Development and Manufacturing</U><FONT STYLE="font-weight: normal">.
The development, purchasing and manufacture of the Company&rsquo;s products and active pharmaceutical ingredients by or, to the knowledge
of the Company, on behalf of the Company is being conducted in compliance with all applicable Health Care Laws or other Health Regulatory
Agencies. Except as disclosed in the Registration Statement, the Pricing Disclosure Package and the Prospectus, the Company has not had
any manufacturing site (whether owned by the Company or, to the knowledge of the Company, that of a third party manufacturer for the
Company&rsquo;s products) subject to an FDA, European Commission, EMA, TGA or other Health Regulatory Agency shutdown or import or export
prohibition, nor received any FDA, European Commission, EMA or other Health Regulatory Agency &ldquo;warning letters,&rdquo; or &ldquo;untitled
letters&rdquo; alleging or asserting material noncompliance with any applicable Health Care Laws, requests to make material changes to
the Company&rsquo;s products, processes or operations, or similar correspondence or notice from the FDA, the European Commission, the
EMA or other Health Regulatory Agency alleging or asserting material noncompliance with any applicable Health Care Laws, other than those
that have been satisfactorily addressed and/or closed with the FDA, the European Commission, the EMA or other Health Regulatory Agency.
To the knowledge of the Company, none of the FDA, the European Commission, the EMA or any other Health Regulatory Agency is considering
such action.</FONT></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal">2.5.47.
</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Dividend Restrictions</U><FONT STYLE="font-weight: normal">.
Except as described in the Registration Statement, the Pricing Disclosure Package and the Prospectus, no Subsidiary of the Company is
prohibited or restricted, directly or indirectly, from paying dividends to the Company, or from making any other distribution with respect
to such Subsidiary&rsquo;s equity securities or from repaying to the Company or any other Subsidiary of the Company any amounts that
may from time to time become due under any loans or advances to such Subsidiary from the Company or from transferring any property or
assets to the Company or to any other Subsidiary.</FONT></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 20; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->19<!-- Field: /Sequence --> -</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal">3.
</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Covenants of the Company</U><FONT STYLE="font-weight: normal">.
The Company covenants and agrees as follows:</FONT></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-weight: normal">3.1
</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal"><U>Amendments to Registration Statement</U><FONT STYLE="font-weight: normal">.
The Company shall deliver to the Representative, prior to filing, any amendment or supplement to the Registration Statement or the Prospectus
proposed to be filed after the date of this Agreement and not file any such amendment or supplement to which the Representative shall
reasonably object in writing.</FONT></FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-weight: normal">3.2
</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal"><U>Federal Securities Laws</U><FONT STYLE="font-weight: normal">.</FONT></FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal">3.2.1.
</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Compliance</U>. <FONT STYLE="font-weight: normal">The
Company, subject to <U>Section 3.2.2</U>, shall comply with the requirements of Rule 424(b) and Rule 430B, and will notify the Representative
promptly, and confirm the notice in writing, (i) when any post-effective amendment to the Registration Statement or any amendment or
supplement to any Preliminary Prospectus, the Pricing Disclosure Package or the Prospectus shall have been filed and when any post-effective
amendment to the Registration Statement shall become effective; (ii) of the receipt of any comments from the Commission; (iii) of any
request by the Commission for any amendment to the Registration Statement or any amendment or supplement to any Preliminary Prospectus,
the Pricing Disclosure Package or the Prospectus, including any document incorporated or deemed to be incorporated by reference therein,
or for additional information; (iv) of the issuance by the Commission of any stop order suspending the effectiveness of the Registration
Statement or any post-effective amendment or of any order preventing or suspending the use of any Preliminary Prospectus or the Prospectus,
or of the suspension of the qualification of the Securities for offering or sale in any jurisdiction, or of the initiation or, to the
Company&rsquo;s knowledge, threatening of any proceedings for any of such purposes or of any examination pursuant to Section 8(d) or
8(e) of the Securities Act concerning the Registration Statement and (v) if the Company becomes the subject of a proceeding under Section
8A of the Securities Act in connection with the Offering of the Securities. The Company shall effect all filings required under Rule
424(b) of the Securities Act Regulations, in the manner and within the time period required by Rule 424(b) (without reliance on Rule
424(b)(8)), and shall take such steps as it deems necessary to ascertain promptly whether the form of prospectus transmitted for filing
under Rule 424(b) was received for filing by the Commission and, in the event that it was not, it will promptly file such prospectus.
The Company shall use its best efforts to prevent the issuance of any stop order, prevention or suspension and, if any such order is
issued, to obtain the lifting thereof at the earliest possible moment.</FONT></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal">3.2.2.
</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Continued Compliance</U><FONT STYLE="font-weight: normal">.
The Company shall comply with the Securities Act, the Securities Act Regulations, the Exchange Act and the Exchange Act Regulations so
as to permit the completion of the distribution of the Securities as contemplated in this Agreement and in the Registration Statement,
the Pricing Disclosure Package and the Prospectus. If at any time when a prospectus relating to the Securities is (or, but for the exception
afforded by Rule 172 of the Securities Act Regulations (&ldquo;</FONT>Rule 172<FONT STYLE="font-weight: normal">&rdquo;), would be) required
by the Securities Act to be delivered in connection with sales of the Securities, any event shall occur or condition shall exist as a
result of which it is necessary, in the opinion of counsel for the Underwriters or for the Company, to (i) amend the Registration Statement
in order that the Registration Statement will not include an untrue statement of a material fact or omit to state a material fact required
to be stated therein or necessary to make the statements therein not misleading; (ii) amend or supplement the Pricing Disclosure Package
or the Prospectus in order that the Pricing Disclosure Package or the Prospectus, as the case may be, will not include any untrue statement
of a material fact or omit to state a material fact necessary in order to make the statements therein not misleading in the light of
the circumstances existing at the time it is delivered to a purchaser or (iii) amend the Registration Statement or amend or supplement
the Pricing Disclosure Package or the Prospectus, as the case may be, in order to comply with the requirements of the Securities Act
or the Securities Act Regulations, the Company will promptly (A) give the Representative notice of such event; (B) prepare any amendment
or supplement as may be necessary to correct such statement or omission or to make the Registration Statement, the Pricing Disclosure
Package or the Prospectus comply with such requirements and, a reasonable amount of time prior to any proposed filing or use, furnish
the Representative with copies of any such amendment or supplement and (C) file with the Commission any such amendment or supplement;
provided that the Company shall not file or use any such amendment or supplement to which the Representative or counsel for the Underwriters
shall reasonably object. The Company will furnish to the Underwriters such number of copies of such amendment or supplement as the Underwriters
may reasonably request. The Company has given the Representative notice of any filings made pursuant to the Exchange Act or the Exchange
Act Regulations within 48 hours prior to the Applicable Time. The Company shall give the Representative notice of its intention to make
any such filing from the Applicable Time until the later of the Closing Date and the exercise in full or expiration of the Over-allotment
Option specified in <U>Section 1.2</U> and will furnish the Representative with copies of the related document(s) a reasonable amount
of time prior to such proposed filing, as the case may be, and will not file or use any such document to which the Representative or
counsel for the Underwriters shall reasonably object.</FONT></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 21; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->20<!-- Field: /Sequence --> -</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-weight: normal">3.3
</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal"><U>Delivery to the Underwriters
of Registration Statements</U><FONT STYLE="font-weight: normal">. The Company has delivered or made available or shall deliver or make
available to the Representative and counsel for the Representative, without charge, signed copies of the Registration Statement as originally
filed and each amendment thereto (including exhibits filed therewith or incorporated by reference therein and documents incorporated
or deemed to be incorporated by reference therein) and signed copies of all consents and certificates of experts, and will also deliver
to the Underwriters, without charge, a conformed copy of the Registration Statement as originally filed and each amendment thereto (without
exhibits) for each of the Underwriters. The copies of the Registration Statement and each amendment thereto furnished to the Underwriters
will be identical to the electronically transmitted copies thereof filed with the Commission pursuant to EDGAR, except to the extent
permitted by Regulation S-T.</FONT></FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-weight: normal">3.4
</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal"><U>Delivery to the Underwriters
of Prospectuses</U><FONT STYLE="font-weight: normal">. The Company has delivered or made available or will deliver or make available
to each Underwriter, without charge, as many copies of each Preliminary Prospectus as such Underwriter reasonably requested, and the
Company hereby consents to the use of such copies for purposes permitted by the Securities Act. The Company will furnish to each Underwriter,
without charge, during the period when a prospectus relating to the Securities is (or, but for the exception afforded by Rule 172, would
be) required to be delivered under the Securities Act, such number of copies of the Prospectus (as amended or supplemented) as such Underwriter
may reasonably request. The Prospectus and any amendments or supplements thereto furnished to the Underwriters will be identical to the
electronically transmitted copies thereof filed with the Commission pursuant to EDGAR, except to the extent permitted by Regulation S-T.</FONT></FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-weight: normal">3.5
</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal"><U>Events Requiring Notice to the
Representative</U><FONT STYLE="font-weight: normal">. The Company shall use its best efforts to cause the Registration Statement to remain
effective with a current prospectus for at least nine (9) months after the Applicable Time, and shall notify the Representative immediately
and confirm the notice in writing: (i) of the issuance by the Commission of any stop order or of the initiation, or the threatening,
of any proceeding for that purpose; (ii) of the issuance by any state securities commission of any proceedings for the suspension of
the qualification of the Securities for offering or sale in any jurisdiction or of the initiation, or the threatening, of any proceeding
for that purpose; (iii) of the mailing and delivery to the Commission for filing of any amendment or supplement to the Registration Statement
or Prospectus; (iv) of the receipt of any comments or request for any additional information from the Commission; and (v) of the happening
of any event during the period described in this <U>Section 3.5</U> that, in the judgment of the Company, makes any statement of a material
fact made in the Registration Statement, the Pricing Disclosure Package or the Prospectus untrue or that requires the making of any changes
in (a) the Registration Statement in order to make the statements therein not misleading, or (b) in the Pricing Disclosure Package or
the Prospectus in order to make the statements therein, in light of the circumstances under which they were made, not misleading. If
the Commission or any state securities commission shall enter a stop order or suspend such qualification at any time, the Company shall
make every reasonable effort to obtain promptly the lifting of such order.</FONT></FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 22; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->21<!-- Field: /Sequence --> -</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>&nbsp;</I></FONT></P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-weight: normal">3.6
</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal"><U>[Reserved].</U></FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-weight: normal">3.7
</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal"><U>Free Writing Prospectuses</U><FONT STYLE="font-weight: normal">.
The Company agrees that, unless it obtains the prior written consent of the Representative, it shall not make any offer relating to the
Securities that would constitute an Issuer Free Writing Prospectus or that would otherwise constitute a &ldquo;free writing prospectus,&rdquo;
or a portion thereof, required to be filed by the Company with the Commission or retained by the Company under Rule 433; <U>provided</U>,
<U>however</U>, that the Representative shall be deemed to have consented to each Issuer General Use Free Writing Prospectus hereto and
any &ldquo;road show that is a written communication&rdquo; within the meaning of Rule 433(d)(8)(i) that has been reviewed by the Representative.
The Company represents that it has treated or agrees that it will treat each such free writing prospectus consented to, or deemed consented
to, by the Underwriters as an &ldquo;issuer free writing prospectus,&rdquo; as defined in Rule 433, and that it has complied and will
comply with the applicable requirements of Rule 433 with respect thereto, including timely filing with the Commission where required,
legending and record keeping. If at any time following issuance of an Issuer Free Writing Prospectus there occurred or occurs an event
or development as a result of which such Issuer Free Writing Prospectus conflicted or would conflict with the information contained in
the Registration Statement or included or would include an untrue statement of a material fact or omitted or would omit to state a material
fact necessary in order to make the statements therein, in the light of the circumstances existing at that subsequent time, not misleading,
the Company will promptly notify the Underwriters and will promptly amend or supplement, at its own expense, such Issuer Free Writing
Prospectus to eliminate or correct such conflict, untrue statement or omission.</FONT></FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-weight: normal">3.8
</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal"><U>[Reserved].</U></FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-weight: normal">3.9
</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal"><U>Reports to the Representative</U><FONT STYLE="font-weight: normal">.</FONT></FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-weight: normal; text-underline-style: double">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal">3.9.1.
</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Periodic Reports, etc</U><FONT STYLE="font-weight: normal">.
For a period of one (1) year after the date of this Agreement, the Company shall furnish to the Representative copies of such financial
statements and other periodic and special reports as the Company from time to time furnishes generally to holders of any class of its
securities and also promptly furnish to the Representative: (i) a copy of each periodic report the Company shall be required to file
with the Commission under the Exchange Act and the Exchange Act Regulations; (ii) a copy of every press release and every news item and
article with respect to the Company or its affairs which was released by the Company; (iii) a copy of each Form 8-K prepared and filed
by the Company; (iv) five copies of each registration statement filed by the Company under the Securities Act; and (v) such additional
documents and information with respect to the Company and the affairs of any future subsidiaries of the Company as the Representative
may from time to time reasonably request; provided the Representative shall sign, if requested by the Company, a Regulation FD compliant
confidentiality agreement which is reasonably acceptable to the Representative and Representative Counsel in connection with the Representative&rsquo;s
receipt of such information. Documents filed with the Commission pursuant to its EDGAR system shall be deemed to have been delivered
to the Representative pursuant to this <U>Section 3.9.1</U>.</FONT></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal; text-underline-style: double">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal">3.9.2.
</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Transfer Agent</U><FONT STYLE="font-weight: normal">.
The Company shall engage and maintain, at its expense, a registrar and transfer agent for the Common Stock.</FONT></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 23; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->22<!-- Field: /Sequence --> -</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-weight: normal">3.10
</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal"><U>Payment of Expenses</U><FONT STYLE="font-weight: normal">.
The Company agrees to pay on the Closing Date and each Option Closing Date (if any), all expenses incident to the performance of the
obligations of the Company under this Agreement, including but not limited to (a) all filing fees and communication expenses relating
to the registration of the Securities with the Commission; (b) all Public Filing System filing fees associated with the review of the
Offering by FINRA; (c) all fees and expenses relating to the listing of such Securities on the Exchange and on such other stock exchanges
as the Company and Representative together determine; (d) all fees, expenses and disbursements relating to the registration or qualification
of the Securities offered under the &ldquo;blue sky&rdquo; securities laws of such states and other jurisdictions as the Representative
may reasonably designate (including, without limitation, all filing and registration fees, and the reasonable fees of &ldquo;blue sky&rdquo;
counsel); (e) all fees, expenses and disbursements relating to the registration, qualification or exemption of the Securities under the
securities laws of such foreign jurisdictions as the Representative may reasonably designate; (f) the costs of all mailing and printing
of the underwriting documents (including, without limitation, this Agreement, any Blue Sky Surveys and, if appropriate, any Agreement
Among Underwriters, Selected Dealers&rsquo; Agreement, Underwriters&rsquo; Questionnaire and Power of Attorney), registration statements,
Prospectuses and all amendments, supplements and exhibits thereto and as many preliminary and final Prospectuses as the Representative
may reasonably deem necessary; (g) the costs and expenses of its public relations firm; (h) the costs of preparing, printing and delivering
certificates representing the Securities to be offered in this offering; (i) fees and expenses of the transfer agent for the applicable
Securities; (j) stock transfer and/or stamp taxes, if any, payable upon the transfer of the Securities from the Company to the Representative;
(k) the fees and expenses of the Company&rsquo;s accountant; (l) the fees and expenses of the Company&rsquo;s legal counsel and other
agents and representatives; and (m) $75,000 incurred by the Underwriters for legal fees of counsel to the Underwriters, in aggregate
(including any legal fees incurred in connection with clauses (b), (d) and (e) of this <U>Section 3.10</U>). Notwithstanding the foregoing,
any advance received by the Underwriters will be reimbursed to the Company to the extent not actually incurred in compliance with FINRA
Rule 5110(f)(2)(C). In the event that this Agreement shall not be carried out for any reason whatsoever, except in the case of a default
by the Underwriters, pursuant to Section 6.2 below, within the time specified herein or any extensions thereof pursuant to the terms
herein, the Company shall be obligated to pay to the Underwriters their actual and accountable out-of-pocket expenses related to the
transactions contemplated herein then due and payable (including the fees and disbursements of Representative Counsel) up to $75,000
and upon demand the Company shall pay the full amount thereof to the Underwriters; <U>provided</U>, <U>however</U>, that such expense
cap in no way limits or impairs the indemnification and contribution provisions of this Agreement. The Representative may deduct from
the net proceeds of the Offering payable to the Company on the Closing Date, or the Option Closing Date (if any), the expenses set forth
herein to be paid by the Company to the Underwriters.</FONT></FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-weight: normal">3.11
</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal"><U>Application of Net Proceeds</U><FONT STYLE="font-weight: normal">.
The Company shall use the net proceeds from the sale of the Securities hereunder for working capital and to fund other general corporate
purposes and shall not use such proceeds: (a) for the satisfaction of any portion of the Company&rsquo;s debt (other than payment of
trade payables in the ordinary course of the Company&rsquo;s business and prior practices), (b) for the redemption of any Common Stock
or Common Stock Equivalents, (c) for the settlement of any outstanding litigation or (d) in violation of FCPA or OFAC regulations.</FONT></FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-weight: normal; text-underline-style: double">&nbsp;</FONT></P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-weight: normal">3.12
</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal"><U>Delivery of Earnings Statements
to Security Holders</U><FONT STYLE="font-weight: normal">. The Company shall make generally available to its security holders as soon
as practicable, but not later than the first day of the fifteenth (15<SUP>th</SUP>) full calendar month following the date of this Agreement,
an earnings statement (which need not be certified by independent registered public accounting firm unless required by the Securities
Act or the Securities Act Regulations, but which shall satisfy the provisions of Rule 158(a) under Section 11(a) of the Securities Act)
covering a period of at least twelve (12) consecutive months beginning after the date of this Agreement.</FONT></FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-weight: normal; text-underline-style: double">&nbsp;</FONT></P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-weight: normal">3.13
</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal"><U>Stabilization</U><FONT STYLE="font-weight: normal">.
The Company (without the consent of the Representative) shall not take, directly or indirectly, any action designed to or that has constituted
or that might reasonably be expected to cause or result in, under Regulation M of the Exchange Act, or otherwise, stabilization or manipulation
of the price of any security of the Company to facilitate the sale or resale of the Securities, other than payment of compensation to
A.G.P. (to the extent applicable).</FONT></FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-weight: normal; text-underline-style: double">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 24; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->23<!-- Field: /Sequence --> -</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-underline-style: double">&nbsp;</FONT></P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-weight: normal">3.14
</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal"><U>Internal Controls</U><FONT STYLE="font-weight: normal">.
Until the earlier of (i) the date that is the third anniversary of the Closing Date or (ii) the date as of which none of the Firm Warrants
sold and purchased pursuant to this Agreement are exercisable, the Company shall maintain a system of internal accounting controls: (1)
to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external
purposes in accordance with generally accepted accounting principles, (2) that pertain to the maintenance of records that in reasonable
detail accurately and fairly reflect the transactions and dispositions of the assets of the Company, (3) that provide reasonable assurance
that transactions are recorded as necessary to permit preparation of financial statements in accordance with generally accepted accounting
principles, and that receipts and expenditures of the Company are being made only in accordance with authorizations of management and
directors of the Company; and (4) that provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition,
use or disposition of the Company&rsquo;s assets that could have a material effect on the financial statements.</FONT></FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-weight: normal">3.15
</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal"><U>Accountants</U><FONT STYLE="font-weight: normal">.
Until the earlier of (i) the date that is the third anniversary of the Closing Date or (ii) the date as of which none of the Firm Warrants
sold and purchased pursuant to this Agreement are exercisable, the Company shall continue to retain a nationally recognized independent
registered public accounting firm for a period of at least three (3) years after the date of this Agreement. The Representative acknowledges
that Friedman LLP is acceptable to the Representative.</FONT></FONT></P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-underline-style: double">&nbsp;</FONT></P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-weight: normal">3.16
</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal"><U>FINRA</U><FONT STYLE="font-weight: normal">.
The Company shall advise the Representative (who shall make an appropriate filing with FINRA) if, prior to the Closing Date, it becomes
aware that the Company or any of its affiliates (within the meaning of FINRA&rsquo;s Conduct Rule 5121(f)(1)) directly or indirectly
controls, is controlled by, or is under common control with, or is an associated person (within the meaning of Article I, Section 1(ee)
of the By-laws of FINRA) of, any member firm of FINRA.</FONT></FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-weight: normal; text-underline-style: double">&nbsp;</FONT></P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-weight: normal">3.17
</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal"><U>No Fiduciary Duties</U><FONT STYLE="font-weight: normal">.
The Company acknowledges and agrees that the Underwriters&rsquo; responsibility to the Company is solely contractual in nature and that
none of the Underwriters or their affiliates or any selling agent shall be deemed to be acting in a fiduciary capacity, or otherwise
owes any fiduciary duty to the Company or any of its affiliates in connection with the Offering and the other transactions contemplated
by this Agreement.</FONT></FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-weight: normal; text-underline-style: double">&nbsp;</FONT></P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-weight: normal">3.18
</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal"><U>Company Lock-Up Agreements</U><FONT STYLE="font-weight: normal">.
The Company, on behalf of itself and any successor entity, agrees that, without the prior written consent of the Representative, it will
not, for a period of 90 days after the date of this Agreement, (i) offer, pledge, sell, contract to sell, sell any option or contract
to purchase, purchase any option or contract to sell, grant any option, right or warrant to purchase, lend, or otherwise transfer or
dispose of, directly or indirectly, any shares of capital stock of the Company or any securities convertible into or exercisable or exchangeable
for shares of capital stock of the Company; (ii) file or cause to be filed any registration statement with the Commission relating to
the offering of any shares of capital stock of the Company or any securities convertible into or exercisable or exchangeable for shares
of capital stock of the Company; or (iii) enter into any swap or other arrangement that transfers to another, in whole or in part, any
of the economic consequences of ownership of capital stock of the Company, whether any such transaction described in <U>clause (i)</U>,
<U>(ii)</U> or <U>(iii)</U> above is to be settled by delivery of shares of capital stock of the Company or such other securities, in
cash or otherwise.</FONT></FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-weight: normal">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 25; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->24<!-- Field: /Sequence --> -</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-weight: normal">The
restrictions contained in this <U>Section 3.18</U> shall not apply to (i) the shares of Common Stock, the Firm Warrants, the Option Warrants
or the Warrant Shares to be sold hereunder, (ii) the issuance of shares of Common Stock, options or other security-based compensation
to employees, officers, directors, consultants or advisors of the Company pursuant to any stock option plan, omnibus long-term incentive
plan or similar arrangement duly adopted for such purpose, by a majority of the non-employee members of the Board of Directors, or a
majority of the members of a committee of non-employee directors established for such purpose; <U>provided</U>, that any issuance of
securities to consultants or advisors pursuant to <U>clause (ii)</U> above that are not issued pursuant to a Form S-8 shall be issued
as &ldquo;restricted securities&rdquo; (as defined in Rule 144) and carry no registration rights that require or permit the filing of
any registration statement in connection therewith during the 90 day period following the Closing Date; (iii) securities issued upon
the exercise, exchange of or conversion of any Securities issued hereunder and/or securities exercisable or exchangeable for or convertible
into shares of Common Stock issued and outstanding on the date of this Agreement, provided that such securities have not been amended
since the date of this Agreement to increase the number of such securities or to decrease the exercise price, exchange price or conversion
price of such securities (other than in connection with stock splits or combinations) or to extend the term of such securities; (iv)
securities issued pursuant to acquisitions or strategic transactions, provided that such securities shall be issued as &ldquo;restricted
securities&rdquo; (as defined in Rule 144) and carry no registration rights that require or permit the filing of any registration statement
in connection therewith during the 90 day period following the Closing Date, and provided further that any such issuance shall only be
to a Person (or to the equityholders of a Person) which is, itself or through its subsidiaries, an operating company or an owner of an
asset in a business synergistic with the business of the Company and shall provide to the Company additional benefits in addition to
the investment of funds, but shall not include a transaction in which the Company is issuing securities primarily for the purpose of
raising capital or to an entity whose primary business is investing in securities; and (v) shares of Common Stock, RSUs or options in
connection with existing employment contracts and the hire of new executive officers/consultants of the Company; provided, that any issuance
of securities to consultants pursuant to clause (d) above that are not issued pursuant to a Form S-8 shall be issued as &ldquo;restricted
securities&rdquo; (as defined in Rule 144) and carry no registration rights that require or permit the filing of any registration statement
in connection therewith during the 90 day period following the Closing Date.</FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-weight: normal; text-underline-style: double">&nbsp;</FONT></P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-weight: normal">3.19
</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal"><U>Release of D&amp;O Lock-up Period</U><FONT STYLE="font-weight: normal">.
If the Representative, in its sole discretion, agrees to release or waive the restrictions set forth in the Lock-Up Agreements for an
officer or director of the Company and provide the Company with notice of the impending release or waiver at least three (3) Business
Days before the effective date of the release or waiver, the Company agrees to announce the impending release or waiver by a press release
substantially in the form of <U>Exhibit B</U> hereto through a major news service at least two (2) Business Days before the effective
date of the release or waiver.</FONT></FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-weight: normal; text-underline-style: double">&nbsp;</FONT></P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-weight: normal">3.20
</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal"><U>Blue Sky Qualifications</U><FONT STYLE="font-weight: normal">.
The Company shall use its best efforts, in cooperation with the Underwriters, if necessary, to qualify the Securities for offering and
sale under the applicable securities laws of such states and other jurisdictions (domestic or foreign) as the Representative may designate
and to maintain such qualifications in effect so long as required to complete the distribution of the Securities; <U>provided</U>, <U>however</U>,
that the Company shall not be obligated to file any general consent to service of process or to qualify as a foreign corporation or as
a dealer in securities in any jurisdiction in which it is not so qualified or to subject itself to taxation in respect of doing business
in any jurisdiction in which it is not otherwise so subject.</FONT></FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-weight: normal; text-underline-style: double">&nbsp;</FONT></P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-weight: normal">3.21
</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal"><U>Reporting Requirements</U><FONT STYLE="font-weight: normal">.
The Company, during the period when a prospectus relating to the Securities is (or, but for the exception afforded by Rule 172, would
be) required to be delivered under the Securities Act, will file all documents required to be filed with the Commission pursuant to the
Exchange Act within the time periods required by the Exchange Act and Exchange Act Regulations. Additionally, the Company shall report
the use of proceeds from the issuance of the Securities as may be required under Rule 463 under the Securities Act Regulations.</FONT></FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-weight: normal; text-underline-style: double">&nbsp;</FONT></P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-weight: normal">3.22
</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal"><U>Smaller Reporting Company</U><FONT STYLE="font-weight: normal">.
As of the time of the initial filing of the Registration Statement and as of the date hereof, the Company was a &ldquo;smaller reporting
company,&rdquo; as defined in Rule 12b-2 of the Exchange Act Regulations.</FONT></FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-weight: normal; text-underline-style: double">&nbsp;</FONT></P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-weight: normal">3.23
</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal"><U>Capital Changes</U><FONT STYLE="font-weight: normal">.
Until the six-month anniversary of the Closing Date, the Company shall not undertake a reverse or forward stock split or reclassification
of the Common Stock, unless taking such action is reasonably required to maintain the listing of the Common Stock on the Nasdaq.</FONT></FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-weight: normal">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 26; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->25<!-- Field: /Sequence --> -</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal">4.
</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Conditions of Underwriters&rsquo; Obligations</U><FONT STYLE="font-weight: normal">.
The obligations of the Underwriters to purchase and pay for the Securities, as provided herein, shall be subject to (i) the continuing
accuracy of the representations and warranties of the Company as of the date hereof and as of the Closing Date; (ii) the accuracy of
the statements of officers of the Company made pursuant to the provisions hereof; (iii) the performance by the Company of its obligations
hereunder; and (iv) the following conditions:</FONT></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-weight: normal">4.1
</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal"><U>Regulatory Matters</U><FONT STYLE="font-weight: normal">.</FONT></FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal">4.1.1.
</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Rule 430B Information</U><FONT STYLE="font-weight: normal">.
The Company shall have filed the Prospectus with the Commission (including the information required by Rule 430B under the Securities
Act) in the manner and within the time period required by Rule 424(b) under the Securities Act; or the Company shall have filed a post-effective
amendment to the Registration Statement containing the information required by such Rule 430B, and such post-effective amendment shall
have become effective.</FONT></FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal">4.1.2.
</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>FINRA Clearance</U><FONT STYLE="font-weight: normal">.
FINRA shall have raised no objection to the fairness and reasonableness of the underwriting terms and arrangements.</FONT></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal">4.1.3.
</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Stock Market Clearance</U><FONT STYLE="font-weight: normal">.
The Company shall have submitted the Listing of Additional Shares Notification Form to the Exchange with respect to the Offering of the
Securities and the Exchange shall not have raised any objection to the submission prior the Closing Date.</FONT></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-weight: normal">4.2
</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal"><U>Company Counsel Matters</U><FONT STYLE="font-weight: normal">.</FONT></FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal">4.2.1.
</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Closing Date Opinion of Counsel</U><FONT STYLE="font-weight: normal">.
On the Closing Date, the Representative shall have received the favorable opinion and negative assurance letter of Haynes and Boone,
LLP, with offices located at 30 Rockefeller Plaza, 26th Floor, New York, NY 10012, counsel to the Company, each dated the Closing Date
and addressed to the Representative, each in form and substance reasonably satisfactory to the Representative.</FONT></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal">4.2.2.
</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Option Closing Date Opinion of Counsel</U><FONT STYLE="font-weight: normal">.
On each Option Closing Date, if any, the Representative shall have received the favorable opinion and negative assurance letter of the
legal counsel listed in <U>Section 4.2.1</U>, dated such Option Closing Date, addressed to the Representative, each in form and substance
reasonably satisfactory to the Representative.</FONT></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal">4.2.3.
</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Reliance</U><FONT STYLE="font-weight: normal">. In
rendering such opinions, such counsel may rely: (i) as to matters involving the application of laws other than the laws of the United
States and jurisdictions in which they are admitted, to the extent such counsel deems proper and to the extent specified in such opinion,
if at all, upon an opinion or opinions (in form and substance reasonably satisfactory to the Representative) of other counsel reasonably
acceptable to the Representative, familiar with the applicable laws; and (ii) as to matters of fact, to the extent they deem proper,
on certificates or other written statements of officers of the Company and officers of departments of various jurisdictions having custody
of documents respecting the corporate existence or good standing of the Company.</FONT></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-weight: normal">4.3
</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal"><U>Comfort Letters</U><FONT STYLE="font-weight: normal">.</FONT></FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal">4.3.1.
</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Comfort Letter</U><FONT STYLE="font-weight: normal">.
At the time this Agreement is executed, you shall have received a comfort letter containing statements and information of the type customarily
included in accountants&rsquo; comfort letters with respect to the financial statements and certain financial information contained or
incorporated or deemed incorporated by reference in the Registration Statement, the Pricing Disclosure Package and the Prospectus, addressed
to the Representative and in form and substance satisfactory in all respects to you, dated as of the date of this Agreement, from each
of Friedman LLP and Marcum LLP.</FONT></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal">4.3.2.
</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Bring-down Comfort Letter</U><FONT STYLE="font-weight: normal">.
On the Closing Date and each Option Closing Date (if any), you shall have received from each of Friedman LLP and Marcum LLP a letter,
dated as of the Closing Date or the applicable Option Closing Date, as applicable, to the effect that such firm reaffirms the statements
made in the letter furnished pursuant to <U>Section 4.3.1</U>, except that the specified date referred to shall be a date not more than
three (3) business days prior to the Closing Date or the applicable Option Closing Date, as applicable.</FONT></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 27; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->26<!-- Field: /Sequence --> -</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-weight: normal">4.4
</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal"><U>Officer&rsquo;s Certificates</U><FONT STYLE="font-weight: normal">.</FONT></FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal">4.4.1.
</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Officer&rsquo;s Certificate</U><FONT STYLE="font-weight: normal">.
The Company shall have furnished to the Representative a certificate, dated the Closing Date and each Option Closing Date (if any), of
its Chief Executive Officer and the Chief Financial Officer stating that (i) such officers have carefully examined the Registration Statement,
the Pricing Disclosure Package, any Issuer Free Writing Prospectus and the Prospectus and, in their opinion, the Registration Statement
and each amendment thereto, as of the Applicable Time and as of the Closing Date or such Option Closing Date did not include any untrue
statement of a material fact and did not omit to state a material fact required to be stated therein or necessary to make the statements
therein not misleading, and the Pricing Disclosure Package, as of the Applicable Time and as of the Closing Date and such Option Closing
Date, any Issuer Free Writing Prospectus as of its date and as of the Closing Date or such Option Closing Date, the Prospectus and each
amendment or supplement thereto, as of the respective date thereof and as of the Closing Date or such Option Closing Date, did not include
any untrue statement of a material fact and did not omit to state a material fact necessary in order to make the statements therein,
in the light of the circumstances in which they were made, not misleading, (ii) since the Applicable Time, no event has occurred which
should have been set forth in a supplement or amendment to the Registration Statement, the Pricing Disclosure Package or the Prospectus,
(iii) to the best of their knowledge after reasonable investigation, as of the Closing Date or such Option Closing Date, the representations
and warranties of the Company in this Agreement are true and correct in all material respects (except for those representations and warranties
qualified as to materiality, which shall be true and correct in all respects, and except for those representations and warranties which
refer to facts existing at a specific date, which shall be true and correct as of such date) and the Company has complied with all agreements
and satisfied all conditions on its part to be performed or satisfied hereunder at or prior to the Closing Date or such Option Closing
Date, and (iv) there has not been, subsequent to the date of the most recent audited financial statements included or incorporated by
reference in the Pricing Disclosure Package, any event that has caused a Material Adverse Effect in the financial position or results
of operations of the Company, or any change or development that, singularly or in the aggregate, would involve a Material Adverse Effect
or a prospective Material Adverse Effect, in or affecting the condition (financial or otherwise), results of operations, business, assets
or prospects of the Company, except as set forth in the Prospectus.</FONT></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal">4.4.2.
</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Secretary&rsquo;s Certificate</U><FONT STYLE="font-weight: normal">.
At the Closing Date and each Option Closing Date (if any), the Representative shall have received a certificate of the Company signed
by the Secretary of the Company, dated the Closing Date or such Option Closing Date, certifying: (i) that each of the Company&rsquo;s
certificate of incorporation and by-laws, each as amended, is true and complete, has not been modified and is in full force and effect;
(ii) that the resolutions of the Company&rsquo;s Board of Directors relating to the Offering are in full force and effect and have not
been modified; (iii) as to the accuracy and completeness of all correspondence between the Company or its counsel and the Commission;
and (iv) as to the incumbency of the officers of the Company. The documents referred to in such certificate shall be attached to such
certificate.</FONT></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 28; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->27<!-- Field: /Sequence --> -</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-weight: normal">4.5
</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal"><U>No Material Changes</U><FONT STYLE="font-weight: normal">.
Prior to and on the Closing Date and each Option Closing Date (if any): (i) there shall have been no Material Adverse Effect or development
involving a prospective Material Adverse Effect in the condition or prospects or the business activities, financial or otherwise, of
the Company from the latest dates as of which such condition is set forth in the Registration Statement, the Pricing Disclosure Package
and the Prospectus; (ii) no action, suit or proceeding, at law or in equity, shall have been pending or threatened against the Company
or any director or executive officer of the Company before or by any court or federal or state commission, board or other administrative
agency wherein an unfavorable decision, ruling or finding may materially adversely affect the business, operations, prospects or financial
condition or income of the Company, except as set forth in the Registration Statement, the Pricing Disclosure Package and the Prospectus;
(iii) no stop order suspending the effectiveness of the Registration Statement or any post-effective amendment thereto has been issued
under the Securities Act, no order preventing or suspending the use of any Preliminary Prospectus or the Prospectus has been issued and
no proceedings for any of those purposes have been instituted or are pending or, to the Company&rsquo;s knowledge, contemplated by the
Commission; and (iv) the Registration Statement, the Pricing Disclosure Package and the Prospectus and any amendments or supplements
thereto shall contain all material statements which are required to be stated therein in accordance with the Securities Act and the Securities
Act Regulations and shall conform in all material respects to the requirements of the Securities Act and the Securities Act Regulations,
and neither the Registration Statement, the Pricing Disclosure Package nor the Prospectus nor any amendment or supplement thereto shall
contain any untrue statement of a material fact or omit to state any material fact required to be stated therein or necessary to make
the statements therein, in light of the circumstances under which they were made, not misleading.</FONT></FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-weight: normal">4.6
</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal"><U>Delivery of Agreements</U><FONT STYLE="font-weight: normal">.</FONT></FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal">4.6.1.
</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Lock-Up Agreements</U><FONT STYLE="font-weight: normal">.
On or before the date of this Agreement, the Company shall have delivered to the Representative executed copies of the Lock-Up Agreements
from each of the persons listed in <U>Schedule 3</U> hereto.</FONT></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal">4.6.2.
</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Warrants</U><FONT STYLE="font-weight: normal">. On
the Closing Date and each Option Closing Date, the Company shall have delivered to the Representative executed copies of the Firm Warrants
or the Option Warrants, as applicable.</FONT></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-weight: normal">4.7
</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal"><U>Additional Documents</U><FONT STYLE="font-weight: normal">.
At the Closing Date and each Option Closing Date (if any), Representative Counsel shall have been furnished with such documents and opinions
as they may reasonably require for the purpose of enabling Representative Counsel to deliver an opinion to the Underwriters, or in order
to evidence the accuracy of any of the representations or warranties, or the fulfillment of any of the conditions, herein contained;
and all proceedings taken by the Company in connection with the issuance and sale of the Securities as herein contemplated shall be reasonably
satisfactory in form and substance to the Representative and Representative Counsel.</FONT></FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal">5.
</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Indemnification</U><FONT STYLE="font-weight: normal">.</FONT></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-weight: normal">5.1
</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal"><U>Indemnification of the Underwriters</U><FONT STYLE="font-weight: normal">.</FONT></FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal">5.1.1.
</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>General</U><FONT STYLE="font-weight: normal">. Subject
to the conditions set forth below, the Company agrees to indemnify and hold harmless each Underwriter, its affiliates and each of its
and their respective directors, officers, members, employees, representatives and agents and each person, if any, who controls any such
Underwriter within the meaning of Section 15 of the Securities Act or Section 20 of the Exchange Act (collectively the &ldquo;</FONT>Underwriter
Indemnified Parties<FONT STYLE="font-weight: normal">,&rdquo; and each an &ldquo;</FONT>Underwriter Indemnified Party<FONT STYLE="font-weight: normal">&rdquo;),
against any and all loss, liability, claim, damage and reasonable and documented expense whatsoever (including but not limited to any
and all legal or other expenses reasonably incurred in investigating, preparing or defending against any litigation, commenced or threatened,
or any claim whatsoever, whether arising out of any action between any of the Underwriter Indemnified Parties and the Company or between
any of the Underwriter Indemnified Parties and any third party, or otherwise) to which they or any of them may become subject under the
Securities Act, the Exchange Act or any other statute or at common law or otherwise or under the laws of foreign countries (a &ldquo;Claim&rdquo;),
arising out of or based upon any untrue statement or alleged untrue statement of a material fact contained in (i) the Registration Statement,
the Pricing Disclosure Package, the Preliminary Prospectus, or the Prospectus (as from time to time each may be amended and supplemented);
(ii) any materials or information provided to investors by, or with the approval of, the Company in connection with the marketing of
the Offering, including any &ldquo;road show&rdquo; or investor presentations made to investors by the Company (whether in person or
electronically); or (iii) any application or other document or written communication (in this Section 5, collectively called &ldquo;application&rdquo;)
executed by the Company or based upon written information furnished by the Company in any jurisdiction in order to qualify the Securities
under the securities laws thereof or filed with the Commission, any state securities commission or agency, the Exchange or any other
national securities exchange; or the omission or alleged omission therefrom of a material fact required to be stated therein or necessary
to make the statements therein, in the light of the circumstances under which they were made, not misleading, unless such statement or
omission was made in reliance upon, and in conformity with, the Underwriters&rsquo; Information; provided, however, that the Company
shall not be required to indemnify and hold harmless any Underwriter Indemnified Party with respect to any Claims or expenses incurred
by it that are finally judicially determined (and not subject to any right of appeal) to have resulted from the fraud, gross negligence,
willful misconduct or bad faith of such Underwriter Indemnified Party, and in any such event, any expenses advanced by the Company to
such Underwriter Indemnified Party with respect to the foregoing shall be reimbursed.</FONT></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 29; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->28<!-- Field: /Sequence --> -</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal">5.1.2.
</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Procedure</U><FONT STYLE="font-weight: normal">.
If any action is brought against an Underwriter Indemnified Party in respect of which indemnity may be sought against the Company pursuant
to <U>Section 5.1.1</U>, such Underwriter Indemnified Party shall promptly notify the Company in writing of the institution of such action
and the Company shall assume the defense of such action, including the employment and fees of counsel (subject to the reasonable approval
of such Underwriter Indemnified Party) (which such approval shall not be unreasonably withheld, delayed or conditioned) and payment of
reasonable and documented expenses if an Underwriter Indemnified Party requests that the Company do so. Such Underwriter Indemnified
Party shall have the right to employ its or their own counsel in any such case, but the fees and expenses of such counsel shall be at
the expense of such Underwriter Indemnified Party unless (i) the employment of such counsel at the expense of the Company shall have
been authorized in writing by the Company in connection with the defense of such action, or (ii) the Company shall not have employed
counsel to have charge of the defense of such action, or (iii) such indemnified party or parties shall have reasonably concluded that
there may be defenses available to it or them which are different from or additional to those available to the Company (in which case
the Company shall not have the right to direct the defense of such action on behalf of the indemnified party or parties), in any of which
events the reasonable fees and expenses of not more than one additional firm of attorneys selected by the Underwriter Indemnified Party
(in addition to local counsel) shall be borne by the Company. Notwithstanding anything to the contrary contained herein, if any Underwriter
Indemnified Party shall assume the defense of such action as provided above, the Company shall have the right to approve the terms of
any settlement of such action, which approval shall not be unreasonably withheld.</FONT></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-weight: normal">5.2
</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal"><U>Indemnification of the Company</U><FONT STYLE="font-weight: normal">.
Each Underwriter, severally and not jointly, agrees to indemnify and hold harmless the Company, its directors, its officers who signed
the Registration Statement and persons who control the Company within the meaning of Section 15 of the Securities Act or Section 20 of
the Exchange Act against any and all loss, liability, claim, damage and expense described in the foregoing indemnity from the Company
to the several Underwriters, as incurred, but only with respect to untrue statements or omissions, or alleged untrue statements or omissions
made in the Registration Statement, any Preliminary Prospectus, the Pricing Disclosure Package or Prospectus or any amendment or supplement
thereto or in any application, in reliance upon, and in strict conformity with, the Underwriters&rsquo; Information. In case any action
shall be brought against the Company or any other person so indemnified based on any Preliminary Prospectus, the Registration Statement,
the Pricing Disclosure Package or the Prospectus or any amendment or supplement thereto or any application, and in respect of which indemnity
may be sought against any Underwriter, such Underwriter shall have the rights and duties given to the Company, and the Company and each
other person so indemnified shall have the rights and duties given to the several Underwriters by the provisions of <U>Section 5.1.2</U>.
The Company agrees promptly to notify the Representative of the commencement of any litigation or proceedings against the Company or
any of its officers, directors or any person, if any, who controls the Company within the meaning of Section 15 of the Securities Act
or Section 20 of the Exchange Act, in connection with the issuance and sale of the Securities or in connection with the Registration
Statement, the Pricing Disclosure Package, or the Prospectus or any Issuer Free Writing Prospectus.</FONT></FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-weight: normal">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 30; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->29<!-- Field: /Sequence --> -</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-weight: normal">5.3
</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal"><U>Contribution</U><FONT STYLE="font-weight: normal">.</FONT></FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal">5.3.1.
</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Contribution Rights</U><FONT STYLE="font-weight: normal">.
If the indemnification provided for in this <U>Section 5</U> shall for any reason be unavailable to or insufficient to hold harmless
an indemnified party under <U>Section 5.1</U> or <U>5.2</U> in respect of any loss, claim, damage or liability, or any action in respect
thereof, referred to therein, then each indemnifying party shall, in lieu of indemnifying such indemnified party, contribute to the amount
paid or payable by such indemnified party as a result of such loss, claim, damage or liability, or action in respect thereof, (i) in
such proportion as shall be appropriate to reflect the relative benefits received by the Company, on the one hand, and the Underwriters,
on the other, from the Offering of the Securities, or (ii) if the allocation provided by clause (i) above is not permitted by applicable
law, in such proportion as is appropriate to reflect not only the relative benefits referred to in <U>clause (i)</U> above but also the
relative fault of the Company, on the one hand, and the Underwriters, on the other, with respect to the statements or omissions that
resulted in such loss, claim, damage or liability, or action in respect thereof, as well as any other relevant equitable considerations.
The relative benefits received by the Company, on the one hand, and the Underwriters, on the other, with respect to such Offering shall
be deemed to be in the same proportion as the total net proceeds from the Offering of the Securities purchased under this Agreement (before
deducting expenses) received by the Company, as set forth in the table on the cover page of the Prospectus, on the one hand, and the
total underwriting discounts and commissions received by the Underwriters with respect to the shares of Common Stock purchased under
this Agreement, as set forth in the table on the cover page of the Prospectus, on the other hand. The relative fault shall be determined
by reference to whether the untrue or alleged untrue statement of a material fact or omission or alleged omission to state a material
fact relates to information supplied by the Company or the Underwriters, the intent of the parties and their relative knowledge, access
to information and opportunity to correct or prevent such statement or omission. The Company and the Underwriters agree that it would
not be just and equitable if contributions pursuant to this <U>Section 5.3.1</U> were to be determined by pro rata allocation (even if
the Underwriters were treated as one entity for such purpose) or by any other method of allocation that does not take into account the
equitable considerations referred to herein. The amount paid or payable by an indemnified party as a result of the loss, claim, damage
or liability, or action in respect thereof, referred to above in this <U>Section 5.3.1</U> shall be deemed to include, for purposes of
this <U>Section 5.3.1</U>, any legal or other expenses reasonably incurred by such indemnified party in connection with investigating
or defending any such action or claim. Notwithstanding the provisions of this <U>Section 5.3.1</U> in no event shall an Underwriter be
required to contribute any amount in excess of the amount by which the total underwriting discounts and commissions received by such
Underwriter with respect to the Offering of the Securities exceeds the amount of any damages that such Underwriter has otherwise been
required to pay by reason of such untrue or alleged untrue statement or omission or alleged omission. No person guilty of fraudulent
misrepresentation (within the meaning of Section 11(f) of the Securities Act) shall be entitled to contribution from any person who was
not guilty of such fraudulent misrepresentation.</FONT></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal">5.3.2.
</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Contribution Procedure</U><FONT STYLE="font-weight: normal">.
Within fifteen (15) days after receipt by any party to this Agreement (or its representative) of notice of the commencement of any action,
suit or proceeding, such party will, if a claim for contribution in respect thereof is to be made against another party (&ldquo;</FONT>contributing
party<FONT STYLE="font-weight: normal">&rdquo;), notify the contributing party of the commencement thereof, but the failure to so notify
the contributing party will not relieve it from any liability which it may have to any other party other than for contribution hereunder.
In case any such action, suit or proceeding is brought against any party, and such party notifies a contributing party or its representative
of the commencement thereof within the aforesaid 15 days, the contributing party will be entitled to participate therein with the notifying
party and any other contributing party similarly notified. Any such contributing party shall not be liable to any party seeking contribution
on account of any settlement of any claim, action or proceeding affected by such party seeking contribution on account of any settlement
of any claim, action or proceeding affected by such party seeking contribution without the written consent of such contributing party.
The contribution provisions contained in this <U>Section 5.3.2</U> are intended to supersede, to the extent permitted by law, any right
to contribution under the Securities Act, the Exchange Act or otherwise available. Each Underwriter&rsquo;s obligations to contribute
pursuant to this <U>Section 5.3</U> are several and not joint.</FONT></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 31; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->30<!-- Field: /Sequence --> -</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal">6.
</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Default by an Underwriter</U><FONT STYLE="font-weight: normal">.</FONT></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-weight: normal">6.1
</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal"><U>Default Not Exceeding 10% of
Firm Securities or Option Securities</U><FONT STYLE="font-weight: normal">. If any Underwriter or Underwriters shall default in its or
their obligations to purchase the Firm Securities or the Option Securities, if the Over-allotment Option is exercised hereunder, and
if the number of the Firm Securities or the Option Securities with respect to which such default relates does not exceed in the aggregate
10% of the number of Firm Securities or Option Securities that all Underwriters have agreed to purchase hereunder, then such Firm Securities
or Option Securities to which the default relates shall be purchased by the non-defaulting Underwriters in proportion to their respective
commitments hereunder.</FONT></FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-weight: normal">6.2
</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal"><U>Default Exceeding 10% of Firm
Securities or Option Securities</U><FONT STYLE="font-weight: normal">. In the event that the default addressed in <U>Section 6.1</U>
relates to more than 10% of the Firm Securities or the Option Securities, you may in your discretion arrange for yourself or for another
party or parties to purchase such Firm Securities or Option Securities to which such default relates on the terms contained herein. If,
within one (1) Business Day after such default relating to more than 10% of the Firm Securities or the Option Securities, you do not
arrange for the purchase of such Firm Securities or Option Securities, then the Company shall be entitled to a further period of one
(1) Business Day within which to procure another party or parties satisfactory to you to purchase said Firm Securities or Option Securities
on such terms. In the event that neither you nor the Company arrange for the purchase of the Firm Securities or the Option Securities
to which a default relates as provided in this <U>Section 6</U>, this Agreement will automatically be terminated by you or the Company
without liability on the part of the Company (except as provided in <U>Sections 3.10</U> and <U>5</U> hereof) or the several Underwriters
(except as provided in <U>Section 5</U>); <U>provided</U>, <U>however</U>, that if such default occurs with respect to the Option Securities,
this Agreement will not terminate as to the Firm Securities; and <U>provided</U>, <U>further</U>, that nothing herein shall relieve a
defaulting Underwriter of its liability, if any, to the other Underwriters and to the Company for damages occasioned by its default hereunder.</FONT></FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-weight: normal">6.3
</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal"><U>Postponement of Closing Date</U><FONT STYLE="font-weight: normal">.
In the event that the Firm Securities or the Option Securities to which the default relates are to be purchased by the non-defaulting
Underwriters, or are to be purchased by another party or parties as aforesaid, you or the Company shall have the right to postpone the
Closing Date or such Option Closing Date for a reasonable period, but not in any event exceeding five (5) Business Days, in order to
effect whatever changes may thereby be made necessary in the Registration Statement, the Pricing Disclosure Package or the Prospectus
or in any other documents and arrangements, and the Company agrees to file promptly any amendment to the Registration Statement, the
Pricing Disclosure Package or the Prospectus that in the opinion of counsel for the Underwriter may thereby be made necessary. The term
&ldquo;Underwriter&rdquo; as used in this Agreement shall include any party substituted under this <U>Section 6</U> with like effect
as if it had originally been a party to this Agreement with respect to such Securities.</FONT></FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal">7.
</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>[Reserved]</U><FONT STYLE="font-weight: normal">.</FONT></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal">8.
</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Effective Date of this Agreement and Termination
Thereof</U><FONT STYLE="font-weight: normal">.</FONT></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal; text-underline-style: double">&nbsp;</FONT></P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-weight: normal">8.1
</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal"><U>Effective Date</U><FONT STYLE="font-weight: normal">.
This Agreement shall become effective when both the Company and the Representative have executed the same and delivered counterparts
of such signatures to the other party.</FONT></FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-weight: normal; text-underline-style: double">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 32; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->31<!-- Field: /Sequence --> -</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-underline-style: double">&nbsp;</FONT></P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-weight: normal">8.2
</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal"><U>Termination</U><FONT STYLE="font-weight: normal">.
The Representative shall have the right to terminate this Agreement at any time prior to any Closing Date (i) if any domestic or international
event or act or occurrence has materially disrupted, or in your opinion will in the immediate future materially disrupt, general securities
markets in the United States; or (ii) if trading on the New York Stock Exchange or the Nasdaq Stock Market LLC shall have been suspended
or materially limited, or minimum or maximum prices for trading shall have been fixed, or maximum ranges for prices for securities shall
have been required by FINRA or by order of the Commission or any other government authority having jurisdiction; or (iii) if the United
States shall have become involved in a new war or an increase in major hostilities; or (iv) if a banking moratorium has been declared
by a New York State or federal authority; or (v) if a moratorium on foreign exchange trading has been declared which materially adversely
impacts the United States securities markets; or (vi) if the Company shall have sustained a material loss by fire, flood, accident, hurricane,
earthquake, theft, sabotage or other calamity or malicious act which, whether or not such loss shall have been insured, will, in your
opinion, make it inadvisable to proceed with the delivery of the Firm Securities or Option Securities; or (vii) if the Company is in
material breach of any of its representations, warranties or covenants hereunder; or (viii) if the Representative shall have become aware
after the date hereof of a material adverse change in the conditions or prospects of the Company, or such adverse material change in
general market conditions as in the Representative&rsquo;s reasonable judgment would make it impracticable to proceed with the offering,
sale and/or delivery of the Securities or to enforce contracts made by the Underwriters for the sale of the Securities.</FONT></FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-weight: normal; text-underline-style: double">&nbsp;</FONT></P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-weight: normal">8.3
</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal"><U>Expenses</U><FONT STYLE="font-weight: normal">.
Notwithstanding anything to the contrary in this Agreement, except in the case of a default by the Underwriters, pursuant to <U>Section
6.2</U>, in the event that this Agreement is terminated prior to the Closing Date for any reason whatsoever, within the time specified
herein or any extensions thereof pursuant to the terms herein, the Company shall be obligated to pay to the Underwriters their actual
and accountable out-of-pocket documented expenses related to the transactions contemplated herein then due and payable (including the
out-of-pocket and documented fees and disbursements of Representative Counsel) up to $75,000, and upon demand the Company shall pay the
full amount thereof up to the cap to the Representative on behalf of the Underwriters; <U>provided</U>, <U>however</U>, that such expense
cap in no way limits or impairs the indemnification and contribution provisions of this Agreement. Notwithstanding the foregoing, any
advance received by the Representative will be reimbursed to the Company to the extent not actually incurred in compliance with FINRA
Rule 5110(f)(2)(C).</FONT></FONT></P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-underline-style: double">&nbsp;</FONT></P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-weight: normal">8.4
</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal"><U>Survival of Indemnification</U><FONT STYLE="font-weight: normal">.
Notwithstanding any contrary provision contained in this Agreement, any election hereunder or any termination of this Agreement, and
whether or not this Agreement is otherwise carried out, the provisions of Section 5 shall remain in full force and effect and shall not
be in any way affected by, such election or termination or failure to carry out the terms of this Agreement or any part hereof.</FONT></FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-weight: normal; text-underline-style: double">&nbsp;</FONT></P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-weight: normal">8.5
</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal"><U>Representations, Warranties,
Agreements to Survive</U><FONT STYLE="font-weight: normal">. All representations, warranties and agreements contained in this Agreement
or in certificates of officers of the Company submitted pursuant hereto, shall remain operative and in full force and effect regardless
of (i) any investigation made by or on behalf of any Underwriter or its Affiliates or selling agents, any person controlling any Underwriter,
its officers or directors or any person controlling the Company or (ii) delivery of and payment for the Securities.</FONT></FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-weight: normal; text-underline-style: double">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal">9.
</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Miscellaneous</U><FONT STYLE="font-weight: normal">.</FONT></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal; text-underline-style: double">&nbsp;</FONT></P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-weight: normal">9.1
</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal"><U>Notices</U><FONT STYLE="font-weight: normal">.
All communications hereunder, except as herein otherwise specifically provided, shall be in writing and shall be mailed (registered or
certified mail, return receipt requested), personally delivered or sent by email transmission and confirmed and shall be deemed given
when so delivered or faxed or emailed and confirmed or if mailed, two (2) days after such mailing.</FONT></FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-weight: normal; text-underline-style: double">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 33; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->32<!-- Field: /Sequence --> -</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-underline-style: double">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
to the Representative:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">A.G.P./Alliance
Global Partners</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">590
Madison Avenue, 36<SUP>th</SUP> Floor</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">New
York, New York 10022</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Attn:
Mr. David Bocchi, Managing Director of Investment Banking</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Fax
No.: (212) 813-1047</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Email:
db@allianceg.com</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">with
a copy (which shall not constitute notice) to:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">McGuireWoods
LLP</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1251
Avenue of the Americas, 20<SUP>th</SUP> Floor</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">New
York, New York 10020</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Attention:
Stephen E. Older; David S. Wolpa</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Email:
solder@mcguirewoods.com; dwolpa@mcguirewoods.com</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
to the Company:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Enveric
BioSciences, Inc.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4851
Tamiami Trail N, Suite 200</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Naples,
Florida</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Attn:
Joseph Tucker, Chief Executive Officer</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Email:
jtucker@enveric.com</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">with
a copy (which shall not constitute notice) to:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Haynes
and Boone, LLP</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">30
Rockefeller Plaza, 26th Floor</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">New
York, New York 10012</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Attention:
Rick Werner, Esq.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Rick.Werner@haynesboone.com</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-weight: normal">9.2
</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal"><U>Headings</U><FONT STYLE="font-weight: normal">.
The headings contained herein are for the sole purpose of convenience of reference, and shall not in any way limit or affect the meaning
or interpretation of any of the terms or provisions of this Agreement.</FONT></FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-weight: normal; text-underline-style: double">&nbsp;</FONT></P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-weight: normal">9.3
</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal"><U>Amendment</U><FONT STYLE="font-weight: normal">.
This Agreement may only be amended by a written instrument executed by each of the parties hereto.</FONT></FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-weight: normal; text-underline-style: double">&nbsp;</FONT></P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-weight: normal">9.4
</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal"><U>Entire Agreement</U><FONT STYLE="font-weight: normal">.
This Agreement (together with the other agreements and documents being delivered pursuant to or in connection with this Agreement) constitutes
the entire agreement of the parties hereto with respect to the subject matter hereof and thereof, and supersedes all prior agreements
and understandings of the parties, oral and written, with respect to the subject matter hereof.</FONT></FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-weight: normal">9.5
</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal"><U>Binding Effect</U><FONT STYLE="font-weight: normal">.
This Agreement shall inure solely to the benefit of and shall be binding upon the Representative, the Underwriters, the Company and the
controlling persons, directors and officers referred to in <U>Section 5</U>, and their respective successors, legal representatives,
heirs and assigns, and no other person shall have or be construed to have any legal or equitable right, remedy or claim under or in respect
of or by virtue of this Agreement or any provisions herein contained. The term &ldquo;successors and assigns&rdquo; shall not include
a purchaser, in its capacity as such, of securities from any of the Underwriters.</FONT></FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-weight: normal; text-underline-style: double">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 34; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->33<!-- Field: /Sequence --> -</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-underline-style: double">&nbsp;</FONT></P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-weight: normal">9.6
</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal"><U>Governing Law; Consent to Jurisdiction;
Trial by Jury</U><FONT STYLE="font-weight: normal">. This Agreement shall be governed by and construed and enforced in accordance with
the laws of the State of New York, without giving effect to conflict of laws principles thereof. The Company hereby agrees that any action,
proceeding or claim against it arising out of, or relating in any way to this Agreement shall be brought and enforced in the New York
Supreme Court, County of New York, or in the United States District Court for the Southern District of New York, and irrevocably submits
to such jurisdiction, which jurisdiction shall be exclusive. The Company hereby waives any objection to such exclusive jurisdiction and
that such courts represent an inconvenient forum. Any such process or summons to be served upon the Company may be served by transmitting
a copy thereof by registered or certified mail, return receipt requested, postage prepaid, addressed to it at the address set forth in
<U>Section 9.1</U>. Such mailing shall be deemed personal service and shall be legal and binding upon the Company in any action, proceeding
or claim. The Company agrees that the prevailing party(ies) in any such action shall be entitled to recover from the other party(ies)
all of its reasonable attorneys&rsquo; fees and expenses relating to such action or proceeding and/or incurred in connection with the
preparation therefor. The Company (on its behalf and, to the extent permitted by applicable law, on behalf of its stockholders and affiliates)
and each of the Underwriters hereby irrevocably waives, to the fullest extent permitted by applicable law, any and all right to trial
by jury in any legal proceeding arising out of or relating to this Agreement or the transactions contemplated hereby.</FONT></FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-weight: normal; text-underline-style: double">&nbsp;</FONT></P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-weight: normal">9.7
</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal"><U>Execution in Counterparts</U><FONT STYLE="font-weight: normal">.
This Agreement may be executed in one or more counterparts, and by the different parties hereto in separate counterparts, each of which
shall be deemed to be an original, but all of which taken together shall constitute one and the same agreement, and shall become effective
when one or more counterparts has been signed by each of the parties hereto and delivered to each of the other parties hereto. Delivery
of a signed counterpart of this Agreement by email/pdf transmission shall constitute valid and sufficient delivery thereof.</FONT></FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-weight: normal; text-underline-style: double">&nbsp;</FONT></P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-weight: normal">9.8
</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal"><U>Waiver, etc</U><FONT STYLE="font-weight: normal">.
The failure of any of the parties hereto to at any time enforce any of the provisions of this Agreement shall not be deemed or construed
to be a waiver of any such provision, nor to in any way effect the validity of this Agreement or any provision hereof or the right of
any of the parties hereto to thereafter enforce each and every provision of this Agreement. No waiver of any breach, non-compliance or
non-fulfillment of any of the provisions of this Agreement shall be effective unless set forth in a written instrument executed by the
party or parties against whom or which enforcement of such waiver is sought; and no waiver of any such breach, non-compliance or non-fulfillment
shall be construed or deemed to be a waiver of any other or subsequent breach, non-compliance or non-fulfillment.</FONT></FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-weight: normal; text-underline-style: double">&nbsp;</FONT></P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-weight: normal">9.9
</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal"><U>Defined Terms</U><FONT STYLE="font-weight: normal">.
In addition to the terms defined elsewhere in this Agreement, for all purposes of this Agreement, the following terms have the meanings
set forth in this <U>Section 9.9</U>:</FONT></FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-weight: normal; text-underline-style: double">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal">9.9.1.
&ldquo;</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Affiliate<FONT STYLE="font-weight: normal">&rdquo;
means any Person that, directly or indirectly through one or more intermediaries, controls or is controlled by or is under common control
with a Person as such terms are used in and construed under Rule 405 under the Securities Act.</FONT></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal">9.9.2.
&ldquo;</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Common Stock Equivalents<FONT STYLE="font-weight: normal">&rdquo;
means any securities of the Company or the Subsidiaries which would entitle the holder thereof to acquire at any time Common Stock, including,
without limitation, any debt, preferred stock, right, option, warrant or other instrument that is at any time convertible into or exercisable
or exchangeable for, or otherwise entitles the holder thereof to receive, Common Stock.</FONT></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal">9.9.3.
&ldquo;</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Person<FONT STYLE="font-weight: normal">&rdquo;
means an individual or corporation, partnership, trust, incorporated or unincorporated association, joint venture, limited liability
company, joint stock company, government (or an agency or subdivision thereof) or other entity of any kind.</FONT></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">[Signature
Page Follows]</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 35; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->34<!-- Field: /Sequence --> -</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-weight: normal">If
the foregoing correctly sets forth the understanding between the Underwriters and the Company, please so indicate in the space provided
below for that purpose, whereupon this letter shall constitute a binding agreement between us.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Very
    truly yours,</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">ENVERIC
    BIOSCIENCES, INC.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 50%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 5%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 45%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>/s/
    Joseph Tucker</I></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name:</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Joseph
    Tucker</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title:</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief
    Executive Officer</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 204pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Confirmed
    as of the date first written above mentioned, on behalf of itself and as Representative of the several Underwriters named on <U>Schedule
    1</U> hereto:</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">A.G.P./ALLIANCE
    GLOBAL PARTNERS</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 5%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 45%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 50%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>/s/
    Thomas J. Higgins</I></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name:</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Thomas
    J. Higgins</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title:</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Managing
    Director, Investment Banking</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>[Signature
Page to Underwriting Agreement]</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 36; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->35<!-- Field: /Sequence --> -</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><U>SCHEDULE
1</U></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <TR STYLE="font-family: Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="font-family: Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold"><FONT STYLE="font-family: Times New Roman, Times, Serif">Underwriter</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font-family: Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: center"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Total
                                            Number of</B></FONT></P> <P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Firm
                                            Shares to be Purchased</B></FONT></P></TD><TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center; font-weight: bold"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font-family: Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold"><FONT STYLE="font-family: Times New Roman, Times, Serif">Total
    Number of Firm Warrants to be Purchased</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center; font-weight: bold"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center; font-weight: bold"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font-family: Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold"><FONT STYLE="font-family: Times New Roman, Times, Serif">Number
    of Option Shares that May be Purchased if the Over-allotment Option is Fully Exercised for Option Shares</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center; font-weight: bold"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center; font-weight: bold"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font-family: Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold"><FONT STYLE="font-family: Times New Roman, Times, Serif">Number
    of Firm Warrants that May be Purchased if the Over-allotment Option is Fully Exercised for Option Warrants</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center; font-weight: bold"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; width: 20%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">A.G.P./Alliance
    Global Partners</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; width: 16%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">20,000,000</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; width: 16%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">20,000,000</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; width: 16%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">3,000,000</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; width: 16%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">3,000,000</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">TOTAL</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">20,000,000</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">20,000,000</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">3,000,000</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">3,000,000</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>


<!-- Field: Page; Sequence: 37; Options: NewSection; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; width: 100%">Sch. 1-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><U>SCHEDULE
2-A</U></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Pricing
Information</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 60%">
  <TR STYLE="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-family: Times New Roman, Times, Serif; width: 78%"><FONT STYLE="font-family: Times New Roman, Times, Serif">Number
    of Shares:</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; width: 18%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">20,000,000</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">Number of Warrants:</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">20,000,000</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">Number of Option
    Shares:</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">3,000,000</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">Number
    of Option Warrants:</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">3,000,000</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">Public Offering Price
    per Share:</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">0.499</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">Public Offering Price
    per Warrant:</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">0.001</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">Warrant Exercise
    Price per share:</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">0.55</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">Underwriting Discount
    per Share:</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">0.032435</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">Underwriting
    Discount per Warrant:</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">0.000065</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">Proceeds
    to Company per Share (before expenses):</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">0.466565</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">Proceeds
    to Company per Warrant (before expenses):</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">0.000935</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 38; Options: NewSection; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; width: 100%">Sch. 2-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><U>SCHEDULE
2-B</U></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Issuer
General Use Free Writing Prospectus</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">None.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 39; Options: NewSection; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; width: 100%">Sch. 2-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><U>SCHEDULE
3</U></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>List
of Lock-Up Parties</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Joseph
    Tucker</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Carter
    Ward</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Avani
    Kanubaddi</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Brad
    Thompson</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Peter
    Facchini</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">6.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Jillian
    Hagel</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">7.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">David
    Johnson</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">8.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">George
    Kegler</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">9.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Sol
    Mayer</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Marcus
    Schabacker</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">11.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Douglas
    Lind</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 40; Options: NewSection; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; width: 100%">Sch. 3-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><U>EXHIBIT
A</U></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Lock-Up
Agreement</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 41 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>LOCK-UP
AGREEMENT</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: right; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">February
____, 2022</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Enveric
BioSciences, Inc.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4851
Tamiami Trail N, Suite 200</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Naples,
Florida 34103</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Re:</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Underwriting
    Agreement, to be entered into in February, 2022 (the &ldquo;<B>Underwriting Agreement</B>&rdquo;), between Enveric BioSciences, Inc.
    (the &ldquo;<B>Company</B>&rdquo;) and A.G.P./Alliance Global Partners (the &ldquo;<B>Representative</B>&rdquo;) and, collectively
    with the underwriters named on Schedule 1 to the Underwriting Agreement, the &ldquo;<B>Underwriters</B>&rdquo;), as representative
    of the several Underwriters</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Ladies
and Gentlemen:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 4.5pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
undersigned, a holder of shares of common stock, par value $0.01 (the &ldquo;<B>Common Stock</B>&rdquo;), of the Company, or rights to
acquire shares of Common Stock, understands that you, as Representative of the several Underwriters, propose to enter into the Underwriting
Agreement with the Company, providing for the purchase by the Underwriters of shares of Common Stock (the &ldquo;<B>Shares</B>&rdquo;),
and that the Underwriters propose to reoffer the Shares to the public. Defined terms not otherwise defined in this letter agreement (the
&ldquo;<B>Letter Agreement</B>&rdquo;) shall have the meanings set forth in the Underwriting Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 4.5pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pursuant
to Section 4.7.1 of the Underwriting Agreement and in satisfaction of a condition of the Company&rsquo;s obligations under the Underwriting
Agreement, the undersigned irrevocably agrees with the Company that, from the date hereof until 90 days following the Closing Date (such
period, the &ldquo;<B>Restriction Period</B>&rdquo;), the undersigned will not offer, sell, contract to sell, sell any option or contract
to purchase, purchase any option or contract to sell, grant any option, right or warrant to purchase, lend or hypothecate, pledge or
otherwise dispose of (or enter into any transaction which is designed to, or might reasonably be expected to, result in the disposition
(whether by actual disposition or effective economic disposition due to cash settlement or otherwise) by the undersigned or any Affiliate
of the undersigned or any person in privity with the undersigned or any Affiliate of the undersigned), directly or indirectly, or establish
or increase a put equivalent position or liquidate or decrease a call equivalent position within the meaning of Section 16 of the Securities
Exchange Act of 1934, as amended (the &ldquo;<B>Exchange Act</B>&rdquo;), enter into any swap or other agreement, arrangement, hedge
or transaction that transfers to another, in whole or in part, directly or indirectly, any of the economic consequences of ownership
of shares of Common Stock or any securities convertible into or exercisable or exchangeable for Common Stock, whether any transaction
described in any of the foregoing is to be settled by delivery of shares of Common Stock, other securities, in cash or otherwise, or
publicly announce an intention to do any of the foregoing with respect to, any shares of Common Stock of the Company or securities convertible,
exchangeable or exercisable into, shares of Common Stock of the Company beneficially owned, held or hereafter acquired by the undersigned
(the &ldquo;<B>Securities</B>&rdquo;). </FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 4.5pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 42; Options: NewSection -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Beneficial
ownership shall be calculated in accordance with Section 13(d) of the Exchange Act. In order to enforce this covenant, the Company shall
impose irrevocable stop-transfer instructions preventing the transfer agent of the Company from effecting any actions in violation of
this Letter Agreement. The Company, upon the express written consent of A.G.P./Alliance Global Partners, may consent to an early release
from the Restriction Period if, in its sole and absolute discretion, the market for the Securities would not be adversely impacted by
sales and in cases of financial emergency.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Notwithstanding
the foregoing, and subject to the conditions below, the undersigned may transfer the Securities provided that (1) the Company receives
a signed lock-up letter agreement (in the form of this Letter Agreement) for the balance of the Restriction Period from each donee, trustee,
distributee, or transferee, as the case may be, prior to such transfer, (2) any such transfer shall not involve a disposition for value,
(3) such transfer is not required to be reported with the Securities and Exchange Commission in accordance with the Exchange Act and
no report of such transfer shall be made voluntarily, and (4) neither the undersigned nor any donee, trustee, distributee or transferee,
as the case may be, otherwise voluntarily effects any public filing or report regarding such transfers, with respect to transfer:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 4.5pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">i)</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">as
    a <I>bona fide</I> gift or gifts;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">ii)</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">to
    any immediate family member or to any trust for the direct or indirect benefit of the undersigned or the immediate family of the
    undersigned (for purposes of this Letter Agreement, &ldquo;immediate family&rdquo; shall mean any relationship by blood, marriage
    or adoption, not more remote than first cousin);</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">iii)</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">to
    any corporation, partnership, limited liability company, or other business entity all of the equity holders of which consist of the
    undersigned and/or the immediate family of the undersigned;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">iv)</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">if
    the undersigned is a corporation, partnership, limited liability company, trust or other business entity (a) to another corporation,
    partnership, limited liability company, trust or other business entity that is an Affiliate of the undersigned or (b) in the form
    of a distribution to limited partners, limited liability company members or stockholders of the undersigned;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">v)</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">if
    the undersigned is a trust, to the beneficiary of such trust; or</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">vi)</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">by
    will, other testamentary document or intestate succession to the legal representative, heir, beneficiary or a member of the immediate
    family of the undersigned.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 4.5pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition, notwithstanding the foregoing, this Letter Agreement shall not restrict the delivery of shares of Common Stock to the undersigned
upon (i) exercise of any options granted under any employee benefit plan of the Company; provided that any shares of Common Stock or
Securities acquired in connection with any such exercise will be subject to the restrictions set forth in this Letter Agreement, or (ii)
the exercise of warrants; provided that such shares of Common Stock delivered to the undersigned in connection with such exercise are
subject to the restrictions set forth in this Letter Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 4.5pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 43 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Furthermore,
the undersigned may enter into any new plan established in compliance with Rule 10b5-1 of the Exchange Act; provided that (i) such plan
may only be established if no public announcement or filing with the Securities and Exchange Commission, or other applicable regulatory
authority, is made in connection with the establishment of such plan during the Restriction Period and (ii) no sale of shares of Common
Stock are made pursuant to such plan during the Restriction Period.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
undersigned acknowledges that the execution, delivery and performance of this Letter Agreement is a material inducement to the Underwriters
to complete the transactions contemplated by the Underwriting Agreement and the Company shall be entitled to specific performance of
the undersigned&rsquo;s obligations hereunder. The undersigned hereby represents that the undersigned has the power and authority to
execute, deliver and perform this Letter Agreement, that the undersigned has received adequate consideration therefor and that the undersigned
will indirectly benefit from the closing of the transactions contemplated by the Underwriting Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 4.5pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
Letter Agreement may not be amended or otherwise modified in any respect without the written consent of each of the Company and the undersigned.
This Letter Agreement shall be construed and enforced in accordance with the laws of the State of New York without regard to the principles
of conflict of laws. The undersigned hereby irrevocably submits to the exclusive jurisdiction of the United States District Court sitting
in the Southern District of New York and the courts of the State of New York located in Manhattan, for the purposes of any suit, action
or proceeding arising out of or relating to this Letter Agreement, and hereby waives, and agrees not to assert in any such suit, action
or proceeding, any claim that (i) it is not personally subject to the jurisdiction of such court, (ii) the suit, action or proceeding
is brought in an inconvenient forum, or (iii) the venue of the suit, action or proceeding is improper. The undersigned hereby irrevocably
waives personal service of process and consents to process being served in any such suit, action or proceeding by receiving a copy thereof
sent to the Company at the address in effect for notices to it under the Underwriting Agreement and agrees that such service shall constitute
good and sufficient service of process and notice thereof. The undersigned hereby waives any right to a trial by jury. Nothing contained
herein shall be deemed to limit in any way any right to serve process in any manner permitted by law. The undersigned agrees and understands
that this Letter Agreement does not intend to create any relationship between the undersigned and any Underwriter and that no Underwriter
is entitled to cast any votes on the matters herein contemplated and that no issuance or sale of the Securities is created or intended
by virtue of this Letter Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
undersigned understands that, if the Underwriting Agreement is not executed by March 1, 2022 or if the Underwriting Agreement (other
than the provisions thereof which survive termination) shall terminate or be terminated prior to payment for and delivery of the Securities
to be sold thereunder, then this Letter Agreement shall be void and of no further force or effect.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
Letter Agreement shall be binding on successors and assigns of the undersigned with respect to the Securities and any such successor
or assign shall enter into a similar agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">***
SIGNATURE PAGE FOLLOWS***</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>


<!-- Field: Page; Sequence: 44 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
Letter Agreement may be executed in two or more counterparts, all of which when taken together may be considered one and the same agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 50%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 50%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Signature</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Print
    Name</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Position
    in Company, if any</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 50%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Address
    for Notice:</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 50%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Number
    of shares of Common Stock</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Number
    of shares of Common Stock underlying subject to warrants, options, debentures or other convertible securities</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By
signing below, the Company agrees to enforce the restrictions on transfer set forth in this Letter Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>ENVERIC
    BIOSCIENCES, INC. </B></FONT></TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 5%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 45%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 50%">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:
    </FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD>
    <TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name:
    </FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Joseph
    Tucker</FONT></TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title:</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief
    Executive Officer</FONT></TD>
    <TD>&nbsp;</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 6.9pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 45 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I></I></FONT></P>




<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I></I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><U>EXHIBIT
B</U></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Form
of Press Release</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Enveric
BioSciences, Inc.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>[Date]</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Enveric
BioSciences, Inc. (the &ldquo;Company&rdquo;) announced today that A.G.P./Alliance Global Partners, acting as representative for the
underwriters in the Company&rsquo;s recent public offering of 20,000,000 shares of Common Stock and warrants to purchase 20,000,000 shares
of Common Stock, is [waiving] [releasing] a lock-up restriction with respect to &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares of Common Stock held by [certain officers or directors]
[an officer or director] of the Company. The [waiver] [release] will take effect on&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; , 20&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; , and the shares may be sold on or after such
date.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>This
press release is not an offer or sale of the securities in the United States or in any other jurisdiction where such offer or sale is
prohibited, and such securities may not be offered or sold in the United States absent registration or an exemption from registration
under the Securities Act of 1933, as amended</B>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 46; Options: Last -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-4.1
<SEQUENCE>3
<FILENAME>ex4-1.htm
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0; text-transform: uppercase; text-align: center">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0; text-transform: none; text-align: right"><B>Exhibit 4.1</B></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0; text-transform: uppercase; text-align: center">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-transform: uppercase; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">COMMON
STOCK PURCHASE WARRANT</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-transform: uppercase; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">ENVERIC
BIOSCIENCES, INC.</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0; text-transform: uppercase; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; width: 18%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Warrant
    Shares:</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; width: 22%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">[&bull;]</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; width: 60%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Initial
    Exercise Date:</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">February
    15, 2022</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Issue
    Date:</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">February
    15, 2022</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">THIS
COMMON STOCK PURCHASE WARRANT (the &ldquo;<B>Warrant</B>&rdquo;) certifies that, for value received, [&bull;] or its assigns (the &ldquo;<B>Holder</B>&rdquo;)
is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after
the date hereof (the &ldquo;<B>Initial Exercise Date</B>&rdquo;) and on or prior to 5:00 p.m. (New York City time) on February 15, 2027
(the &ldquo;<B>Termination Date</B>&rdquo;) but not thereafter, to subscribe for and purchase from Enveric BioSciences, Inc., a Delaware
corporation (the &ldquo;<B>Company</B>&rdquo;), up to [&bull;] shares (as subject to adjustment hereunder, the &ldquo;<B>Warrant Shares</B>&rdquo;)
of Common Stock. The purchase price of one share of Common Stock under this Warrant shall be equal to the Exercise Price, as defined
in <U>Section 2(b)</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section
1. <U>Definitions</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Capitalized
terms used and not otherwise defined herein shall have the meanings set forth in that certain Underwriting Agreement (the &ldquo;<B>Underwriting
Agreement</B>&rdquo;), dated February [&bull;], 2022, among the Company and the underwriters referred to therein.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section
2. <U>Exercise</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)
<U>Exercise of Warrant</U>. Exercise of the purchase rights represented by this Warrant may be made, in whole or in part, at any time
or times on or after the Initial Exercise Date and on or before the Termination Date by delivery to the Company of a duly executed facsimile
copy or PDF copy submitted by e-mail (or e-mail attachment) of the Notice of Exercise in the form annexed hereto (the &ldquo;<B>Notice
of Exercise</B>&rdquo;). Within the earlier of (i) two (2) Trading Days and (ii) the number of Trading Days comprising the Standard Settlement
Period (as defined in <U>Section 2(d)(i)</U>) following the date of exercise as aforesaid, the Holder shall deliver the aggregate Exercise
Price for the Warrant Shares specified in the applicable Notice of Exercise by wire transfer or cashier&rsquo;s check drawn on a United
States bank unless the cashless exercise procedure specified in <U>Section 2(c)</U> below is permitted and specified in the applicable
Notice of Exercise. No ink-original Notice of Exercise shall be required, nor shall any medallion guarantee (or other type of guarantee
or notarization) of any Notice of Exercise be required. Notwithstanding anything herein to the contrary, the Holder shall not be required
to physically surrender this Warrant to the Company until the Holder has purchased all of the Warrant Shares available hereunder and
the Warrant has been exercised in full, in which case, the Holder shall surrender this Warrant to the Company for cancellation within
three (3) Trading Days of the date on which the final Notice of Exercise is delivered to the Company. Partial exercises of this Warrant
resulting in purchases of a portion of the total number of Warrant Shares available hereunder shall have the effect of lowering the outstanding
number of Warrant Shares purchasable hereunder in an amount equal to the applicable number of Warrant Shares purchased. The Holder and
the Company shall maintain records showing the number of Warrant Shares purchased and the date of such purchases. The Company shall deliver
any objection to any Notice of Exercise within one (1) Business Day of receipt of such notice. The Holder and any assignee, by acceptance
of this Warrant, acknowledge and agree that, by reason of the provisions of this paragraph, following the purchase of a portion of the
Warrant Shares hereunder, the number of Warrant Shares available for purchase hereunder at any given time may be less than the amount
stated on the face hereof.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)
<U>Exercise Price</U>. The exercise price per share of Common Stock under this Warrant shall be $[&bull;], subject to adjustment hereunder
(the &ldquo;<B>Exercise Price</B>&rdquo;).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)
<U>Cashless Exercise</U>. If at the time of exercise hereof there is no effective registration statement registering, or the prospectus
contained therein is not available for, the issuance or resale of the Warrant Shares to or by the Holder, then this Warrant may also
be exercised, in whole or in part, at such time by means of a &ldquo;cashless exercise&rdquo; in which the Holder shall be entitled to
receive a number of Warrant Shares equal to the quotient obtained by dividing [(A-B) (X)] by (A), where:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(A)
= as applicable: (i) the VWAP on the Trading Day immediately preceding the date of the applicable Notice of Exercise if such Notice of
Exercise is (1) both executed and delivered pursuant to <U>Section 2(a)</U> on a day that is not a Trading Day or (2) both executed and
delivered pursuant to <U>Section 2(a)</U> on a Trading Day prior to the opening of &ldquo;regular trading hours&rdquo; (as defined in
Rule 600(b) of Regulation NMS promulgated under the federal securities laws) on such Trading Day, (ii) at the option of the Holder, either
(y) the VWAP on the Trading Day immediately preceding the date of the applicable Notice of Exercise or (z) the Bid Price of the Common
Stock on the principal Trading Market as reported by Bloomberg L.P. (&ldquo;<B>Bloomberg</B>&rdquo;) as of the time of the Holder&rsquo;s
execution of the applicable Notice of Exercise if such Notice of Exercise is executed during &ldquo;regular trading hours&rdquo; on a
Trading Day and is delivered within two (2) hours thereafter (including until two (2) hours after the close of &ldquo;regular trading
hours&rdquo; on a Trading Day) pursuant to <U>Section 2(a)</U> or (iii) the VWAP on the date of the applicable Notice of Exercise if
the date of such Notice of Exercise is a Trading Day and such Notice of Exercise is both executed and delivered pursuant to <U>Section
2(a)</U> after the close of &ldquo;regular trading hours&rdquo; on such Trading Day;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(B)
= the Exercise Price of this Warrant, as adjusted hereunder; and</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(X)
= the number of Warrant Shares that would be issuable upon exercise of this Warrant in accordance with the terms of this Warrant if such
exercise were by means of a cash exercise rather than a cashless exercise.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
Warrant Shares are issued in such a cashless exercise, the parties acknowledge and agree that in accordance with Section 3(a)(9) of the
Securities Act, the Warrant Shares shall take on the registered characteristics of the Warrants being exercised. The Company agrees not
to take any position contrary to this <U>Section 2(c)</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 2; Options: NewSection; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<B>Bid
Price</B>&rdquo; means, for any date, the price determined by the first of the following clauses that applies: (a) if the Common Stock
is then listed or quoted on a Trading Market, the bid price of the Common Stock for the time in question (or the nearest preceding date)
on the Trading Market on which the Common Stock is then listed or quoted as reported by Bloomberg (based on a Trading Day from 9:30 a.m.
(New York City time) to 4:02 p.m. (New York City time)) or (b) in all other cases, the fair market value of a share of Common Stock as
determined by an independent appraiser selected in good faith by the Purchasers of a majority in interest of the Securities then outstanding
and reasonably acceptable to the Company, the fees and expenses of which shall be paid by the Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<B>Trading
Day</B>&rdquo; means any day on which the Trading Market is open for trading, including any day on which the Trading Market is open for
trading for a period of time less than the customary time; <I><U>provided</U></I>, that in the event that the shares of Common Stock
are not listed or quoted on a Trading Market, then Trading Day shall mean a Business Day.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<B>VWAP</B>&rdquo;
means, for any date, the price determined by the first of the following clauses that applies: (a) if the Common Stock is then listed
or quoted on a Trading Market, the daily volume weighted average price of the Common Stock for such date (or the nearest preceding date)
on the Trading Market on which the Common Stock is then listed or quoted as reported by Bloomberg (based on a Trading Day from 9:30 a.m.
(New York City time) to 4:02 p.m. (New York City time)) or (b) in all other cases, the fair market value of a share of Common Stock as
determined by an independent appraiser selected in good faith by the Purchasers of a majority in interest of the Securities then outstanding
and reasonably acceptable to the Company, the fees and expenses of which shall be paid by the Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Notwithstanding
anything herein to the contrary, on the Termination Date, this Warrant shall be automatically exercised via cashless exercise pursuant
to this <U>Section 2(c)</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(d)
<U>Mechanics of Exercise</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">i.
<U>Delivery of Warrant Shares Upon Exercise</U>. The Company shall cause the Warrant Shares purchased hereunder to be transmitted by
the Transfer Agent to the Holder by crediting the account of the Holder&rsquo;s or its designee&rsquo;s balance account with The Depository
Trust Company through its Deposit or Withdrawal at Custodian system (&ldquo;<B>DWAC</B>&rdquo;) if the Company is then a participant
in such system and either (A) there is an effective registration statement permitting the issuance of the Warrant Shares to or resale
of the Warrant Shares by the Holder or (B) this Warrant is being exercised via cashless exercise, and otherwise by physical delivery
of a certificate, registered in the Company&rsquo;s share register in the name of the Holder or its designee, for the number of Warrant
Shares to which the Holder is entitled pursuant to such exercise to the address specified by the Holder in the Notice of Exercise by
the date that is the earliest of (i) two (2) Trading Days after the delivery to the Company of the Notice of Exercise, (ii) one (1) Trading
Day after delivery of the aggregate Exercise Price to the Company and (iii) the number of Trading Days comprising the Standard Settlement
Period after the delivery to the Company of the Notice of Exercise (such date, the &ldquo;<B>Warrant Share Delivery Date</B>&rdquo;).
Upon delivery of the Notice of Exercise, the Holder shall be deemed for all corporate purposes to have become the holder of record of
the Warrant Shares with respect to which this Warrant has been exercised, irrespective of the date of delivery of the Warrant Shares,
provided that payment of the aggregate Exercise Price (other than in the case of a cashless exercise) is received within the earlier
of (i) two (2) Trading Days and (ii) the number of Trading Days comprising the Standard Settlement Period following delivery of the Notice
of Exercise. If the Company fails for any reason to deliver to the Holder the Warrant Shares subject to a Notice of Exercise by the Warrant
Share Delivery Date, the Company shall pay to the Holder, in cash, as liquidated damages and not as a penalty, for each $1,000 of Warrant
Shares subject to such exercise (based on the VWAP of the Common Stock on the date of the applicable Notice of Exercise), $10 per Trading
Day (increasing to $20 per Trading Day on the third Trading Day after the Warrant Share Delivery Date) for each Trading Day after such
Warrant Share Delivery Date until such Warrant Shares are delivered or Holder rescinds such exercise. The Company agrees to use commercially
reasonable efforts to maintain a transfer agent that is a participant in the FAST program so long as this Warrant remains outstanding
and exercisable. As used herein, &ldquo;<B>Standard Settlement Period</B>&rdquo; means the standard settlement period, expressed in a
number of Trading Days, on the Company&rsquo;s primary Trading Market with respect to the Common Stock as in effect on the date of delivery
of a duly executed Notice of Exercise.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 3; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">ii.
<U>Delivery of New Warrants Upon Exercise</U>. If this Warrant shall have been exercised in part, the Company shall, at the request of
a Holder and upon surrender of this Warrant certificate, at the time of delivery of the Warrant Shares, deliver to the Holder a new Warrant
evidencing the rights of the Holder to purchase the unpurchased Warrant Shares called for by this Warrant, which new Warrant shall in
all other respects be identical with this Warrant.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">iii.
<U>Rescission Rights</U>. If the Company fails to cause the Transfer Agent to transmit to the Holder the Warrant Shares pursuant to <U>Section
2(d)(i)</U> by the Warrant Share Delivery Date, then the Holder will have the right to rescind such exercise.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">iv.
<U>Compensation for Buy-In on Failure to Timely Deliver Warrant Shares Upon Exercise</U>. In addition to any other rights available to
the Holder, if the Company fails to cause the Transfer Agent to transmit to the Holder the Warrant Shares in accordance with the provisions
of <U>Section 2(d)(i)</U> above pursuant to an exercise on or before the Warrant Share Delivery Date, and if after such date the Holder
is required by its broker to purchase (in an open market transaction or otherwise) or the Holder&rsquo;s brokerage firm otherwise purchases,
shares of Common Stock to deliver in satisfaction of a sale by the Holder of the Warrant Shares which the Holder anticipated receiving
upon such exercise (a &ldquo;<B>Buy-In</B>&rdquo;), then the Company shall (A) pay in cash to the Holder the amount, if any, by which
(x) the Holder&rsquo;s total purchase price (including brokerage commissions, if any) for the shares of Common Stock so purchased exceeds
(y) the amount obtained by multiplying (1) the number of Warrant Shares that the Company was required to deliver to the Holder in connection
with the exercise at issue times (2) the price at which the sell order giving rise to such purchase obligation was executed, and (B)
at the option of the Holder, either reinstate the portion of the Warrant and equivalent number of Warrant Shares for which such exercise
was not honored (in which case such exercise shall be deemed rescinded) or deliver to the Holder the number of shares of Common Stock
that would have been issued had the Company timely complied with its exercise and delivery obligations hereunder. For example, if the
Holder purchases Common Stock having a total purchase price of $11,000 to cover a Buy-In with respect to an attempted exercise of shares
of Common Stock with an aggregate sale price giving rise to such purchase obligation of $10,000, under clause (A) of the immediately
preceding sentence the Company shall be required to pay the Holder $1,000. The Holder shall provide the Company written notice indicating
the amounts payable to the Holder in respect of the Buy-In and, upon request of the Company, evidence of the amount of such loss. Nothing
herein shall limit a Holder&rsquo;s right to pursue any other remedies available to it hereunder, at law or in equity including, without
limitation, a decree of specific performance and/or injunctive relief with respect to the Company&rsquo;s failure to timely deliver shares
of Common Stock upon exercise of the Warrant as required pursuant to the terms hereof.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 4; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">v.
<U>No Fractional Shares or Scrip</U>. No fractional shares or scrip representing fractional shares shall be issued upon the exercise
of this Warrant. As to any fraction of a share which the Holder would otherwise be entitled to purchase upon such exercise, the Company
shall, at its election, either pay a cash adjustment in respect of such final fraction in an amount equal to such fraction multiplied
by the Exercise Price or round up to the next whole share.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">vi.
<U>Charges, Taxes and Expenses</U>. Issuance of Warrant Shares shall be made without charge to the Holder for any issue or transfer tax
or other incidental expense in respect of the issuance of such Warrant Shares, all of which taxes and expenses shall be paid by the Company,
and such Warrant Shares shall be issued in the name of the Holder or in such name or names as may be directed by the Holder; provided,
however, that, in the event that Warrant Shares are to be issued in a name other than the name of the Holder, this Warrant when surrendered
for exercise shall be accompanied by the Assignment Form attached hereto duly executed by the Holder and the Company may require, as
a condition thereto, the payment of a sum sufficient to reimburse it for any transfer tax incidental thereto. The Company shall pay all
Transfer Agent fees required for same-day processing of any Notice of Exercise and all fees to the Depository Trust Company (or another
established clearing corporation performing similar functions) required for same-day electronic delivery of the Warrant Shares.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">vii.
<U>Closing of Books</U>. The Company will not close its stockholder books or records in any manner which prevents the timely exercise
of this Warrant, pursuant to the terms hereof.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 5; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(e)
<U>Holder&rsquo;s Exercise Limitations</U>. The Company shall not effect any exercise of this Warrant, and a Holder shall not have the
right to exercise any portion of this Warrant, pursuant to <U>Section 2</U> or otherwise, to the extent that after giving effect to such
issuance after exercise as set forth on the applicable Notice of Exercise, the Holder (together with the Holder&rsquo;s Affiliates, and
any other Persons acting as a group together with the Holder or any of the Holder&rsquo;s Affiliates (such Persons, &ldquo;<B>Attribution
Parties</B>&rdquo;)), would beneficially own in excess of the Beneficial Ownership Limitation (as defined below). For purposes of the
foregoing sentence, the number of shares of Common Stock beneficially owned by the Holder and its Affiliates and Attribution Parties
shall include the number of shares of Common Stock issuable upon exercise of this Warrant with respect to which such determination is
being made, but shall exclude the number of shares of Common Stock which would be issuable upon (i) exercise of the remaining, nonexercised
portion of this Warrant beneficially owned by the Holder or any of its Affiliates or Attribution Parties and (ii) exercise or conversion
of the unexercised or nonconverted portion of any other securities of the Company (including, without limitation, any other Common Stock
Equivalents) subject to a limitation on conversion or exercise analogous to the limitation contained herein beneficially owned by the
Holder or any of its Affiliates or Attribution Parties. Except as set forth in the preceding sentence, for purposes of this <U>Section
2(e)</U>, beneficial ownership shall be calculated in accordance with Section 13(d) of the Exchange Act and the rules and regulations
promulgated thereunder, it being acknowledged by the Holder that the Company is not representing to the Holder that such calculation
is in compliance with Section 13(d) of the Exchange Act and the Holder is solely responsible for any schedules required to be filed in
accordance therewith. To the extent that the limitation contained in this <U>Section 2(e)</U> applies, the determination of whether this
Warrant is exercisable (in relation to other securities owned by the Holder together with any Affiliates and Attribution Parties) and
of which portion of this Warrant is exercisable shall be in the sole discretion of the Holder, and the submission of a Notice of Exercise
shall be deemed to be the Holder&rsquo;s determination of whether this Warrant is exercisable (in relation to other securities owned
by the Holder together with any Affiliates and Attribution Parties) and of which portion of this Warrant is exercisable, in each case
subject to the Beneficial Ownership Limitation, and the Company shall have no obligation to verify or confirm the accuracy of such determination.
In addition, a determination as to any group status as contemplated above shall be determined in accordance with Section 13(d) of the
Exchange Act and the rules and regulations promulgated thereunder. For purposes of this <U>Section 2(e)</U>, in determining the number
of outstanding shares of Common Stock, a Holder may rely on the number of outstanding shares of Common Stock as reflected in (A) the
Company&rsquo;s most recent periodic or annual report filed with the Commission, as the case may be, (B) a more recent public announcement
by the Company or (C) a more recent written notice by the Company or the Transfer Agent setting forth the number of shares of Common
Stock outstanding. Upon the written or oral request of a Holder, the Company shall within one (1) Trading Day confirm orally and in writing
to the Holder the number of shares of Common Stock then outstanding. In any case, the number of outstanding shares of Common Stock shall
be determined after giving effect to the conversion or exercise of securities of the Company, including this Warrant, by the Holder or
its Affiliates or Attribution Parties since the date as of which such number of outstanding shares of Common Stock was reported. The
&ldquo;<B>Beneficial Ownership Limitation</B>&rdquo; shall be [4.99%/9.99%] of the number of shares of the Common Stock outstanding immediately
after giving effect to the issuance of shares of Common Stock issuable upon exercise of this Warrant. The Holder, upon notice to the
Company, may increase or decrease the Beneficial Ownership Limitation provisions of this <U>Section 2(e)</U>, <I><U>provided</U></I>
that the Beneficial Ownership Limitation in no event exceeds 9.99% of the number of shares of the Common Stock outstanding immediately
after giving effect to the issuance of shares of Common Stock upon exercise of this Warrant held by the Holder and the provisions of
this <U>Section 2(e)</U> shall continue to apply. Any increase in the Beneficial Ownership Limitation will not be effective until the
61st day after such notice is delivered to the Company. The provisions of this paragraph shall be construed and implemented in a manner
otherwise than in strict conformity with the terms of this <U>Section 2(e)</U> to correct this paragraph (or any portion hereof) which
may be defective or inconsistent with the intended Beneficial Ownership Limitation herein contained or to make changes or supplements
necessary or desirable to properly give effect to such limitation. The limitations contained in this paragraph shall apply to a successor
holder of this Warrant.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 6; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section
3. <U>Certain Adjustments</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)
<U>Stock Dividends and Splits</U>. If the Company, at any time while this Warrant is outstanding: (i) pays a stock dividend or otherwise
makes a distribution or distributions on shares of its Common Stock or any other equity or equity equivalent securities payable in shares
of Common Stock (which, for avoidance of doubt, shall not include any shares of Common Stock issued by the Company upon exercise of this
Warrant), (ii) subdivides outstanding shares of Common Stock into a larger number of shares, (iii) combines (including by way of reverse
stock split) outstanding shares of Common Stock into a smaller number of shares, or (iv) issues by reclassification of shares of the
Common Stock any shares of capital stock of the Company, then in each case the Exercise Price shall be multiplied by a fraction of which
the numerator shall be the number of shares of Common Stock (excluding treasury shares, if any) outstanding immediately before such event
and of which the denominator shall be the number of shares of Common Stock outstanding immediately after such event, and the number of
shares issuable upon exercise of this Warrant shall be proportionately adjusted such that the aggregate Exercise Price of this Warrant
shall remain unchanged. Any adjustment made pursuant to this <U>Section 3(a)</U> shall become effective immediately after the record
date for the determination of stockholders entitled to receive such dividend or distribution and shall become effective immediately after
the effective date in the case of a subdivision, combination or re-classification.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)
<U>Reserved</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)
<U>Subsequent Rights Offerings</U>. In addition to any adjustments pursuant to <U>Section 3(a)</U> above, if at any time the Company
grants, issues or sells any Common Stock Equivalents or rights to purchase stock, warrants, securities or other property pro rata to
the record holders of any class of shares of Common Stock (the &ldquo;<B>Purchase Rights</B>&rdquo;), then the Holder will be entitled
to acquire, upon the terms applicable to such Purchase Rights, the aggregate Purchase Rights which the Holder could have acquired if
the Holder had held the number of shares of Common Stock acquirable upon complete exercise of this Warrant (without regard to any limitations
on exercise hereof, including without limitation, the Beneficial Ownership Limitation) immediately before the date on which a record
is taken for the grant, issuance or sale of such Purchase Rights, or, if no such record is taken, the date as of which the record holders
of shares of Common Stock are to be determined for the grant, issue or sale of such Purchase Rights (<I><U>provided</U></I>, <I><U>however</U></I>,
that, to the extent that the Holder&rsquo;s right to participate in any such Purchase Right would result in the Holder exceeding the
Beneficial Ownership Limitation, then the Holder shall not be entitled to participate in such Purchase Right to such extent (or beneficial
ownership of such shares of Common Stock as a result of such Purchase Right to such extent) and such Purchase Right to such extent shall
be held in abeyance for the Holder until such time, if ever, as its right thereto would not result in the Holder exceeding the Beneficial
Ownership Limitation).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(d)
<U>Pro Rata Distributions</U>. During such time as this Warrant is outstanding, if the Company shall declare or make any dividend or
other distribution of its assets (or rights to acquire its assets) to holders of shares of Common Stock, by way of return of capital
or otherwise (including, without limitation, any distribution of cash, stock or other securities, property or options by way of a dividend,
spin off, reclassification, corporate rearrangement, scheme of arrangement or other similar transaction) (a &ldquo;<B>Distribution</B>&rdquo;),
at any time after the issuance of this Warrant, then, in each such case, the Holder shall be entitled to participate in such Distribution
to the same extent that the Holder would have participated therein if the Holder had held the number of shares of Common Stock acquirable
upon complete exercise of this Warrant (without regard to any limitations on exercise hereof, including without limitation, the Beneficial
Ownership Limitation) immediately before the date of which a record is taken for such Distribution, or, if no such record is taken, the
date as of which the record holders of shares of Common Stock are to be determined for the participation in such Distribution (<I><U>provided</U></I>,
<I><U>however</U></I>, that, to the extent that the Holder&rsquo;s right to participate in any such Distribution would result in the
Holder exceeding the Beneficial Ownership Limitation, then the Holder shall not be entitled to participate in such Distribution to such
extent (or in the beneficial ownership of any shares of Common Stock as a result of such Distribution to such extent) and the portion
of such Distribution shall be held in abeyance for the benefit of the Holder until such time, if ever, as its right thereto would not
result in the Holder exceeding the Beneficial Ownership Limitation). To the extent that this Warrant has not been partially or completely
exercised at the time of such Distribution, such portion of the Distribution shall be held in abeyance for the benefit of the Holder
until the Holder has exercised this Warrant.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 7; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(e)
<U>Fundamental Transaction</U>. If, at any time while this Warrant is outstanding, (i) the Company, directly or indirectly, in one or
more related transactions effects any merger or consolidation of the Company with or into another Person, (ii) the Company or any Subsidiary,
directly or indirectly, effects any sale, lease, license, assignment, transfer, conveyance or other disposition of all or substantially
all of its assets in one or a series of related transactions, (iii) any, direct or indirect, purchase offer, tender offer or exchange
offer (whether by the Company or another Person) is completed pursuant to which holders of Common Stock are permitted to sell, tender
or exchange their shares for other securities, cash or property and has been accepted by the holders of 50% or more of the outstanding
Common Stock, (iv) the Company, directly or indirectly, in one or more related transactions effects any reclassification, reorganization
or recapitalization of the Common Stock or any compulsory share exchange pursuant to which the Common Stock is effectively converted
into or exchanged for other securities, cash or property, or (v) the Company, directly or indirectly, in one or more related transactions
consummates a stock or share purchase agreement or other business combination (including, without limitation, a reorganization, recapitalization,
spin-off, merger or scheme of arrangement) with another Person or group of Persons whereby such other Person or group acquires more than
50% of the outstanding shares of Common Stock (not including any shares of Common Stock held by the other Person or other Persons making
or party to, or associated or affiliated with the other Persons making or party to, such stock or share purchase agreement or other business
combination) (each a &ldquo;<B>Fundamental Transaction</B>&rdquo;), then, upon any subsequent exercise of this Warrant, the Holder shall
have the right to receive, for each Warrant Share that would have been issuable upon such exercise immediately prior to the occurrence
of such Fundamental Transaction, at the option of the Holder (without regard to any limitation in <U>Section 2(e)</U> on the exercise
of this Warrant), the number of shares of Common Stock of the successor or acquiring corporation or of the Company, if it is the surviving
corporation, and any additional consideration (the &ldquo;<B>Alternate Consideration</B>&rdquo;) receivable as a result of such Fundamental
Transaction by a holder of the number of shares of Common Stock for which this Warrant is exercisable immediately prior to such Fundamental
Transaction (without regard to any limitation in <U>Section 2(e)</U> on the exercise of this Warrant). For purposes of any such exercise,
the determination of the Exercise Price shall be appropriately adjusted to apply to such Alternate Consideration based on the amount
of Alternate Consideration issuable in respect of one share of Common Stock in such Fundamental Transaction, and the Company shall apportion
the Exercise Price among the Alternate Consideration in a reasonable manner reflecting the relative value of any different components
of the Alternate Consideration. If holders of Common Stock are given any choice as to the securities, cash or property to be received
in a Fundamental Transaction, then the Holder shall be given the same choice as to the Alternate Consideration it receives upon any exercise
of this Warrant following such Fundamental Transaction. Notwithstanding anything to the contrary, in the event of a Fundamental Transaction,
the Company or any Successor Entity (as defined below) shall, at the Holder&rsquo;s option, exercisable at any time concurrently with,
or within 30 days after, the consummation of the Fundamental Transaction (or, if later, the date of the public announcement of the applicable
Fundamental Transaction), purchase this Warrant from the Holder by paying to the Holder an amount of cash equal to the Black Scholes
Value (as defined below) of the remaining unexercised portion of this Warrant on the date of the consummation of such Fundamental Transaction;
<I><U>provided</U></I>, <I><U>however</U></I>, that, if the Fundamental Transaction is not within the Company&rsquo;s control, including
not approved by the Company&rsquo;s Board of Directors, Holder shall only be entitled to receive from the Company or any Successor Entity
the same type or form of consideration (and in the same proportion), at the Black Scholes Value of the unexercised portion of this Warrant,
that is being offered and paid to the holders of Common Stock of the Company in connection with the Fundamental Transaction, whether
that consideration be in the form of cash, stock or any combination thereof, or whether the holders of Common Stock are given the choice
to receive from among alternative forms of consideration in connection with the Fundamental Transaction; <I><U>provided</U></I>, <I><U>further</U></I>,
that if holders of Common Stock of the Company are not offered or paid any consideration in such Fundamental Transaction, such holders
of Common Stock will be deemed to have received common stock of the Successor Entity (which Successor Entity may be the Company following
such Fundamental Transaction) in such Fundamental Transaction. &ldquo;<B>Black Scholes Value</B>&rdquo; means the value of this Warrant
based on the Black-Scholes Option Pricing Model obtained from the &ldquo;OV&rdquo; function on Bloomberg determined as of the day of
consummation of the applicable Fundamental Transaction for pricing purposes and reflecting (A) a risk-free interest rate corresponding
to the U.S. Treasury rate for a period equal to the time between the date of the public announcement of the applicable Fundamental Transaction
and the Termination Date, (B) an expected volatility equal to the greater of 100% and the 100 day volatility obtained from the HVT function
on Bloomberg (determined utilizing a 365 day annualization factor) as of the Trading Day immediately following the public announcement
of the applicable Fundamental Transaction, (C) the underlying price per share used in such calculation shall be the greater of (i) the
sum of the price per share being offered in cash, if any, plus the value of any non-cash consideration, if any, being offered in such
Fundamental Transaction and (ii) the highest VWAP during the period beginning on the Trading Day immediately preceding the announcement
of the applicable Fundamental Transaction (or the consummation of the applicable Fundamental Transaction, if earlier) and ending on the
Trading Day of the Holder&rsquo;s request pursuant to this <U>Section 3(e)</U> and (D) a remaining option time equal to the time between
the date of the public announcement of the applicable Fundamental Transaction and the Termination Date and (E) a zero cost of borrow.
The payment of the Black Scholes Value will be made by wire transfer of immediately available funds (or such other consideration) within
the later of (i) five Business Days of the Holder&rsquo;s election and (ii) the date of consummation of the Fundamental Transaction.
The Company shall cause any successor entity in a Fundamental Transaction in which the Company is not the survivor (the &ldquo;<B>Successor
Entity</B>&rdquo;) to assume in writing all of the obligations of the Company under this Warrant and the other Transaction Documents.
Upon the occurrence of any such Fundamental Transaction, the Successor Entity shall succeed to, and be substituted for (so that from
and after the date of such Fundamental Transaction, the provisions of this Warrant and the other Transaction Documents referring to the
&ldquo;Company&rdquo; shall refer instead to the Successor Entity), and may exercise every right and power of the Company and shall assume
all of the obligations of the Company under this Warrant and the other Transaction Documents with the same effect as if such Successor
Entity had been named as the Company herein.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 8; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(f)
<U>Calculations</U>. All calculations under this <U>Section 3</U> shall be made to the nearest cent or the nearest 1/100th of a share,
as the case may be. For purposes of this Section 3, the number of shares of Common Stock deemed to be issued and outstanding as of a
given date shall be the sum of the number of shares of Common Stock (excluding treasury shares, if any) issued and outstanding.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(g)
<U>Notice to Holder</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">i.
<U>Adjustment to Exercise Price</U>. Whenever the Exercise Price is adjusted pursuant to any provision of this <U>Section 3</U>, the
Company shall promptly deliver to the Holder by facsimile or email a notice setting forth the Exercise Price after such adjustment and
any resulting adjustment to the number of Warrant Shares and setting forth a brief statement of the facts requiring such adjustment.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">ii.
<U>Notice to Allow Exercise by Holder</U>. If (A) the Company shall declare a dividend (or any other distribution in whatever form) on
the Common Stock, (B) the Company shall declare a special nonrecurring cash dividend on or a redemption of the Common Stock, (C) the
Company shall authorize the granting to all holders of the Common Stock rights or warrants to subscribe for or purchase any shares of
capital stock of any class or of any rights, (D) the approval of any stockholders of the Company shall be required in connection with
any reclassification of the Common Stock, any consolidation or merger to which the Company (or any of its Subsidiaries) is a party, any
sale or transfer of all or substantially all of its assets, or any compulsory share exchange whereby the Common Stock is converted into
other securities, cash or property, or (E) the Company shall authorize the voluntary or involuntary dissolution, liquidation or winding
up of the affairs of the Company, then, in each case, the Company shall cause to be delivered by facsimile or email to the Holder at
its last facsimile number or email address as it shall appear upon the Warrant Register of the Company, at least 10 calendar days prior
to the applicable effective date hereinafter specified, a notice stating (x) the date on which a record is to be taken for the purpose
of such dividend, distribution, redemption, rights or warrants, or if a record is not to be taken, the date as of which the holders of
the Common Stock of record to be entitled to such dividend, distributions, redemption, rights or warrants are to be determined or (y)
the date on which such reclassification, consolidation, merger, sale, transfer or share exchange is expected to become effective or close,
and the date as of which it is expected that holders of the Common Stock of record shall be entitled to exchange their shares of the
Common Stock for securities, cash or other property deliverable upon such reclassification, consolidation, merger, sale, transfer or
share exchange; <I><U>provided</U></I> that the failure to deliver such notice or any defect therein or in the delivery thereof shall
not affect the validity of the corporate action required to be specified in such notice. To the extent that any notice provided in this
Warrant constitutes, or contains, material, non-public information regarding the Company or any of the Subsidiaries, the Company shall
simultaneously file such notice with the Commission pursuant to a Current Report on Form 8-K. The Holder shall remain entitled to exercise
this Warrant during the period commencing on the date of such notice to the effective date of the event triggering such notice except
as may otherwise be expressly set forth herein.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(h)
<U>Voluntary Adjustment By Company</U>. Subject to the rules and regulations of the Trading Market, the Company may at any time during
the term of this Warrant, subject to the prior written consent of the Holder, reduce the then current Exercise Price to any amount and
for any period of time deemed appropriate by the board of directors of the Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 9; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section
4. <U>Transfer of Warrant</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)
<U>Transferability</U>. Subject to compliance with applicable securities laws, this Warrant and all rights hereunder (including, without
limitation, any registration rights) are transferable, in whole or in part, upon surrender of this Warrant at the principal office of
the Company or its designated agent, together with a written assignment of this Warrant substantially in the form attached hereto duly
executed by the Holder or its agent or attorney and funds sufficient to pay any transfer taxes payable upon the making of such transfer.
Upon such surrender and, if required, such payment, the Company shall execute and deliver a new Warrant or Warrants in the name of the
assignee or assignees, as applicable, and in the denomination or denominations specified in such instrument of assignment, and shall
issue to the assignor a new Warrant evidencing the portion of this Warrant not so assigned, and this Warrant shall promptly be cancelled.
Notwithstanding anything herein to the contrary, the Holder shall not be required to physically surrender this Warrant to the Company
unless the Holder has assigned this Warrant in full, in which case, the Holder shall surrender this Warrant to the Company within three
(3) Trading Days of the date on which the Holder delivers an assignment form to the Company assigning this Warrant in full. The Warrant,
if properly assigned in accordance herewith, may be exercised by a new holder for the purchase of Warrant Shares without having a new
Warrant issued.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)
<U>New Warrants</U>. This Warrant may be divided or combined with other Warrants upon presentation hereof at the aforesaid office of
the Company, together with a written notice specifying the names and denominations in which new Warrants are to be issued, signed by
the Holder or its agent or attorney. Subject to compliance with <U>Section 4(a)</U>, as to any transfer which may be involved in such
division or combination, the Company shall execute and deliver a new Warrant or Warrants in exchange for the Warrant or Warrants to be
divided or combined in accordance with such notice. All Warrants issued on transfers or exchanges shall be dated the initial Issue Date
of this Warrant and shall be identical with this Warrant except as to the number of Warrant Shares issuable pursuant thereto.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)
<U>Warrant Register</U>. The Company shall register this Warrant, upon records to be maintained by the Company for that purpose (the
&ldquo;<B>Warrant Register</B>&rdquo;), in the name of the record Holder hereof from time to time. The Company may deem and treat the
registered Holder of this Warrant as the absolute owner hereof for the purpose of any exercise hereof or any distribution to the Holder,
and for all other purposes, absent actual notice to the contrary.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section
5. <U>Miscellaneous</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)
<U>No Rights as Stockholder Until Exercise; No Settlement in Cash</U>. This Warrant does not entitle the Holder to any voting rights,
dividends or other rights as a stockholder of the Company prior to the exercise hereof as set forth in <U>Section 2(d)(i)</U>, except
as expressly set forth in <U>Section 3</U>. Without limiting any rights of a Holder to receive Warrant Shares on a &ldquo;cashless exercise&rdquo;
pursuant to <U>Section 2(c)</U> or to receive cash payments pursuant to <U>Section 2(d)(i)</U> and <U>Section 2(d)(iv)</U>, in no event
shall the Company be required to net cash settle an exercise of this Warrant.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)
<U>Loss, Theft, Destruction or Mutilation of Warrant</U>. The Company covenants that upon receipt by the Company of evidence reasonably
satisfactory to it of the loss, theft, destruction or mutilation of this Warrant or any stock certificate relating to the Warrant Shares,
and in case of loss, theft or destruction, of indemnity or security reasonably satisfactory to it (which, in the case of the Warrant,
shall not include the posting of any bond), and upon surrender and cancellation of such Warrant or stock certificate, if mutilated, the
Company will make and deliver a new Warrant or stock certificate of like tenor and dated as of such cancellation, in lieu of such Warrant
or stock certificate.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 10; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)
<U>Saturdays, Sundays, Holidays, etc</U>. If the last or appointed day for the taking of any action or the expiration of any right required
or granted herein shall not be a Trading Day, then such action may be taken or such right may be exercised on the next succeeding Trading
Day.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(d)
<U>Authorized Shares</U>. The Company covenants that, during the period the Warrant is outstanding, it will reserve from its authorized
and unissued Common Stock a sufficient number of shares to provide for the issuance of the Warrant Shares upon the exercise of any purchase
rights under this Warrant. The Company further covenants that its issuance of this Warrant shall constitute full authority to its officers
who are charged with the duty of issuing the necessary Warrant Shares upon the exercise of the purchase rights under this Warrant. The
Company will take all such reasonable action as may be necessary to assure that such Warrant Shares may be issued as provided herein
without violation of any applicable law or regulation, or of any requirements of the Trading Market upon which the Common Stock may be
listed. The Company covenants that all Warrant Shares which may be issued upon the exercise of the purchase rights represented by this
Warrant will, upon exercise of the purchase rights represented by this Warrant and payment for such Warrant Shares in accordance herewith,
be duly authorized, validly issued, fully paid and nonassessable and free from all taxes, liens and charges created by the Company in
respect of the issue thereof (other than taxes in respect of any transfer occurring contemporaneously with such issue).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Except
and to the extent as waived or consented to by the Holder, the Company shall not by any action, including, without limitation, amending
its certificate of incorporation or through any reorganization, transfer of assets, consolidation, merger, dissolution, issue or sale
of securities or any other voluntary action, avoid or seek to avoid the observance or performance of any of the terms of this Warrant,
but will at all times in good faith assist in the carrying out of all such terms and in the taking of all such actions as may be necessary
or appropriate to protect the rights of Holder as set forth in this Warrant against impairment. Without limiting the generality of the
foregoing, the Company will (i) not increase the par value of any Warrant Shares above the amount payable therefor upon such exercise
immediately prior to such increase in par value, (ii) take all such action as may be necessary or appropriate in order that the Company
may validly and legally issue fully paid and nonassessable Warrant Shares upon the exercise of this Warrant and (iii) use commercially
reasonable efforts to obtain all such authorizations, exemptions or consents from any public regulatory body having jurisdiction thereof,
as may be, necessary to enable the Company to perform its obligations under this Warrant.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Before
taking any action which would result in an adjustment in the number of Warrant Shares for which this Warrant is exercisable or in the
Exercise Price, the Company shall obtain all such authorizations or exemptions thereof, or consents thereto, as may be necessary from
any public regulatory body or bodies having jurisdiction thereof.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 11; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(e)
<U>Jurisdiction</U>. This Warrant shall be governed by and construed and enforced in accordance with the laws of the State of New York,
without giving effect to conflict of laws principles thereof. The Company hereby agrees that any action, proceeding or claim against
it arising out of, or relating in any way to this Warrant shall be brought and enforced in the New York Supreme Court, County of New
York, or in the United States District Court for the Southern District of New York, and irrevocably submits to such jurisdiction, which
jurisdiction shall be exclusive. The Company hereby waives any objection to such exclusive jurisdiction and that such courts represent
an inconvenient forum. Any such process or summons to be served upon the Company may be served by transmitting a copy thereof by registered
or certified mail, return receipt requested, postage prepaid, addressed to it at the address set forth in <U>Section 5(h)</U>. Such mailing
shall be deemed personal service and shall be legal and binding upon the Company in any action, proceeding or claim. The Company agrees
that the prevailing party(ies) in any such action shall be entitled to recover from the other party(ies) all of its reasonable attorneys&rsquo;
fees and expenses relating to such action or proceeding and/or incurred in connection with the preparation therefor. The Company (on
its behalf and, to the extent permitted by applicable law, on behalf of its stockholders and affiliates) and the Holder each hereby irrevocably
waives, to the fullest extent permitted by applicable law, any and all right to trial by jury in any legal proceeding arising out of
or relating to this Warrant or the transactions contemplated hereby.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(f)
<U>Restrictions</U>. The Holder acknowledges that the Warrant Shares acquired upon the exercise of this Warrant, if not registered, and
the Holder does not utilize cashless exercise, will have restrictions upon resale imposed by state and federal securities laws.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(g)
<U>Nonwaiver and Expenses</U>. No course of dealing or any delay or failure to exercise any right hereunder on the part of Holder shall
operate as a waiver of such right or otherwise prejudice the Holder&rsquo;s rights, powers or remedies. Without limiting any other provision
of this Warrant or the Underwriting Agreement, if the Company willfully and knowingly fails to comply with any provision of this Warrant,
which results in any material damages to the Holder, the Company shall pay to the Holder such amounts as shall be sufficient to cover
any costs and expenses including, but not limited to, reasonable attorneys&rsquo; fees, including those of appellate proceedings, incurred
by the Holder in collecting any amounts due pursuant hereto or in otherwise enforcing any of its rights, powers or remedies hereunder.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(h)
<U>Notices</U>. All communications hereunder, except as herein otherwise specifically provided, shall be in writing and shall be mailed
(registered or certified mail, return receipt requested), personally delivered or sent by email transmission and confirmed and shall
be deemed given when so delivered or sent via email and confirmed or if mailed, two (2) days after such mailing.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; width: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(i)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">if
    to the Company, to:</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Enveric
    BioSciences, Inc.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4851
    Tamiami Trail N, Suite 200</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Naples,
    Florida 34103</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Attention:
    Joseph Tucker, Chief Executive Officer</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Email:
    jtucker@enveric.com</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 2in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 12; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; width: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(ii)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">if
    to the Holder, at such address or other contact information delivered by the Holder to Company or as is on the books and records
    of the Company.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(i)
<U>Limitation of Liability</U>. No provision hereof, in the absence of any affirmative action by the Holder to exercise this Warrant
to purchase Warrant Shares, and no enumeration herein of the rights or privileges of the Holder, shall give rise to any liability of
the Holder for the purchase price of any Common Stock or as a stockholder of the Company, whether such liability is asserted by the Company
or by creditors of the Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(j)
<U>Remedies</U>. The Holder, in addition to being entitled to exercise all rights granted by law, including recovery of damages, will
be entitled to specific performance of its rights under this Warrant. The Company agrees that monetary damages would not be adequate
compensation for any loss incurred by reason of a breach by it of the provisions of this Warrant and hereby agrees to waive and not to
assert the defense in any action for specific performance that a remedy at law would be adequate.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(k)
<U>Successors and Assigns</U>. Subject to applicable securities laws, this Warrant and the rights and obligations evidenced hereby shall
inure to the benefit of and be binding upon the successors and permitted assigns of the Company and the successors and permitted assigns
of Holder. The provisions of this Warrant are intended to be for the benefit of any Holder from time to time of this Warrant and shall
be enforceable by the Holder or holder of Warrant Shares.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(l)
<U>Amendment</U>. This Warrant may be modified or amended or the provisions hereof waived with the written consent of the Company and
the Holder.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(m)
<U>Severability</U>. Wherever possible, each provision of this Warrant shall be interpreted in such manner as to be effective and valid
under applicable law, but if any provision of this Warrant shall be prohibited by or invalid under applicable law, such provision shall
be ineffective to the extent of such prohibition or invalidity, without invalidating the remainder of such provisions or the remaining
provisions of this Warrant.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(n)
<U>Headings</U>. The headings used in this Warrant are for the convenience of reference only and shall not, for any purpose, be deemed
a part of this Warrant.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-transform: uppercase; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">********************</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0; text-transform: uppercase; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-transform: uppercase; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal; text-transform: none"><I>(Signature
Page Follows)</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-transform: uppercase; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal; text-transform: none"><I>&nbsp;</I></FONT></P>


<!-- Field: Page; Sequence: 13; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">IN
WITNESS WHEREOF, the Company has caused this Warrant to be executed by its officer thereunto duly authorized as of the date first above
indicated.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>ENVERIC
    BIOSCIENCES, INC.</B></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 50%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 5%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 45%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name:</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Joseph
    Tucker</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title:</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief
    Executive Officer</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 3in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>


<!-- Field: Page; Sequence: 14; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0; text-transform: uppercase; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">NOTICE
OF EXERCISE</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0; text-transform: uppercase; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" BORDER="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: top">
  <TD STYLE="text-align: justify; padding-left: 10pt; text-indent: -10pt; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">TO:</FONT></TD>
  <TD STYLE="text-align: justify; padding-left: 10pt; text-indent: -10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>ENVERIC BIOSCIENCES, INC</B></FONT></TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)
The undersigned hereby elects to purchase ________ Warrant Shares of the Company pursuant to the terms of the attached Warrant (only
if exercised in full), and tenders herewith payment of the exercise price in full, together with all applicable transfer taxes, if any.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(2)
Payment shall take the form of (check applicable box):</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">[&nbsp;&nbsp;] in lawful money of the United States; or</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">[&nbsp;&nbsp;] if permitted, the cancellation of such number of Warrant Shares as is necessary, in accordance with the formula set forth in subsection
2(c), to exercise this Warrant with respect to the maximum number of Warrant Shares purchasable pursuant to the cashless exercise procedure
set forth in subsection 2(c).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(3)
Please issue said Warrant Shares in the name of the undersigned or in such other name as is specified below:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center; width: 30%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif; text-align: center; width: 35%"></TD>
    <TD STYLE="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif; text-align: center; width: 35%"></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Warrant Shares shall be delivered to the following DWAC Account Number:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: center; font: 10pt Times New Roman, Times, Serif; width: 30%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="padding-bottom: 1.5pt; text-align: center; font: 10pt Times New Roman, Times, Serif; width: 35%"></TD>
    <TD STYLE="padding-bottom: 1.5pt; text-align: center; font: 10pt Times New Roman, Times, Serif; width: 35%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: center; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="padding-bottom: 1.5pt; text-align: center; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="padding-bottom: 1.5pt; text-align: center; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif; text-align: center"></TD>
    <TD STYLE="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">[SIGNATURE
OF HOLDER]</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name
of Investing Entity:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center; width: 60%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif; text-align: center; width: 40%"></TD>
    </TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I></I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Signature
of Authorized Signatory of Investing Entity:</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>&nbsp;</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center; width: 60%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif; text-align: center; width: 40%"></TD>
    </TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name
of Authorized Signatory:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center; width: 60%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif; text-align: center; width: 40%"></TD>
    </TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title
of Authorized Signatory:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center; width: 60%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif; text-align: center; width: 40%"></TD>
    </TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Date:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 15 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><B>&nbsp;</B></FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0; text-transform: uppercase; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">EXHIBIT
B</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0; text-transform: uppercase; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-transform: uppercase; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal"><I>ASSIGNMENT
FORM</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-transform: uppercase; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal"><I>&nbsp;</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>(To
assign the foregoing Warrant, execute this form and supply required information. Do not use this form to purchase shares.)</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>&nbsp;</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">FOR
VALUE RECEIVED, the foregoing Warrant and all rights evidenced thereby are hereby assigned to</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif; width: 50%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name:
    </FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; width: 50%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U></U></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Please
    Print)</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Address:
    </FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U></U></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Please
    Print)</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Phone
    Number: </FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U></U></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Email
    Address: </FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U></U></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dated:
    _______________ ___, ________</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Holder&rsquo;s
    Signature: </FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U></U></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Holder&rsquo;s
    Address: </FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U></U></FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 16; Options: Last -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-5.1
<SEQUENCE>4
<FILENAME>ex5-1.htm
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Exhibit
5.1</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">February
11, 2022</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Enveric
Biosciences, Inc.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4851
Tamiami Trail N, Suite 200</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Naples,
Florida 34103</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Ladies
and Gentlemen:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have acted as counsel for Enveric Biosciences, Inc., a Delaware corporation (the &ldquo;<U>Company</U>&rdquo;), in connection with the
filing with the Securities and Exchange Commission (the &ldquo;<B><I>Commission</I></B>&rdquo;) pursuant to Rule 424(b) under the Securities
Act of 1933, as amended (the &ldquo;<B><I>Act</I></B>&rdquo;) of the Company&rsquo;s prospectus supplement, dated February 11, 2022 (the
&ldquo;<B><I>Prospectus Supplement</I></B>&rdquo;), forming part of the registration statement on Form S-3, initially filed by the Company
with the Securities and Exchange Commission on July 2, 2021, and declared effective on July 9, 2021 (the &ldquo;<B><I>Registration Statement</I></B>&rdquo;).
The Prospectus Supplement relates to the proposed sale of up to 23,000,000 shares (the &ldquo;<B><I>Shares</I></B>&rdquo;) of the Company&rsquo;s
common stock, $0.01 par value per share (the &ldquo;<B><I>Common Stock</I></B>&rdquo;) and common warrants (the &ldquo;<B><I>Common Warrants</I></B>&rdquo;)
to purchase up to 23,000,000 shares of Common Stock (the &ldquo;<B><I>Warrant Shares</I></B>&rdquo;), each covered by the Registration
Statement. The Shares and Warrants include an over-allotment option granted to the underwriter of the offering to purchase 3,000,000
additional shares of Common Stock and/or warrants to purchase 3,000,000 shares of common stock. The Shares and Warrants are being sold
to the underwriter named in, and pursuant to, that certain Underwriting Agreement, dated February 11, 2022, by and among the Company
and such underwriter (the &ldquo;<B><I>Underwriting Agreement</I></B>&rdquo;).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
rendering the opinions expressed herein, we have examined and relied upon the originals, or copies certified or otherwise identified
to our satisfaction, of (i) the Company&rsquo;s Amended and Restated Certificate of Incorporation and bylaws, each as amended and/or
restated to date (&ldquo;<B><I>Company Charter Documents</I></B>&rdquo;); (ii) certain resolutions of the Pricing Committee of the Board
of Directors of the Company related to the filing of the Prospectus Supplement, the authorization and issuance of the Shares and related
matters; (iii) the Registration Statement, including the prospectus, and all exhibits thereto; (iv) the Prospectus Supplement and the
prospectus included in the Registration Statement dated July 9, 2021 (the &ldquo;<B><I>Base Prospectus</I></B>&rdquo; and together with
the Prospectus Supplement, the &ldquo;<B><I>Prospectus</I></B>&rdquo;); (iv) the Underwriting Agreement; (v) a specimen of the Company&rsquo;s
Common Stock certificate; (vi) a certificate executed by an officer of the Company, dated as of the date hereof; and (vii) such other
corporate records of the Company, as we have deemed necessary or appropriate for the purposes of the opinions hereafter expressed.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
to questions of fact material to the opinions expressed below, we have, without independent verification of their accuracy, relied to
the extent we deem reasonably appropriate upon the representations and warranties of the Company contained in such documents, records,
certificates, instruments or representations furnished or made available to us by the Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
making the foregoing examination, we have assumed (i) the genuineness of all signatures, (ii) the authenticity of all documents submitted
to us as originals, (iii) the conformity to original documents of all documents submitted to us as certified or photostatic copies, (iv)
that all agreements or instruments we have examined are the valid, binding and enforceable obligations of the parties thereto, and (v)
that all factual information on which we have relied was accurate and complete.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 1; Options: NewSection; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Enveric Biosciences, Inc.</FONT></P><P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">February 11, 2022</FONT></P><P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Page <!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></FONT></P></TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have also assumed that, at the time of the issuance of the Shares and the Warrant Shares, respectively: (i) the Company will continue
to be incorporated and in existence and good standing in its jurisdiction of organization; (ii) the Registration Statement, and any amendments
thereto (including post-effective amendments) will have remained effective, (iii) no stop order of the Commission preventing or suspending
the use of the Prospectus will have been issued; (iv) the resolutions of the Pricing Committee of the Board of Directors of the Company
referred to above will not have been modified or rescinded; (vi) the Company will receive consideration for the issuance of the Shares
and, when issued, the Warrant Shares, that is at least equal to the par value of the Common Stock, (v) the Underwriting Agreement will
have been duly authorized and validly executed and delivered by the parties thereto (other than the Company) and will be enforceable
obligations of the parties thereto (other than the Company); (vi) all requirements of the DGCL and the Company Charter Documents will
be complied with when the Shares and the Warrant Shares (if any) are issued; (vii) all Shares and Warrant Shares (if any) will be issued
and sold in compliance with applicable federal and state securities laws and in the manner stated in the Prospectus, and (viii) neither
the issuance nor sale of the Shares or the Warrant Shares (if any) will result in a violation of any agreement or instrument then binding
upon the Company or any order of any court or governmental body having jurisdiction over the Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Based
upon the foregoing and subject to the assumptions and qualifications stated herein, we are of the opinion that upon payment and delivery
in accordance with the Underwriting Agreement the Shares will be validly issued, fully paid and non-assessable.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Based
upon the foregoing and subject to the assumptions and qualifications stated herein, we are of the opinion that upon payment and delivery
in accordance with the Warrants the Warrant Shares will be validly issued, fully paid and non-assessable.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
opinions expressed herein are limited exclusively to the General Corporation Law of the State of Delaware (the &ldquo;<U>DGCL</U>&rdquo;)
and applicable provisions of the Delaware Constitution and reported judicial decisions interpreting the DGCL and such provisions of the
Delaware Constitution and we have not considered, and express no opinion on, any other laws or the laws of any other jurisdiction.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
hereby consent to the filing of this opinion with the Commission as Exhibit 5.1 to the Registration Statement and to the reference to
our firm under the heading &ldquo;Legal Matters&rdquo; in the Prospectus. In giving such consent, we do not hereby admit that we are
in the category of persons whose consent is required under Section 7 of the Securities Act or the rules and regulations of the Commission
thereunder.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Very
truly yours,</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/
Haynes and Boone, LLP</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Haynes
and Boone, LLP</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 2; Options: Last -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>5
<FILENAME>ex99-1.htm
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: right"><B>Exhibit 99.1<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Enveric
Biosciences Announces Proposed Public Offering</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">NAPLES,
Fla., Feb. 10, 2022 /PRNewswire/ - Enveric Biosciences (NASDAQ: <U>ENVB</U>) (&ldquo;Enveric&rdquo; or the &ldquo;Company&rdquo;), a
neuroscience company developing next-generation, psychedelic-inspired mental health, and oncology treatments, today announced that it
intends to offer shares of its common stock (or common stock equivalents in lieu thereof) and warrants to purchase common stock for sale,
subject to market and other conditions, in an underwritten public offering. All of the securities to be sold in the offering are to be
offered by Enveric. The Company intends to use the net proceeds from this offering for working capital and to fund other general corporate
purposes. The offering is subject to market conditions, and there can be no assurance as to whether or when the offering may be completed,
or as to the actual size or terms of the offering.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">A.G.P./Alliance
Global Partners is acting as sole book-running manager for the offering.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
offering is being made pursuant to an effective shelf registration statement on Form S-3 (No. 333-257690) previously filed with the U.S.
Securities and Exchange Commission (the &ldquo;SEC&rdquo;) that was declared effective by the SEC on July 9, 2021. The offering will
be made only by means of a prospectus supplement and accompanying base prospectus, as may be further supplemented by any free writing
prospectus and/or pricing supplement that Enveric may file with the SEC. The preliminary prospectus supplement and accompanying prospectus
describing the terms of the proposed offering will be filed with the SEC and will be available on the SEC&rsquo;s website located at
http://www.sec.gov. Electronic copies of the preliminary prospectus supplement may be obtained, when available, from A.G.P./Alliance
Global Partners, 590 Madison Avenue, 28<SUP>th</SUP> Floor, New York, NY 10022 or via telephone at 212-624-2060 or email: prospectus@allianceg.com.
Before investing in this offering, interested parties should read in their entirety the prospectus supplement and the accompanying prospectus
and the other documents that Enveric has filed with the SEC that are incorporated by reference in such prospectus supplement and the
accompanying prospectus, which provide more information about Enveric and such offering.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
press release shall not constitute an offer to sell or the solicitation of an offer to buy nor shall there be any sale of these securities
in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under
the securities laws of any such state or jurisdiction.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>About
Enveric Biosciences</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Enveric
Biosciences (NASDAQ: ENVB) is an innovative biotechnology company developing next-generation mental health and oncology treatments and
clinical discovery platform, leveraging psychedelic-derived molecules for the mind and synthetic cannabinoids for the body. Enveric&rsquo;s
robust pipeline supports drug discovery efforts and clinical development programs to enable the potential commercialization of effective
treatments for millions of patients in need around the world. For more information, please visit www.enveric.com.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Cautionary
Statement Regarding Forward-Looking Statements</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
press release contains forward-looking statements that are made pursuant to the safe harbor provisions within the meaning of Section
27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements
are any statements that express the current beliefs and expectations of management, including but not limited to statements related to
the proposed public offering, the satisfaction of customary closing conditions related to the proposed public offering and the intended
use of proceeds therefrom and expected clinical development of Enveric&rsquo;s drug product candidates. Any statements contained herein
that do not describe historical facts are forward-looking statements that are subject to risks and uncertainties, market and other conditions,
that could cause actual results, performance and achievements to differ materially from those discussed in such forward-looking statements.
These and other risks are discussed in Enveric&rsquo;s filings with the SEC, including, without limitation, its Annual Report on Form
10-K, filed on April 1, 2021, and its periodic reports on Form 10-Q and Current Reports on Form 8-K. Enveric cautions readers not to
place undue reliance on any forward-looking statements, which speak only as of the date they were made. Enveric undertakes no obligation
to update or revise forward-looking statements, except as otherwise required by law, whether as a result of new information, future events
or otherwise.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 1; Options: Last -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.2
<SEQUENCE>6
<FILENAME>ex99-2.htm
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: right"><B>Exhibit 99.2</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Enveric
Biosciences Announces Pricing of $10 Million Public Offering</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">NAPLES,
Fla., Feb. 11, 2022 /CNW/ &ndash; Enveric Biosciences (NASDAQ: ENVB) (&ldquo;Enveric&rdquo; or the &ldquo;Company&rdquo;), a neuroscience
company developing next-generation, psychedelic-inspired mental health and oncology treatments, today announced the pricing of its previously
announced underwritten public offering of 20,000,000 shares of its common stock and warrants to purchase up to 20,000,000 shares of its
common stock. Each share of common stock is being sold together with one warrant to purchase one share of common stock at an effective
combined public offering price of $0.50 per share of common stock and accompanying warrant, less underwriting discounts and commissions.
The warrants have an exercise price of $0.55 per share, are exercisable immediately, and will expire five years following the date of
issuance.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">A.G.P./Alliance
Global Partners is acting as sole book-running manager for the offering.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition, Enveric has granted the underwriter a 45-day option to purchase up to an additional 3,000,000 shares of common stock and/or
warrants to purchase up to an additional 3,000,000 shares of common stock at the public offering price, less the underwriting discounts
and commissions.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">All
the securities being sold in the offering are being offered by Enveric. The offering is expected to close on or about February 15, 2022,
subject to satisfaction of customary closing conditions.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
gross proceeds from the offering to Enveric, before deducting underwriting discounts and commissions and other offering expenses, excluding
any proceeds that may be received upon the exercise of the option to purchase additional securities and any exercise of the warrants
to purchase common stock, are expected to be $10 million. The Company intends to use the net proceeds from this offering for working
capital and to fund other general corporate purposes.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
offering is being made pursuant to an effective shelf registration statement on Form S-3 (No. 333-257690) previously filed with the U.S.
Securities and Exchange Commission (the &ldquo;SEC&rdquo;) that was declared effective by the SEC on July 9, 2021. The offering will
be made only by means of a prospectus supplement and accompanying base prospectus, as may be further supplemented by any free writing
prospectus and/or pricing supplement that Enveric may file with the SEC. The preliminary prospectus supplement and accompanying prospectus
relating to the offering were filed with the SEC and are available on the SEC&rsquo;s website located at http://www.sec.gov. The final
prospectus supplement will be filed with the SEC and, once filed, will be available on the SEC website located at http://www.sec.gov,
and electronic copies may be also obtained from A.G.P./Alliance Global Partners, 590 Madison Avenue, 28th Floor, New York, NY 10022 or
via telephone at 212-624-2060 or email: prospectus@allianceg.com.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
press release shall not constitute an offer to sell or the solicitation of an offer to buy nor shall there be any sale of these securities
in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under
the securities laws of any such state or jurisdiction.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>About
Enveric Biosciences</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Enveric
Biosciences (NASDAQ: ENVB) is an innovative biotechnology company developing next-generation mental health and oncology treatments and
clinical discovery platform, leveraging psychedelic-derived molecules for the mind and synthetic cannabinoids for the body. Enveric&rsquo;s
robust pipeline supports drug discovery efforts and clinical development programs to enable the potential commercialization of effective
treatments for millions of patients in need around the world. For more information, please visit www.enveric.com.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Cautionary
Statement Regarding Forward-Looking Statements</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
press release contains forward-looking statements that are made pursuant to the safe harbor provisions within the meaning of Section
27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements
are any statements that express the current beliefs and expectations of management, including but not limited to statements related to
the public offering, the satisfaction of customary closing conditions related to the public offering and the intended use of proceeds
therefrom and expected clinical development of Enveric&rsquo;s drug product candidates. Any statements contained herein that do not describe
historical facts are forward-looking statements that are subject to risks and uncertainties, market and other conditions, that could
cause actual results, performance and achievements to differ materially from those discussed in such forward-looking statements. These
and other risks are discussed in Enveric&rsquo;s filings with the SEC, including, without limitation, its Annual Report on Form 10-K,
filed on April 1, 2021, and its periodic reports on Form 10-Q and Current Reports on Form 8-K. Enveric cautions readers not to place
undue reliance on any forward-looking statements, which speak only as of the date they were made. Enveric undertakes no obligation to
update or revise forward-looking statements, except as otherwise required by law, whether as a result of new information, future events
or otherwise.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<!-- Field: Page; Sequence: 1; Options: Last -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>7
<FILENAME>envb-20220211.xsd
<DESCRIPTION>XBRL SCHEMA FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" ?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 5.12a -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
    <!-- Field: Doc-Info; Name: Misc; Value: 96Mps7xRiXgen8uDanwsWamPybP9z5Z8eekhvWB/bekanygnfUvRHyF6r/6mkUgO -->
<schema xmlns="http://www.w3.org/2001/XMLSchema" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:dei="http://xbrl.sec.gov/dei/2021q4" xmlns:us-gaap="http://fasb.org/us-gaap/2021-01-31" xmlns:srt="http://fasb.org/srt/2021-01-31" xmlns:srt-types="http://fasb.org/srt-types/2021-01-31" xmlns:ENVB="http://enveric.com/20220211" elementFormDefault="qualified" targetNamespace="http://enveric.com/20220211">
    <annotation>
      <appinfo>
	<link:roleType roleURI="http://enveric.com/role/Cover" id="Cover">
	  <link:definition>00000001 - Document - Cover</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:linkbaseRef xlink:type="simple" xlink:href="envb-20220211_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Presentation Links" />
	<link:linkbaseRef xlink:type="simple" xlink:href="envb-20220211_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Label Links" />
      </appinfo>
    </annotation>
    <import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" />
    <import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" />
    <import namespace="http://xbrl.sec.gov/dei/2021q4" schemaLocation="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd" />
    <import namespace="http://fasb.org/us-gaap/2021-01-31" schemaLocation="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd" />
    <import namespace="http://fasb.org/us-types/2021-01-31" schemaLocation="https://xbrl.fasb.org/us-gaap/2021/elts/us-types-2021-01-31.xsd" />
    <import namespace="http://www.xbrl.org/dtr/type/2020-01-21" schemaLocation="https://www.xbrl.org/dtr/type/2020-01-21/types.xsd" />
    <import namespace="http://xbrl.sec.gov/country/2021" schemaLocation="https://xbrl.sec.gov/country/2021/country-2021.xsd" />
    <import namespace="http://fasb.org/srt/2021-01-31" schemaLocation="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd" />
    <import namespace="http://fasb.org/srt-types/2021-01-31" schemaLocation="https://xbrl.fasb.org/srt/2021/elts/srt-types-2021-01-31.xsd" />
</schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>8
<FILENAME>envb-20220211_lab.xml
<DESCRIPTION>XBRL LABEL FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 5.12a -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" roleURI="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel" roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" roleURI="http://www.xbrl.org/2009/role/netLabel" />
    <link:labelLink xlink:type="extended" xlink:role="http://www.xbrl.org/2003/role/link">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CoverAbstract" xlink:label="dei_CoverAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CoverAbstract" xlink:to="dei_CoverAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CoverAbstract_lbl" xml:lang="en-US">Cover [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentType" xlink:label="dei_DocumentType" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentType_lbl" xml:lang="en-US">Document Type</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AmendmentFlag_lbl" xml:lang="en-US">Amendment Flag</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AmendmentDescription" xlink:label="dei_AmendmentDescription" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentDescription" xlink:to="dei_AmendmentDescription_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AmendmentDescription_lbl" xml:lang="en-US">Amendment Description</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentRegistrationStatement" xlink:label="dei_DocumentRegistrationStatement" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentRegistrationStatement" xlink:to="dei_DocumentRegistrationStatement_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentRegistrationStatement_lbl" xml:lang="en-US">Document Registration Statement</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentAnnualReport" xlink:label="dei_DocumentAnnualReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentAnnualReport" xlink:to="dei_DocumentAnnualReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentAnnualReport_lbl" xml:lang="en-US">Document Annual Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentQuarterlyReport" xlink:label="dei_DocumentQuarterlyReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentQuarterlyReport" xlink:to="dei_DocumentQuarterlyReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentQuarterlyReport_lbl" xml:lang="en-US">Document Quarterly Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentTransitionReport" xlink:label="dei_DocumentTransitionReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentTransitionReport" xlink:to="dei_DocumentTransitionReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentTransitionReport_lbl" xml:lang="en-US">Document Transition Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentShellCompanyReport" xlink:label="dei_DocumentShellCompanyReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentShellCompanyReport" xlink:to="dei_DocumentShellCompanyReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentShellCompanyReport_lbl" xml:lang="en-US">Document Shell Company Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentShellCompanyEventDate" xlink:label="dei_DocumentShellCompanyEventDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentShellCompanyEventDate" xlink:to="dei_DocumentShellCompanyEventDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentShellCompanyEventDate_lbl" xml:lang="en-US">Document Shell Company Event Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentPeriodStartDate" xlink:label="dei_DocumentPeriodStartDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodStartDate" xlink:to="dei_DocumentPeriodStartDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentPeriodStartDate_lbl" xml:lang="en-US">Document Period Start Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentPeriodEndDate_lbl" xml:lang="en-US">Document Period End Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="dei_DocumentFiscalPeriodFocus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalPeriodFocus" xlink:to="dei_DocumentFiscalPeriodFocus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalPeriodFocus_lbl" xml:lang="en-US">Document Fiscal Period Focus</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentFiscalYearFocus" xlink:label="dei_DocumentFiscalYearFocus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalYearFocus" xlink:to="dei_DocumentFiscalYearFocus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalYearFocus_lbl" xml:lang="en-US">Document Fiscal Year Focus</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CurrentFiscalYearEndDate" xlink:label="dei_CurrentFiscalYearEndDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CurrentFiscalYearEndDate" xlink:to="dei_CurrentFiscalYearEndDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CurrentFiscalYearEndDate_lbl" xml:lang="en-US">Current Fiscal Year End Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFileNumber" xlink:to="dei_EntityFileNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFileNumber_lbl" xml:lang="en-US">Entity File Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityRegistrantName_lbl" xml:lang="en-US">Entity Registrant Name</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCentralIndexKey_lbl" xml:lang="en-US">Entity Central Index Key</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityPrimarySicNumber" xlink:label="dei_EntityPrimarySicNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityPrimarySicNumber" xlink:to="dei_EntityPrimarySicNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityPrimarySicNumber_lbl" xml:lang="en-US">Entity Primary SIC Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityTaxIdentificationNumber" xlink:to="dei_EntityTaxIdentificationNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xml:lang="en-US">Entity Tax Identification Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine1_lbl" xml:lang="en-US">Entity Address, Address Line One</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressAddressLine2" xlink:label="dei_EntityAddressAddressLine2" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine2" xlink:to="dei_EntityAddressAddressLine2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine2_lbl" xml:lang="en-US">Entity Address, Address Line Two</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressAddressLine3" xlink:label="dei_EntityAddressAddressLine3" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine3" xlink:to="dei_EntityAddressAddressLine3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine3_lbl" xml:lang="en-US">Entity Address, Address Line Three</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressCityOrTown_lbl" xml:lang="en-US">Entity Address, City or Town</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressStateOrProvince" xlink:to="dei_EntityAddressStateOrProvince_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressStateOrProvince_lbl" xml:lang="en-US">Entity Address, State or Province</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressCountry" xlink:label="dei_EntityAddressCountry" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCountry" xlink:to="dei_EntityAddressCountry_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressCountry_lbl" xml:lang="en-US">Entity Address, Country</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressPostalZipCode_lbl" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CountryRegion" xlink:label="dei_CountryRegion" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CountryRegion" xlink:to="dei_CountryRegion_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CountryRegion_lbl" xml:lang="en-US">Country Region</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CityAreaCode" xlink:to="dei_CityAreaCode_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CityAreaCode_lbl" xml:lang="en-US">City Area Code</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_LocalPhoneNumber_lbl" xml:lang="en-US">Local Phone Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_Extension" xlink:label="dei_Extension" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Extension" xlink:to="dei_Extension_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Extension_lbl" xml:lang="en-US">Extension</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_WrittenCommunications" xlink:label="dei_WrittenCommunications" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_WrittenCommunications" xlink:to="dei_WrittenCommunications_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_WrittenCommunications_lbl" xml:lang="en-US">Written Communications</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_SolicitingMaterial" xlink:label="dei_SolicitingMaterial" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SolicitingMaterial" xlink:to="dei_SolicitingMaterial_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SolicitingMaterial_lbl" xml:lang="en-US">Soliciting Material</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_PreCommencementTenderOffer" xlink:label="dei_PreCommencementTenderOffer" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementTenderOffer" xlink:to="dei_PreCommencementTenderOffer_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_PreCommencementTenderOffer_lbl" xml:lang="en-US">Pre-commencement Tender Offer</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="dei_PreCommencementIssuerTenderOffer" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementIssuerTenderOffer" xlink:to="dei_PreCommencementIssuerTenderOffer_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_PreCommencementIssuerTenderOffer_lbl" xml:lang="en-US">Pre-commencement Issuer Tender Offer</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12bTitle" xlink:to="dei_Security12bTitle_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Security12bTitle_lbl" xml:lang="en-US">Title of 12(b) Security</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_NoTradingSymbolFlag" xlink:label="dei_NoTradingSymbolFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_NoTradingSymbolFlag" xlink:to="dei_NoTradingSymbolFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_NoTradingSymbolFlag_lbl" xml:lang="en-US">No Trading Symbol Flag</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_TradingSymbol_lbl" xml:lang="en-US">Trading Symbol</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityExchangeName" xlink:to="dei_SecurityExchangeName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SecurityExchangeName_lbl" xml:lang="en-US">Security Exchange Name</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_Security12gTitle" xlink:label="dei_Security12gTitle" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12gTitle" xlink:to="dei_Security12gTitle_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Security12gTitle_lbl" xml:lang="en-US">Title of 12(g) Security</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_SecurityReportingObligation" xlink:label="dei_SecurityReportingObligation" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityReportingObligation" xlink:to="dei_SecurityReportingObligation_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SecurityReportingObligation_lbl" xml:lang="en-US">Security Reporting Obligation</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AnnualInformationForm" xlink:label="dei_AnnualInformationForm" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AnnualInformationForm" xlink:to="dei_AnnualInformationForm_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AnnualInformationForm_lbl" xml:lang="en-US">Annual Information Form</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AuditedAnnualFinancialStatements" xlink:label="dei_AuditedAnnualFinancialStatements" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditedAnnualFinancialStatements" xlink:to="dei_AuditedAnnualFinancialStatements_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AuditedAnnualFinancialStatements_lbl" xml:lang="en-US">Audited Annual Financial Statements</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="dei_EntityWellKnownSeasonedIssuer" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityWellKnownSeasonedIssuer" xlink:to="dei_EntityWellKnownSeasonedIssuer_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityWellKnownSeasonedIssuer_lbl" xml:lang="en-US">Entity Well-known Seasoned Issuer</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityVoluntaryFilers" xlink:label="dei_EntityVoluntaryFilers" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityVoluntaryFilers" xlink:to="dei_EntityVoluntaryFilers_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityVoluntaryFilers_lbl" xml:lang="en-US">Entity Voluntary Filers</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCurrentReportingStatus" xlink:label="dei_EntityCurrentReportingStatus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCurrentReportingStatus" xlink:to="dei_EntityCurrentReportingStatus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCurrentReportingStatus_lbl" xml:lang="en-US">Entity Current Reporting Status</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityInteractiveDataCurrent" xlink:label="dei_EntityInteractiveDataCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityInteractiveDataCurrent" xlink:to="dei_EntityInteractiveDataCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityInteractiveDataCurrent_lbl" xml:lang="en-US">Entity Interactive Data Current</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityFilerCategory" xlink:label="dei_EntityFilerCategory" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFilerCategory" xlink:to="dei_EntityFilerCategory_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFilerCategory_lbl" xml:lang="en-US">Entity Filer Category</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntitySmallBusiness" xlink:label="dei_EntitySmallBusiness" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntitySmallBusiness" xlink:to="dei_EntitySmallBusiness_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntitySmallBusiness_lbl" xml:lang="en-US">Entity Small Business</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xml:lang="en-US">Entity Emerging Growth Company</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityExTransitionPeriod" xlink:label="dei_EntityExTransitionPeriod" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityExTransitionPeriod" xlink:to="dei_EntityExTransitionPeriod_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityExTransitionPeriod_lbl" xml:lang="en-US">Elected Not To Use the Extended Transition Period</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentAccountingStandard" xlink:label="dei_DocumentAccountingStandard" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentAccountingStandard" xlink:to="dei_DocumentAccountingStandard_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentAccountingStandard_lbl" xml:lang="en-US">Document Accounting Standard</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_OtherReportingStandardItemNumber" xlink:label="dei_OtherReportingStandardItemNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_OtherReportingStandardItemNumber" xlink:to="dei_OtherReportingStandardItemNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_OtherReportingStandardItemNumber_lbl" xml:lang="en-US">Other Reporting Standard Item Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityShellCompany" xlink:label="dei_EntityShellCompany" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityShellCompany" xlink:to="dei_EntityShellCompany_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityShellCompany_lbl" xml:lang="en-US">Entity Shell Company</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityPublicFloat" xlink:label="dei_EntityPublicFloat" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityPublicFloat" xlink:to="dei_EntityPublicFloat_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityPublicFloat_lbl" xml:lang="en-US">Entity Public Float</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityBankruptcyProceedingsReportingCurrent" xlink:label="dei_EntityBankruptcyProceedingsReportingCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityBankruptcyProceedingsReportingCurrent" xlink:to="dei_EntityBankruptcyProceedingsReportingCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityBankruptcyProceedingsReportingCurrent_lbl" xml:lang="en-US">Entity Bankruptcy Proceedings, Reporting Current</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="dei_EntityCommonStockSharesOutstanding" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCommonStockSharesOutstanding" xlink:to="dei_EntityCommonStockSharesOutstanding_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCommonStockSharesOutstanding_lbl" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentsIncorporatedByReferenceTextBlock" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentsIncorporatedByReferenceTextBlock" xlink:to="dei_DocumentsIncorporatedByReferenceTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock_lbl" xml:lang="en-US">Documents Incorporated by Reference [Text Block]</link:label>
    </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>9
<FILENAME>envb-20220211_pre.xml
<DESCRIPTION>XBRL PRESENTATION FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 5.12a -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef roleURI="http://enveric.com/role/Cover" xlink:href="envb-20220211.xsd#Cover" xlink:type="simple" />
    <link:presentationLink xlink:type="extended" xlink:role="http://enveric.com/role/Cover" xlink:title="00000001 - Document - Cover">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CoverAbstract" xlink:label="loc_deiCoverAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentType" xlink:label="loc_deiDocumentType" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentType" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AmendmentFlag" xlink:label="loc_deiAmendmentFlag" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAmendmentFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AmendmentDescription" xlink:label="loc_deiAmendmentDescription" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAmendmentDescription" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentRegistrationStatement" xlink:label="loc_deiDocumentRegistrationStatement" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentRegistrationStatement" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentAnnualReport" xlink:label="loc_deiDocumentAnnualReport" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentAnnualReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentQuarterlyReport" xlink:label="loc_deiDocumentQuarterlyReport" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentQuarterlyReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentTransitionReport" xlink:label="loc_deiDocumentTransitionReport" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentTransitionReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentShellCompanyReport" xlink:label="loc_deiDocumentShellCompanyReport" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentShellCompanyReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentShellCompanyEventDate" xlink:label="loc_deiDocumentShellCompanyEventDate" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentShellCompanyEventDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentPeriodStartDate" xlink:label="loc_deiDocumentPeriodStartDate" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentPeriodStartDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentPeriodEndDate" xlink:label="loc_deiDocumentPeriodEndDate" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentPeriodEndDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="loc_deiDocumentFiscalPeriodFocus" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentFiscalPeriodFocus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentFiscalYearFocus" xlink:label="loc_deiDocumentFiscalYearFocus" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentFiscalYearFocus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CurrentFiscalYearEndDate" xlink:label="loc_deiCurrentFiscalYearEndDate" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiCurrentFiscalYearEndDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityFileNumber" xlink:label="loc_deiEntityFileNumber" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityFileNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityRegistrantName" xlink:label="loc_deiEntityRegistrantName" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityRegistrantName" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCentralIndexKey" xlink:label="loc_deiEntityCentralIndexKey" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityCentralIndexKey" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityPrimarySicNumber" xlink:label="loc_deiEntityPrimarySicNumber" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityPrimarySicNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityTaxIdentificationNumber" xlink:label="loc_deiEntityTaxIdentificationNumber" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityTaxIdentificationNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="loc_deiEntityIncorporationStateCountryCode" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityIncorporationStateCountryCode" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressAddressLine1" xlink:label="loc_deiEntityAddressAddressLine1" />
      <link:presentationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressAddressLine1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressAddressLine2" xlink:label="loc_deiEntityAddressAddressLine2" />
      <link:presentationArc order="210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressAddressLine2" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressAddressLine3" xlink:label="loc_deiEntityAddressAddressLine3" />
      <link:presentationArc order="220" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressAddressLine3" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressCityOrTown" xlink:label="loc_deiEntityAddressCityOrTown" />
      <link:presentationArc order="230" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressCityOrTown" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressStateOrProvince" xlink:label="loc_deiEntityAddressStateOrProvince" />
      <link:presentationArc order="240" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressStateOrProvince" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressCountry" xlink:label="loc_deiEntityAddressCountry" />
      <link:presentationArc order="250" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressCountry" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressPostalZipCode" xlink:label="loc_deiEntityAddressPostalZipCode" />
      <link:presentationArc order="260" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressPostalZipCode" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CountryRegion" xlink:label="loc_deiCountryRegion" />
      <link:presentationArc order="270" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiCountryRegion" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CityAreaCode" xlink:label="loc_deiCityAreaCode" />
      <link:presentationArc order="280" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiCityAreaCode" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_LocalPhoneNumber" xlink:label="loc_deiLocalPhoneNumber" />
      <link:presentationArc order="290" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiLocalPhoneNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_Extension" xlink:label="loc_deiExtension" />
      <link:presentationArc order="300" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiExtension" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_WrittenCommunications" xlink:label="loc_deiWrittenCommunications" />
      <link:presentationArc order="310" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiWrittenCommunications" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_SolicitingMaterial" xlink:label="loc_deiSolicitingMaterial" />
      <link:presentationArc order="320" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSolicitingMaterial" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_PreCommencementTenderOffer" xlink:label="loc_deiPreCommencementTenderOffer" />
      <link:presentationArc order="330" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiPreCommencementTenderOffer" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="loc_deiPreCommencementIssuerTenderOffer" />
      <link:presentationArc order="340" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiPreCommencementIssuerTenderOffer" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_Security12bTitle" xlink:label="loc_deiSecurity12bTitle" />
      <link:presentationArc order="350" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurity12bTitle" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_NoTradingSymbolFlag" xlink:label="loc_deiNoTradingSymbolFlag" />
      <link:presentationArc order="360" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiNoTradingSymbolFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_TradingSymbol" xlink:label="loc_deiTradingSymbol" />
      <link:presentationArc order="370" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiTradingSymbol" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_SecurityExchangeName" xlink:label="loc_deiSecurityExchangeName" />
      <link:presentationArc order="380" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurityExchangeName" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_Security12gTitle" xlink:label="loc_deiSecurity12gTitle" />
      <link:presentationArc order="390" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurity12gTitle" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_SecurityReportingObligation" xlink:label="loc_deiSecurityReportingObligation" />
      <link:presentationArc order="400" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurityReportingObligation" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AnnualInformationForm" xlink:label="loc_deiAnnualInformationForm" />
      <link:presentationArc order="410" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAnnualInformationForm" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AuditedAnnualFinancialStatements" xlink:label="loc_deiAuditedAnnualFinancialStatements" />
      <link:presentationArc order="420" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAuditedAnnualFinancialStatements" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="loc_deiEntityWellKnownSeasonedIssuer" />
      <link:presentationArc order="430" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityWellKnownSeasonedIssuer" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityVoluntaryFilers" xlink:label="loc_deiEntityVoluntaryFilers" />
      <link:presentationArc order="440" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityVoluntaryFilers" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCurrentReportingStatus" xlink:label="loc_deiEntityCurrentReportingStatus" />
      <link:presentationArc order="450" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityCurrentReportingStatus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityInteractiveDataCurrent" xlink:label="loc_deiEntityInteractiveDataCurrent" />
      <link:presentationArc order="460" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityInteractiveDataCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityFilerCategory" xlink:label="loc_deiEntityFilerCategory" />
      <link:presentationArc order="470" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityFilerCategory" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntitySmallBusiness" xlink:label="loc_deiEntitySmallBusiness" />
      <link:presentationArc order="480" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntitySmallBusiness" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityEmergingGrowthCompany" xlink:label="loc_deiEntityEmergingGrowthCompany" />
      <link:presentationArc order="490" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityEmergingGrowthCompany" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityExTransitionPeriod" xlink:label="loc_deiEntityExTransitionPeriod" />
      <link:presentationArc order="500" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityExTransitionPeriod" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentAccountingStandard" xlink:label="loc_deiDocumentAccountingStandard" />
      <link:presentationArc order="510" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentAccountingStandard" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_OtherReportingStandardItemNumber" xlink:label="loc_deiOtherReportingStandardItemNumber" />
      <link:presentationArc order="520" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiOtherReportingStandardItemNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityShellCompany" xlink:label="loc_deiEntityShellCompany" />
      <link:presentationArc order="530" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityShellCompany" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityPublicFloat" xlink:label="loc_deiEntityPublicFloat" />
      <link:presentationArc order="540" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityPublicFloat" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityBankruptcyProceedingsReportingCurrent" xlink:label="loc_deiEntityBankruptcyProceedingsReportingCurrent" />
      <link:presentationArc order="550" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityBankruptcyProceedingsReportingCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="loc_deiEntityCommonStockSharesOutstanding" />
      <link:presentationArc order="560" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityCommonStockSharesOutstanding" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentsIncorporatedByReferenceTextBlock" xlink:label="loc_deiDocumentsIncorporatedByReferenceTextBlock" />
      <link:presentationArc order="570" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentsIncorporatedByReferenceTextBlock" xlink:type="arc" />
    </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>10
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139653370877528">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Cover<br></strong></div></th>
<th class="th"><div>Feb. 11, 2022</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">8-K<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Feb. 11,  2022<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-38286<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">Enveric
Biosciences, Inc.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0000890821<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">95-4484725<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">4851
Tamiami Trail N<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressAddressLine2', window );">Entity Address, Address Line Two</a></td>
<td class="text">Suite 200<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Naples<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">FL<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">34103<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">(239)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">302-1707<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_WrittenCommunications', window );">Written Communications</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_SolicitingMaterial', window );">Soliciting Material</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_PreCommencementTenderOffer', window );">Pre-commencement Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_PreCommencementIssuerTenderOffer', window );">Pre-commencement Issuer Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common
    stock, par value $0.01 per share<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">ENVB<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Address Line 2 such as Street or Suite number</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementIssuerTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 13e<br> -Subsection 4c<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementIssuerTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14d<br> -Subsection 2b<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SolicitingMaterial">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Section 14a<br> -Number 240<br> -Subsection 12<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SolicitingMaterial</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_WrittenCommunications">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 425<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_WrittenCommunications</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>11
<FILENAME>form8-k_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2021q4"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink">
    <link:schemaRef xlink:href="envb-20220211.xsd" xlink:type="simple"/>
    <context id="From2022-02-11to2022-02-11">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000890821</identifier>
        </entity>
        <period>
            <startDate>2022-02-11</startDate>
            <endDate>2022-02-11</endDate>
        </period>
    </context>
    <unit id="USD">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="Shares">
        <measure>shares</measure>
    </unit>
    <unit id="USDPShares">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <dei:EntityCentralIndexKey contextRef="From2022-02-11to2022-02-11">0000890821</dei:EntityCentralIndexKey>
    <dei:AmendmentFlag contextRef="From2022-02-11to2022-02-11">false</dei:AmendmentFlag>
    <dei:DocumentType contextRef="From2022-02-11to2022-02-11">8-K</dei:DocumentType>
    <dei:DocumentPeriodEndDate contextRef="From2022-02-11to2022-02-11">2022-02-11</dei:DocumentPeriodEndDate>
    <dei:EntityRegistrantName contextRef="From2022-02-11to2022-02-11">Enveric Biosciences, Inc.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode contextRef="From2022-02-11to2022-02-11">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityFileNumber contextRef="From2022-02-11to2022-02-11">001-38286</dei:EntityFileNumber>
    <dei:EntityTaxIdentificationNumber contextRef="From2022-02-11to2022-02-11">95-4484725</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1 contextRef="From2022-02-11to2022-02-11">4851 Tamiami Trail N</dei:EntityAddressAddressLine1>
    <dei:EntityAddressAddressLine2 contextRef="From2022-02-11to2022-02-11">Suite 200</dei:EntityAddressAddressLine2>
    <dei:EntityAddressCityOrTown contextRef="From2022-02-11to2022-02-11">Naples</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince contextRef="From2022-02-11to2022-02-11">FL</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode contextRef="From2022-02-11to2022-02-11">34103</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode contextRef="From2022-02-11to2022-02-11">(239)</dei:CityAreaCode>
    <dei:LocalPhoneNumber contextRef="From2022-02-11to2022-02-11">302-1707</dei:LocalPhoneNumber>
    <dei:WrittenCommunications contextRef="From2022-02-11to2022-02-11">false</dei:WrittenCommunications>
    <dei:SolicitingMaterial contextRef="From2022-02-11to2022-02-11">false</dei:SolicitingMaterial>
    <dei:PreCommencementTenderOffer contextRef="From2022-02-11to2022-02-11">false</dei:PreCommencementTenderOffer>
    <dei:PreCommencementIssuerTenderOffer contextRef="From2022-02-11to2022-02-11">false</dei:PreCommencementIssuerTenderOffer>
    <dei:Security12bTitle contextRef="From2022-02-11to2022-02-11">Common     stock, par value $0.01 per share</dei:Security12bTitle>
    <dei:TradingSymbol contextRef="From2022-02-11to2022-02-11">ENVB</dei:TradingSymbol>
    <dei:SecurityExchangeName contextRef="From2022-02-11to2022-02-11">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityEmergingGrowthCompany contextRef="From2022-02-11to2022-02-11">false</dei:EntityEmergingGrowthCompany>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>12
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M%@_&%Q 9Y=VI\0QKRTZ+Y2T].PP_/LG>V)+;.<V"3J9B+7D%=*RHC_#K3),
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MHAVE?QW']I#3Z:]C(K1Z6^CY<6A4"H[<8R6,<6*T_C6"R0_L?@!02P,$%
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M/UY_ 5!+ 0(4 Q0    ( .E83U0'04UB@0   +$    0              "
M 0    !D;V-0<F]P<R]A<' N>&UL4$L! A0#%     @ Z5A/5'A[B0/N
M*P(  !$              ( !KP   &1O8U!R;W!S+V-O<F4N>&UL4$L! A0#
M%     @ Z5A/5)E<G",0!@  G"<  !,              ( !S $  'AL+W1H
M96UE+W1H96UE,2YX;6Q02P$"% ,4    " #I6$]4"+H[OTH$  #:$   &
M            @($-"   >&PO=V]R:W-H965T<R]S:&5E=#$N>&UL4$L! A0#
M%     @ Z5A/5)^@&_"Q @  X@P   T              ( !C0P  'AL+W-T
M>6QE<RYX;6Q02P$"% ,4    " #I6$]4EXJ[',     3 @  "P
M    @ %I#P  7W)E;',O+G)E;'-02P$"% ,4    " #I6$]4JL0B%C,!   B
M @  #P              @ %2$   >&PO=V]R:V)O;VLN>&UL4$L! A0#%
M  @ Z5A/5"0>FZ*M    ^ $  !H              ( !LA$  'AL+U]R96QS
M+W=O<FMB;V]K+GAM;"YR96QS4$L! A0#%     @ Z5A/5&60>9(9 0  SP,
M !,              ( !EQ(  %M#;VYT96YT7U1Y<&5S72YX;6Q02P4&
/  D "0 ^ @  X1,

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>13
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>14
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>15
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.22.0.1</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>1</ContextCount>
  <ElementCount>122</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>0</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>3</UnitCount>
  <MyReports>
    <Report instance="form8-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>00000001 - Document - Cover</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://enveric.com/role/Cover</Role>
      <ShortName>Cover</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="8-K" original="form8-k.htm">form8-k.htm</File>
    <File>envb-20220211.xsd</File>
    <File>envb-20220211_lab.xml</File>
    <File>envb-20220211_pre.xml</File>
    <File>ex1-1.htm</File>
    <File>ex4-1.htm</File>
    <File>ex5-1.htm</File>
    <File>ex99-1.htm</File>
    <File>ex99-2.htm</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy items="23">http://xbrl.sec.gov/dei/2021q4</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>false</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>17
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "instance": {
  "form8-k.htm": {
   "axisCustom": 0,
   "axisStandard": 0,
   "contextCount": 1,
   "dts": {
    "inline": {
     "local": [
      "form8-k.htm"
     ]
    },
    "labelLink": {
     "local": [
      "envb-20220211_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "envb-20220211_pre.xml"
     ]
    },
    "schema": {
     "local": [
      "envb-20220211.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd",
      "https://xbrl.fasb.org/srt/2021/elts/srt-roles-2021-01-31.xsd",
      "https://xbrl.fasb.org/srt/2021/elts/srt-types-2021-01-31.xsd",
      "https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd",
      "https://xbrl.fasb.org/us-gaap/2021/elts/us-roles-2021-01-31.xsd",
      "https://xbrl.fasb.org/us-gaap/2021/elts/us-types-2021-01-31.xsd",
      "https://xbrl.sec.gov/country/2021/country-2021.xsd",
      "https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd"
     ]
    }
   },
   "elementCount": 59,
   "entityCount": 1,
   "hidden": {
    "http://xbrl.sec.gov/dei/2021q4": 2,
    "total": 2
   },
   "keyCustom": 0,
   "keyStandard": 122,
   "memberCustom": 0,
   "memberStandard": 0,
   "nsprefix": "ENVB",
   "nsuri": "http://enveric.com/20220211",
   "report": {
    "R1": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "b",
       "span",
       "p",
       "body",
       "html"
      ],
      "baseRef": "form8-k.htm",
      "contextRef": "From2022-02-11to2022-02-11",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "true",
     "longName": "00000001 - Document - Cover",
     "role": "http://enveric.com/role/Cover",
     "shortName": "Cover",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "b",
       "span",
       "p",
       "body",
       "html"
      ],
      "baseRef": "form8-k.htm",
      "contextRef": "From2022-02-11to2022-02-11",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    }
   },
   "segmentCount": 0,
   "tag": {
    "dei_AmendmentDescription": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Description of changes contained within amended document.",
        "label": "Amendment Description"
       }
      }
     },
     "localname": "AmendmentDescription",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://enveric.com/role/Cover"
     ],
     "xbrltype": "stringItemType"
    },
    "dei_AmendmentFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.",
        "label": "Amendment Flag"
       }
      }
     },
     "localname": "AmendmentFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://enveric.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_AnnualInformationForm": {
     "auth_ref": [
      "r14"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag with value true on a form if it is an annual report containing an annual information form.",
        "label": "Annual Information Form"
       }
      }
     },
     "localname": "AnnualInformationForm",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://enveric.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_AuditedAnnualFinancialStatements": {
     "auth_ref": [
      "r14"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag with value true on a form if it is an annual report containing audited financial statements.",
        "label": "Audited Annual Financial Statements"
       }
      }
     },
     "localname": "AuditedAnnualFinancialStatements",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://enveric.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_CityAreaCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Area code of city",
        "label": "City Area Code"
       }
      }
     },
     "localname": "CityAreaCode",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://enveric.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CountryRegion": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Region code of country",
        "label": "Country Region"
       }
      }
     },
     "localname": "CountryRegion",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://enveric.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CoverAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cover page.",
        "label": "Cover [Abstract]"
       }
      }
     },
     "localname": "CoverAbstract",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "xbrltype": "stringItemType"
    },
    "dei_CurrentFiscalYearEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "End date of current fiscal year in the format --MM-DD.",
        "label": "Current Fiscal Year End Date"
       }
      }
     },
     "localname": "CurrentFiscalYearEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://enveric.com/role/Cover"
     ],
     "xbrltype": "gMonthDayItemType"
    },
    "dei_DocumentAccountingStandard": {
     "auth_ref": [
      "r13"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'.",
        "label": "Document Accounting Standard"
       }
      }
     },
     "localname": "DocumentAccountingStandard",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://enveric.com/role/Cover"
     ],
     "xbrltype": "accountingStandardItemType"
    },
    "dei_DocumentAnnualReport": {
     "auth_ref": [
      "r11",
      "r13",
      "r14"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as an annual report.",
        "label": "Document Annual Report"
       }
      }
     },
     "localname": "DocumentAnnualReport",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://enveric.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentFiscalPeriodFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.",
        "label": "Document Fiscal Period Focus"
       }
      }
     },
     "localname": "DocumentFiscalPeriodFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://enveric.com/role/Cover"
     ],
     "xbrltype": "fiscalPeriodItemType"
    },
    "dei_DocumentFiscalYearFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.",
        "label": "Document Fiscal Year Focus"
       }
      }
     },
     "localname": "DocumentFiscalYearFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://enveric.com/role/Cover"
     ],
     "xbrltype": "gYearItemType"
    },
    "dei_DocumentPeriodEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.",
        "label": "Document Period End Date"
       }
      }
     },
     "localname": "DocumentPeriodEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://enveric.com/role/Cover"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentPeriodStartDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The start date of the period covered in the document, in YYYY-MM-DD format.",
        "label": "Document Period Start Date"
       }
      }
     },
     "localname": "DocumentPeriodStartDate",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://enveric.com/role/Cover"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentQuarterlyReport": {
     "auth_ref": [
      "r12"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as an quarterly report.",
        "label": "Document Quarterly Report"
       }
      }
     },
     "localname": "DocumentQuarterlyReport",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://enveric.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentRegistrationStatement": {
     "auth_ref": [
      "r0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as a registration statement.",
        "label": "Document Registration Statement"
       }
      }
     },
     "localname": "DocumentRegistrationStatement",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://enveric.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentShellCompanyEventDate": {
     "auth_ref": [
      "r13"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Date of event requiring a shell company report.",
        "label": "Document Shell Company Event Date"
       }
      }
     },
     "localname": "DocumentShellCompanyEventDate",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://enveric.com/role/Cover"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentShellCompanyReport": {
     "auth_ref": [
      "r13"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act.",
        "label": "Document Shell Company Report"
       }
      }
     },
     "localname": "DocumentShellCompanyReport",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://enveric.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentTransitionReport": {
     "auth_ref": [
      "r15"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as a transition report.",
        "label": "Document Transition Report"
       }
      }
     },
     "localname": "DocumentTransitionReport",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://enveric.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentType": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
        "label": "Document Type"
       }
      }
     },
     "localname": "DocumentType",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://enveric.com/role/Cover"
     ],
     "xbrltype": "submissionTypeItemType"
    },
    "dei_DocumentsIncorporatedByReferenceTextBlock": {
     "auth_ref": [
      "r3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Documents incorporated by reference.",
        "label": "Documents Incorporated by Reference [Text Block]"
       }
      }
     },
     "localname": "DocumentsIncorporatedByReferenceTextBlock",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://enveric.com/role/Cover"
     ],
     "xbrltype": "textBlockItemType"
    },
    "dei_EntityAddressAddressLine1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name",
        "label": "Entity Address, Address Line One"
       }
      }
     },
     "localname": "EntityAddressAddressLine1",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://enveric.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressAddressLine2": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 2 such as Street or Suite number",
        "label": "Entity Address, Address Line Two"
       }
      }
     },
     "localname": "EntityAddressAddressLine2",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://enveric.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressAddressLine3": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 3 such as an Office Park",
        "label": "Entity Address, Address Line Three"
       }
      }
     },
     "localname": "EntityAddressAddressLine3",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://enveric.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCityOrTown": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the City or Town",
        "label": "Entity Address, City or Town"
       }
      }
     },
     "localname": "EntityAddressCityOrTown",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://enveric.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCountry": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "ISO 3166-1 alpha-2 country code.",
        "label": "Entity Address, Country"
       }
      }
     },
     "localname": "EntityAddressCountry",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://enveric.com/role/Cover"
     ],
     "xbrltype": "countryCodeItemType"
    },
    "dei_EntityAddressPostalZipCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Code for the postal or zip code",
        "label": "Entity Address, Postal Zip Code"
       }
      }
     },
     "localname": "EntityAddressPostalZipCode",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://enveric.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressStateOrProvince": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the state or province.",
        "label": "Entity Address, State or Province"
       }
      }
     },
     "localname": "EntityAddressStateOrProvince",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://enveric.com/role/Cover"
     ],
     "xbrltype": "stateOrProvinceItemType"
    },
    "dei_EntityBankruptcyProceedingsReportingCurrent": {
     "auth_ref": [
      "r6"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For registrants involved in bankruptcy proceedings during the preceding five years, the value Yes indicates that the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court; the value No indicates the registrant has not.  Registrants not involved in bankruptcy proceedings during the preceding five years should not report this element.",
        "label": "Entity Bankruptcy Proceedings, Reporting Current"
       }
      }
     },
     "localname": "EntityBankruptcyProceedingsReportingCurrent",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://enveric.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityCentralIndexKey": {
     "auth_ref": [
      "r2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
        "label": "Entity Central Index Key"
       }
      }
     },
     "localname": "EntityCentralIndexKey",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://enveric.com/role/Cover"
     ],
     "xbrltype": "centralIndexKeyItemType"
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.",
        "label": "Entity Common Stock, Shares Outstanding"
       }
      }
     },
     "localname": "EntityCommonStockSharesOutstanding",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://enveric.com/role/Cover"
     ],
     "xbrltype": "sharesItemType"
    },
    "dei_EntityCurrentReportingStatus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Current Reporting Status"
       }
      }
     },
     "localname": "EntityCurrentReportingStatus",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://enveric.com/role/Cover"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityEmergingGrowthCompany": {
     "auth_ref": [
      "r2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if registrant meets the emerging growth company criteria.",
        "label": "Entity Emerging Growth Company"
       }
      }
     },
     "localname": "EntityEmergingGrowthCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://enveric.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityExTransitionPeriod": {
     "auth_ref": [
      "r19"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.",
        "label": "Elected Not To Use the Extended Transition Period"
       }
      }
     },
     "localname": "EntityExTransitionPeriod",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://enveric.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityFileNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.",
        "label": "Entity File Number"
       }
      }
     },
     "localname": "EntityFileNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://enveric.com/role/Cover"
     ],
     "xbrltype": "fileNumberItemType"
    },
    "dei_EntityFilerCategory": {
     "auth_ref": [
      "r2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Filer Category"
       }
      }
     },
     "localname": "EntityFilerCategory",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://enveric.com/role/Cover"
     ],
     "xbrltype": "filerCategoryItemType"
    },
    "dei_EntityIncorporationStateCountryCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two-character EDGAR code representing the state or country of incorporation.",
        "label": "Entity Incorporation, State or Country Code"
       }
      }
     },
     "localname": "EntityIncorporationStateCountryCode",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://enveric.com/role/Cover"
     ],
     "xbrltype": "edgarStateCountryItemType"
    },
    "dei_EntityInteractiveDataCurrent": {
     "auth_ref": [
      "r16"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).",
        "label": "Entity Interactive Data Current"
       }
      }
     },
     "localname": "EntityInteractiveDataCurrent",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://enveric.com/role/Cover"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityPrimarySicNumber": {
     "auth_ref": [
      "r14"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary Standard Industrial Classification (SIC) Number for the Entity.",
        "label": "Entity Primary SIC Number"
       }
      }
     },
     "localname": "EntityPrimarySicNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://enveric.com/role/Cover"
     ],
     "xbrltype": "sicNumberItemType"
    },
    "dei_EntityPublicFloat": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.",
        "label": "Entity Public Float"
       }
      }
     },
     "localname": "EntityPublicFloat",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://enveric.com/role/Cover"
     ],
     "xbrltype": "monetaryItemType"
    },
    "dei_EntityRegistrantName": {
     "auth_ref": [
      "r2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
        "label": "Entity Registrant Name"
       }
      }
     },
     "localname": "EntityRegistrantName",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://enveric.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityShellCompany": {
     "auth_ref": [
      "r2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.",
        "label": "Entity Shell Company"
       }
      }
     },
     "localname": "EntityShellCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://enveric.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntitySmallBusiness": {
     "auth_ref": [
      "r2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).",
        "label": "Entity Small Business"
       }
      }
     },
     "localname": "EntitySmallBusiness",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://enveric.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityTaxIdentificationNumber": {
     "auth_ref": [
      "r2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.",
        "label": "Entity Tax Identification Number"
       }
      }
     },
     "localname": "EntityTaxIdentificationNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://enveric.com/role/Cover"
     ],
     "xbrltype": "employerIdItemType"
    },
    "dei_EntityVoluntaryFilers": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.",
        "label": "Entity Voluntary Filers"
       }
      }
     },
     "localname": "EntityVoluntaryFilers",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://enveric.com/role/Cover"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityWellKnownSeasonedIssuer": {
     "auth_ref": [
      "r17"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.",
        "label": "Entity Well-known Seasoned Issuer"
       }
      }
     },
     "localname": "EntityWellKnownSeasonedIssuer",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://enveric.com/role/Cover"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_Extension": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Extension number for local phone number.",
        "label": "Extension"
       }
      }
     },
     "localname": "Extension",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://enveric.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_LocalPhoneNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Local phone number for entity.",
        "label": "Local Phone Number"
       }
      }
     },
     "localname": "LocalPhoneNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://enveric.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_NoTradingSymbolFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a security having no trading symbol.",
        "label": "No Trading Symbol Flag"
       }
      }
     },
     "localname": "NoTradingSymbolFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://enveric.com/role/Cover"
     ],
     "xbrltype": "trueItemType"
    },
    "dei_OtherReportingStandardItemNumber": {
     "auth_ref": [
      "r13"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "\"Item 17\" or \"Item 18\" specified when the basis of accounting is neither US GAAP nor IFRS.",
        "label": "Other Reporting Standard Item Number"
       }
      }
     },
     "localname": "OtherReportingStandardItemNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://enveric.com/role/Cover"
     ],
     "xbrltype": "otherReportingStandardItemNumberItemType"
    },
    "dei_PreCommencementIssuerTenderOffer": {
     "auth_ref": [
      "r7"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.",
        "label": "Pre-commencement Issuer Tender Offer"
       }
      }
     },
     "localname": "PreCommencementIssuerTenderOffer",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://enveric.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_PreCommencementTenderOffer": {
     "auth_ref": [
      "r8"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.",
        "label": "Pre-commencement Tender Offer"
       }
      }
     },
     "localname": "PreCommencementTenderOffer",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://enveric.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_Security12bTitle": {
     "auth_ref": [
      "r1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Title of a 12(b) registered security.",
        "label": "Title of 12(b) Security"
       }
      }
     },
     "localname": "Security12bTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://enveric.com/role/Cover"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_Security12gTitle": {
     "auth_ref": [
      "r5"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Title of a 12(g) registered security.",
        "label": "Title of 12(g) Security"
       }
      }
     },
     "localname": "Security12gTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://enveric.com/role/Cover"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_SecurityExchangeName": {
     "auth_ref": [
      "r4"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the Exchange on which a security is registered.",
        "label": "Security Exchange Name"
       }
      }
     },
     "localname": "SecurityExchangeName",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://enveric.com/role/Cover"
     ],
     "xbrltype": "edgarExchangeCodeItemType"
    },
    "dei_SecurityReportingObligation": {
     "auth_ref": [
      "r9"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "15(d), indicating whether the security has a reporting obligation under that section of the Exchange Act.",
        "label": "Security Reporting Obligation"
       }
      }
     },
     "localname": "SecurityReportingObligation",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://enveric.com/role/Cover"
     ],
     "xbrltype": "securityReportingObligationItemType"
    },
    "dei_SolicitingMaterial": {
     "auth_ref": [
      "r10"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.",
        "label": "Soliciting Material"
       }
      }
     },
     "localname": "SolicitingMaterial",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://enveric.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_TradingSymbol": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Trading symbol of an instrument as listed on an exchange.",
        "label": "Trading Symbol"
       }
      }
     },
     "localname": "TradingSymbol",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://enveric.com/role/Cover"
     ],
     "xbrltype": "tradingSymbolItemType"
    },
    "dei_WrittenCommunications": {
     "auth_ref": [
      "r18"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.",
        "label": "Written Communications"
       }
      }
     },
     "localname": "WrittenCommunications",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://enveric.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    }
   },
   "unitCount": 3
  }
 },
 "std_ref": {
  "r0": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12"
  },
  "r1": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b"
  },
  "r10": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "14a",
   "Subsection": "12"
  },
  "r11": {
   "Name": "Form 10-K",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "310"
  },
  "r12": {
   "Name": "Form 10-Q",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "308",
   "Subsection": "a"
  },
  "r13": {
   "Name": "Form 20-F",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "220",
   "Subsection": "f"
  },
  "r14": {
   "Name": "Form 40-F",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "240",
   "Subsection": "f"
  },
  "r15": {
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13",
   "Subsection": "a-1"
  },
  "r16": {
   "Name": "Regulation S-T",
   "Number": "232",
   "Publisher": "SEC",
   "Section": "405"
  },
  "r17": {
   "Name": "Securities Act",
   "Number": "230",
   "Publisher": "SEC",
   "Section": "405"
  },
  "r18": {
   "Name": "Securities Act",
   "Number": "230",
   "Publisher": "SEC",
   "Section": "425"
  },
  "r19": {
   "Name": "Securities Act",
   "Number": "7A",
   "Publisher": "SEC",
   "Section": "B",
   "Subsection": "2"
  },
  "r2": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r3": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-23"
  },
  "r4": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r5": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "g"
  },
  "r6": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12, 13, 15d"
  },
  "r7": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13e",
   "Subsection": "4c"
  },
  "r8": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "14d",
   "Subsection": "2b"
  },
  "r9": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "15",
   "Subsection": "d"
  }
 },
 "version": "2.1"
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>18
<FILENAME>0001493152-22-004649-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001493152-22-004649-xbrl.zip
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M7\)_?46C?YF.RU52KH>#DY,X.GUX>OKU"[+;/D*WH$/.CG\Y?GO\C[/Y/$O
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M6]J!O!2C3%RG6TS^O\_+Q5,,['EFE!XMTVCS)IA=^GYENPEN26G?.PUTQ^[
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M](NZ@,Z)H,*+COO7N'K!U; G6F2#2#U*(6[\*I7DV/,Y', !C>5HQA$<8M^
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M930G%H\)3$5&^2W7P<@&<3F(R[:X7",%*$C&29(F_TLGZU;JGZYRQ?[ !>F
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M_C+/L]@?C]Z]^\B,-^+/PCS;D&!U0>4]/81I";_&TYABQ1_3X'\#WSM^CF2
M:8X0&IRY?^3%5_CI'^B?/CKVFX5B-6HG#L! B )UD]D#9P!B$$4(AS9U5YL(
M=6H!+"A"1+/-07CI,+;#7[HP7%[TU.O=^8MGNT_V?1D@725"[W; :<-V-&N*
M4=_O@2=USBT6C3%@S7RCN M(7C(,EP\H&?.=';_#(44VA>&4[LHIO2\KZU/,
MM;67K?AWFN&^0Z->HR;D_,![Z%=U-!"06,38+8Q#!27C)TB=Q*S1/+U0?K'
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M_V)X5G0%Z8Y4_)V5A?<!<7\V0-Q7#7%_.D#<!XC[8-48+>;Y^K287XA2$'6
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MA?,$(78\T+K/3H$&-^HHX7</86Q1IP:,3&32'@I;+&+QN%015KE#2'>KJ,>
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M3FUWXNICP- @<Q"T('LG0D YHU9MH;D5.\\+/ G^BY?9BI/S0,7[AH#TTUU
M>KT!Z:>[@/0N(+VE"D3W%/UO1SVVP$5L6QTP'0N!SY'+G5,%@[#3*:R%C]JQ
MHQS(OC9QE?-*_!T<[#_RXN/(!G"FU,)+<[<2_#:;@)HG"Y\>(H4T6"6LE;D7
M;A$Z%^HBIT,NCG\&AJ8./Q,[1)C,M(V./ED0PFI8IV+$$2/)1DLC]NMP:4BV
M&\LT)H^M:BP*3ES/-SA?S#'6!&->8 71$=KB2UF1?H^6Q.%/^#E+T"&E92NE
M^S8L"'W91#?/8< P]<S^WEU@]H:*0EWE$6>\%^-9HFF)X)9V+\D1FP3]GG=S
M6K8+I"TLP6%N77=RI;DG9DX8:H$2BD\A7_4O92Y%T<&_".?EQ*/PMB?7.+M2
M62(AJ,5L+SC0?,ZTITR.A,S99%@P100&EIU8F@NVM+\>2VP'>YER04.4SRU;
MQ7@96! F.8?BMBND1$Y2+ JO%H6%4P@C.\:U$ J B@VF@H[)2//A<'PA,=5A
MFB:G"]7TW>!RJ&OE*%28I-Q[PV"KN8Q\3DT7D3H*ID8\<"Z*FOPE9J]F(J'F
MRHB(KS@M_J[S,9.^*.2"@HSQZ)C":<"43KK5HG4%6]E3$#E+Q&"Z;8, 3>V3
M'(HG-[XLR/U2.-;!=U92,(#,+AD2@[J@$G<@S-ZDIPE?>4)'CRK[VXBQ]#1A
M4*&U*6'7_)49(,82ASE6,-,)5['YD2?;/W=<CU2/ FJ^0]^4Z7J$7DPN+KTW
MRZ&AQY:0!)$^R8ETCCWH63J>9B#H,R/5ZFT&I F]394E/0194?#3OR%]J6PS
MRYF[J)Y2E5ZX+L3'!P51S,8R?)<ZSLI=9'E:#]2"W[YI:';@#XKO'<L.?&'E
M$7R&++^&0S[5=W)+!D[ZX';F/ER$?S*AZ)=5S"-FV7 +[C30E7NZ,/K20W&.
M.)0FG9+L\#4ZCGCGDAEBW.E$$,TEIR,4]H-(ZS7).Z'<D&E88MZ,-!Y#VD[D
M*F#Q/,O)U&#IBE68RBW'7%9I2*$$A_K*"*,%4]@J<Q%8O*B<R+"4\6)QIM".
MA8&,1^/F^$$:5TT41W"W_+:(D\B%9MMV+T+[2/T62C9/,3RKR@[0LV$3XWJS
M9J&5*-R?<1ZZ0<>![L%L^@"ZP6>.M.**XJF&SR-9%2Q4:>KEEKH_=AL_K@WZ
M<^B)@U>EOCTTUU80A[-PJDQ95W<:9JX-<EO72_<[Q;@IQF^,#;]>G8P-CB9A
MHYF:P>"D<C [@:J$5E:Z@*PP/X()58O;CMRP+P(HF,\)0ZF<ZY$_2>9&O^=7
MX)/UD>K^7Y92J SBA5/&)L7\[#)806+_PPB"6$V= F3%>:?'-F0:FDF+.7I=
MUOU\-EMDPOWG[-S(*8?41'Q&'H2%@ ON-89BY%19.AUZ7+\!W0V4S8%3C'8'
M-PB[KXI?8OFNE>01,\J@"L,H>V%,;"<QA@DFS6*7%,%Z.\S"?TW(M+SEP5=)
MJ&E(O8<QS2;/"O3)=1X,G@V=[K6L/L3)>JAGP484W0AB/<)XYZEZ <;.0.0C
M"@$ZX<;;OZ E,/E(!Q1M,/+VSZO'-.T4[G47+H[O9=#KUT!8B;3V,=]#6#:9
M\-A\+@WT=%^X$Z!H],8*W]8(W%8,]/Z#_QLF4!NZ*Y]Y6*U7[)<8ZPFRQR<1
M#_ PR<_1\8CP&Z=9M+<3HDT>UL8(T;=__>XIC^X"G@#_A[AD,&G/L( $G-'@
MV?[^3I0V>5@;(TIG(:9-1SS -VE>)'$8//_VZ?[SG0!M\K V1H .D*(+(PXO
M>(S_G9=J?AE<+**/&'HXNL1F4"=$5X5)WG=<K;(3KDT>UL8(UPD&7$2P?JM(
MI/Z?8@MJ+\IG[5(DL*(_&):A_SU+LB^#';H!M?=LA]I;+VKOV0ZUMW&HO5V\
M<Q?OW)!XYY8&/'5Z5,/H-*3,4'91-Z.H\MH6>3W??"(PMX=12<7;G.(>Y_E'
MW:"%"!9Y%%VM2>[AMKY58YY=0K$KG,^,4J8F$7?N;>+Q\9_E3M9>5V@(&)68
M'FU5'V+02)BN3)%W0Y(,<,+-_E/3/E.#7"-XD@*N0&6+F1*4G<YF3KPB/$0V
M)%=)JA H4.O5P_E+3!+"QTO3E"?5DS6DQ#]V4%_/B\3.U&\"5]Q$?8<@6B8X
MIM-H7YIP;\JB6:9,N#CX403G,?EZ^OULWS0&OVG(&P,GZG W.BR@?Q,-?AXK
M K6W-%IS>U9H-A80 0)<6OB(P&()PR&H&,:N43;<:^8H*?YZ!:Y%?MQ(7^$B
MYT'B%7<E%2P.EYMIBI@8;&<B;T;0C\I*/JFZTQ6RLED@[5@SKC'_(AK0<"X0
MGVIJ\HW2:10(DT*H(?MSAE*)KD \#[5M@)/%/!AJ@C >']',[ 5M:\2% HR%
MH49B2!?!LW5FNCN"&S*-P4>A4T(VH;+,!1)]0/T/RD9;F3NUD7'N%_RK6RBK
M>1&-,.I&'9F !,E"4IF:),(;0>+3@-N7_K M[IH;.#0:-NMAW?0]0O>Q$N)#
MO>I(%7@X*J0BU"TU]0WHS6!I[L>BQF#=>DHM2D?*7VC5&XUE[*7IW_V[$[8A
MTQBDP@.%C!4(!>WN&C'+8\:!H>*?L4!I6\K*GY33"->&J:3H:+CH2+YKI.W$
M8T.F,9B) E97M6Y>O^)&(\1Y#O=_0GV2Z*KO! *[ ,1*%?-"54ZC)!A,QB0;
MTKK:-)-%;4-T$-@6B*H,:A4KB-I-)JM1R/;E\)'+9)R(!<9=V?'I0?O#=>69
M/-:JO22S0_3K?33F6[])JH_D/0EVC]=UD/*ST-"#<+/>V$&.NZJ]<#Y#A6'=
M>G]W@C9D&H.,3]"/BFC&'"_B4GZ"U".F3;5W;^N+VA1%LI5?@,U;\%\R0>@;
MHJ*1L<NE;</(U@V"X6Q*%[Y"61G#U7*'N7"$?]_\52=9] R9F0D<BQ=@\(&)
MAMS1_N0YE['.>?[?EG_6.^LO.[\UG_G-VT+YP;5"Q^,%'%CP2]/F:#)PR.&E
MIZ\'Y]0F<H'<,)2%>9.G:7Y=#E\].7U]#\=V\U=$BTAC^C?D5Y_O\JOKS:\^
MW^57-RZ_NF-%N=TT3L_ZO5]/+\Y.SL^#7W\\^7#R[HU?<8CM1J.0#+-ZLU"F
MO#:-=!V^7J8(6&32<->A0I4&"Q2PQ*K 25*4%?/T850I)F[(!]M-<Y>3_YR
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M'G\E*S?%^?S:[ <2-5 DJ1=O85-8I-N92:A76C8I',;Z=-P+"!U=J>$Z'K.
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M$UW7>:68$(T4=15B">O;2F#QZD%;Q_Y%#R;&I'1OXAD'OJ9&QJ>JU#;52:Q
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MXI/UNP%K$/K9&[?%&X=TM;GQSIW=*=/@RD3J'U ,6*YHHGM^4#FSB//6-?=
MWM=9WH6+\/I-O:6W\XACM5_-\_2E15.*TMQIVV9WM:AS/'3:5?5=<JF@ RGZ
M"25+0E<[J4K"9$U_10#;7.R!U^R.[TE6ENEV-J\3V[#$_"-U)^?G#K#?0*IW
M8O@9?F-F[J\I/;4*M,?_/FY]VV88S^'R!(WAI@&.>\2W;5;E;MU+$*B[XNG7
M<-HJ=J45X8]HQ+O=@RA@PTL$_@6 4-"B N5F %TGTMLJ8UW.6F^/3I7D8CT$
MV$!-$ 3?^M<GX@L%*^Q]5USE8J*9X7(P!,,XG:3&%[C>9)D""7P^\:F&DP=?
MVD#=B2GYWJ? :A1)]U-C5;U-V)-09:5!X]"R%W^OX:*I0/C=5V]4667U&R&3
M*ENL]9I=#5T+%OT<.D_0F!^8;*! 0_J8PWEM;TL,VZI3VK-[W<XW<IZ'F#LS
M)E<],1C<;(F!WC9/-/X XY[PC>EAZ\9T0"W!YQO2_Z=KFCWZNVO_A]CT]]K_
M!E!+ P04    " #I6$]4;RP0U1 *   ')   "@   &5X.3DM,2YH=&WM6FMO
M&S<6_2Y _X$;8(,$T,./)JUMU5C9EM-L74>UE +YR)GA2*PI<D)RI*B_?L\E
M9T:28R==(,FN@>1#+,^0E_?%<\^]\N"7Z6]7I^W6X)?1\ (_&?T;3%]/KT:G
M@W[\B;?]ZO7@[,W%.S:9OKL:_?PD-]H?L_V]PK.I7 C'KL6*W9@%UYWXH,,F
MPLK\"39BZ_B_W7?"%MS.I#YF>R?,BP^^RY6<X==4:"_LD]/!Y9OKZ;;4;LX7
M4JV//R<WK'7R+Q'5@*2STZ<Z<<7)H'\&NTDN?HR_M.)6SN;QM-&'N4RD9T='
MO?TO:$:M^=G7T/[1NOVK*#[22[Q,VZTS:5PJA4XA8:BU*<.GL36%<2)CXS)1
M,F5O\AS+]>P16OHM0O1GZ;S,UU]2\^OA^&HTZ;1;EXKW.NQ2)#V\Z;"#O8,#
MUA_?0));22OZK,NJ8++M6#Z['DXNAK\?L\';T]'U'V>#_MO3Y^S94Y6]+\U)
MM>.I#;\Q8YF?"U:]/#>+@NMU]?)YA_%V2XO2UL)9&A>P3"R%,@7R@FGRQDQH
M8;F7!N85;IW.12:0/5VI70%5,[9 @+EB<\&5GT.NSIC1J5%FMF;>"NYI 9SB
M3<;7>!W3,8-RW#/IVRV)!-&9PP)F*"69FW,+:TV.UXX46QC-G#?I+7L&JW8>
MB/>E7')%1S"IF9*B)+.M,/GSH,N*6\OI+<07I4WGW(E=$3ED.HA 7%R9_"E2
M3VN1%;?"1W-((/;H3)(?8 M.XIJ5.A-V9:6'_I =+I6I+E6/#94B$R@&3J0E
MEDD1M$CPP*B,A-#+>@>#T?%UNQ6>P4?)NLZ#'IMB;15%MN6R$N:0& UE"VM2
M(? \MV:!I])MI).5*V-OZ7/*"TDQ(^,@(B\;(V.T%8RUA4'8H0N<1K#AH@:-
M/,C^V%O;/@K"*1(X3I/1VC#N7(EH(-UX4'XU%^%8TFTN[OAC@71)8F(JX46&
M^&!=W$@+>>I+J$H7+"2[L M7>[P)PZ/"AQK6'I'*P]ZKWKC71[)+BFN[]4J9
M!%$9<^N12H[R!($*^>TH[P5+C+GMVE+K&&3-9\B O(*K[X'[1BI/@0X5T%37
M.1$Q()D@H'0E4).N&BZOP"K$< G@F@N5,RMFTOE8%0"B@ G">, ^NS1VP2;=
M0Y0JTV.'AX?=@Q<_OCS:>PYL$DMI2J?6+)<*V+:2?AY"_K8WZ;5;DPU&$G*,
M/@"I]2Q WD(Z1R<]VZIGD]%Y7<MB)5DAO3*1*DZXN5$8"$J[L)S4^W>)XX]"
MP=V_@V<KJ52[!;P)#C :"[%W(;@.H,()7%T!J24!7P%("C:3KCRMBB?)2:B^
M;-9V*.TK),M+&]!NLSU"/"%Z;H5@5$L@ YB[.0L']'$W"M0 $K]U=#"[I@ET
M!/EUXU:8'$V$YY5<2,WM^N\:L5G6;F7"I1:= 1Z3V!V8+6I*N>/&8.MNC,G_
MH1I7K_F22\4319ZN%SRUCN+IV$HD3GK!E$DYN8B#),R]+X[[_=5JU4,U[<W,
MLL=&"BI:HV%^"L8BMM3ZG,551$SBN=0H+;'\-%IU8@7]'+AUV(NC/?8;SZ2#
M&<.ET"6V'OPTF+P=G_KYH$\_V:4RQG;"U7R' HQ/[W 'B?(AKDO)X5(EBKG1
M<(MG!_L'W9<'/W0/]E[NT0*Q@$['6V;\BU?JS'J(&&[.F0!X"G""I7 !: .Q
MV*K]G< 70*G(F05T)U>YN2E!0D#0:B8B<9CVX'1^70?W@5R)U?>!?*D71$*1
MF;0,!' W7<'"[DN1L(8'8QH&$JZ(%42(B#A 5U>F\T]K!RWN5X\"+>/NI<0]
M7T3/P8&+B&8\,>5&31(73OM>EKYI6<(%=@Y!5X+0%/T 4$.;P"]QHB\!#BA+
ML5M B7*"N'8D$* 80$H?HTG O;4N*=<08RN!D9P2& %_J0&HX,-M$W9J3^("
M*G-TR)]XXS*9A@/P,B;4)DLZ=U2(S06X-UTWG%9JQ5=YJ0C235!KIYSBT7O0
M6IG+-#X(74:[=:>/@(Q8ET@U.OM>_;ZGZU=6>7!V.B3$:+?NZ=<?W7SB$0;@
MWIE7,R>A(<GST(+05=5FR2,IE,:+=*[CD.+SDX_=&<=#(PYZWFZE2H*08#%(
M06J@'"B(XIXJ3(<I'&'Y+-2DK5D*+CC4RE"-P&A*!0OJ=@@D)HM5:*WQNR>J
MP[7FH&-&9IMUB<G6/=9,@"*1:K>L2>!R5L@"YX!?4*4T%JIFMIQM:0B^'![3
M21L#HC]"746]G%F^"+VWT(&X!8H /X(RA('!8B%LBH_RKP9[&QH.^-JXB71&
ML!6-"6A5@?7U_$8+XGO6E!6)6!FKLAZU%1^5Z@[\&LK#4H(M,F*&HIJ5$"]Z
M5%G\""\>D.^<EQ0(L&RT;TT7>"-FW&:4XHC:"A^[5VCXZ?=FS7=D_!\Q*? G
M:GC"'0RA455HFB;>;3CX1Y. 0$%X+L#>;1)Z4D-WCZXQL?AJGDDM,XG$S9Z(
MP$+:K8,?AW5OMM7G#U-/3_>/#@]#F\RA0$;-&,%0M1?]T.B>K<UX8"/CAVT9
MO2;Y/K80S8$5&TZW9;7X$-U%A^$H2^F< #E%'J$1[Z%50)^ 7'%X10*HQ4I5
M&=(^00-!9)5:4&I?B*!N#D(H>'P:.5W30M\9('<J=WOI<I[6B)HB3Q!]0':J
MC NSW&;DNB6:?4IRT\+%*;) T:(A,B%Q/3\.U#BTP!NSQ0.E ?ONU)U872 L
M*Q$=U*M,9E#,]=APU^E5.D(RG2<U>01AR$SP7S5X0+J!'1L;#B97N)"=?R>#
MMP;4X,2W,8CT[8.E8RF1.I^<\U?ZI(&ZIYR\5 V=D2:EHF\U"F%#10HS[3!&
MF4LXIU+$H,:&Y@,E"QY"U[&N9_.(3"C I:,0U5WMPU:AT9^&WF2C:663O2/H
M;C309T.4V^FTM_*U$UY0UQL2MJJM],W+4&NR]4809ZBG>^W6_E[WUT[5O=/8
M WV,8OMQJ!;O+FV&8Z1!&P)71<I13P>Q_?>PZKRZ83=W%OS4_;6A,N3U.KD!
M1]:%S*"[ U*54C.5E8(2/TQ$2$08ICWHQ;K_=X7@MW'*QYNQ$24I?5BSE:CP
M;Z-(:,,\OQ6D C.X43,>P8V^A"FRJONB*:?[5'9V<)U2@4)!YU(85[3>TO=8
MU3<^:.TZS3<C!&E5MI&:&O"_PX'RTI?0%2D7D T:-$*_* 7ZZL44^OVCVV67
M4JCLF(V!JR<0\+XD1H^-)^Q-$1+AF%UQ4-INM_K3D,'%ZS]JK:*VW<1X@.0Q
M>UGX$S!CB\ US\Z0-K=LO_<"ME.?GL&PZ?#L:L3.1U=7X^'%Q>OK5S\_V7L2
M?I^,A^?U[]49E3RP?\4+!]7J3R>X1YF?DY%[_[R/,$UO:AG(*$]P5E=_;XI=
M.J!$'G9<U#NV1&_\-[V@/XBYH?_( OR$+VJW;#FS3]Z,'OL_RH*[V=FG/^2)
M?]E#?P#T'U!+ P04    " #I6$]4-;;W\<@*  !P*@  "@   &5X.3DM,BYH
M=&WM6FU3(S<2_NXJ_P<=E=O:K?(;9MED@5!GP&SV0E@"7*[VHV9&MA7&TJRD
ML7%^_3TM:>RQ@814+;GCBJU:8&:D5JO5+\_3,P<_7/]T=MAL'/PP')S@-Z-_
M!]<?K\^&AP?=\!M/N_'QP=&GD\_LZOKSV?#[K9%6;H]M]PK'KN546'8NYNQ2
M3[EJA1LM=B6,'&UA(J9>_-EY^VS*S5BJ/=;;9T[<NC;/Y1B7J5!.F*W#5RJQ
MQ?Y!]^)K+V#D>.*V#@^.#H>W$YE(Q]Z_[_0/ND>'3[#8U]Y-V^G"+Q(O$^V<
MGCZX[,'II_/K^EKM$9_*?+'W1ZOYL5;^)H)RP5QJAH=ILW$DM4VE4"DD#)32
MI?_K L^D&C,]8M]L]]A/,L^E5NRB3'*9LD^C$2:K<; SJ?64YOZJ^Z[.[BD5
M_[6T3HX67U/S\\'%V?"JU6R<YKS38J<BZ;#M[1;K]_I]UCT^_W>7O5(9MY-]
M%D^6U0_V]?G@ZF3P\QX;GO]R](:]?I5G7TJ]'X>^,OZ*:</<1+#X\%A/"ZX6
M\>&;%N-,B=)40IN-- Q@F9B)7!?D+HJL,!9*&.[@+RU6V$4Z$9F U[2ELH4T
M(F-3'"S/V43PW$T85QG3*M6Y'B^8,X([>@Y;.)WQ!1X'G\R\;L7*+Z6SN!0S
MJ4N;+YJ-U<!29<+,C71.*%8$E]7196EFO]?J]?Q_9B?<P#Y1''8TA9=;I],;
MK]><&\.A#'2!()-.N!6L+.CR(2'>+DLI'3;DZ22,H %K*TC+$D$Z69UC>WHL
ML$7#YA)6T4I4JZ\M3O?OE\8=5&8"^TR=G(7S2:2"/39-0$;T\[_I=79[K,":
M#XB$"7@:SYEF1HU:+!?6KNQ,CS)I4]@?MJ)9)$9:"Q^PG6;C>B)6IISPF?":
MW@J32BO6U=E=J0./@TYQ&$]RP>1T*C+)G<@7K7 ^R$L806[%1M@T6PAN+,(G
MS_6<M"*?R3 !XIL-*%1R>$CG685^E;&>D<J#SH?.1:<[0-'@/E5\R'6"B+_@
MQB$W6/)\GGJWX9:\7[!$ZYNV*96BFUB#C^$&HYB1*L]].;@G5OFC0A[-,AF2
M=U5)D'C8F((W)N%EW..(.'N[VZ8\K0N:=$^B1*A7(N$"._=DS<V<T]6FV?B=
MU/MG);I0.N[+@C&3K>UJ+9M175E/9\_J0)^A#R)K-!MT(%:D)1V'6"N34JVE
M!%\CPF-_"RZ:+"K/[;#K^E!D'=0*E$?R8\W27/N"2KB')[IT!*M,R<V";>\&
M: 7 9<OD5TRA"1:@QHXH<=$D>!DVCRUA/(FB%5*M@E^^N,E3JXR3;3;&@*.$
M G4J1(:Z;_1TW3MP:M$76O 2U!/  9&5H?8\#K\$@.J1V5(LN9&RI)ZX3?,R
MPSU*%(N5*FZ"M#-%7DP$,R(5 "< IH4.WKO$/O BK^_=Y%G+<+5 \(@,ZVP*
MJ+(E(J<FHYX&*S2U\G]H1MQN&KA=B)4(^A%EP,Z93[XE!-$22K@[EI9V91,J
MUG-M;KPM4EY(POBD+V2,RJ4- SO(H9LIM"%H!G4+1.)+R#Q]R$@X2#T=AL0Y
MY9D_!4+'+A;8)8] 517Y"#X\EM8%6@>'PKD12Z/L>:K-E%VU=T R=8?M[.RT
M^[O?OGO?>U-C9P#GN<@"LR%?^E?G"K3@:MVOA[?P6C7V3AB#C[VN$=*KX7%%
M1D-XS8%+,I'FG++^2F'D?YJ%X:3>/TLL_]ZG\^V->D#LH=E &'@#:(6!F#L5
M7'D0P<G=+<5+"9!:%D4>]GR'%27<LYAJ;(M ;0S]46F\UZ^FAP)%,38R H$;
MTD^S45LK0* EUZTM[;==P3):@NRZ,BNV'+8(R^=R*A75ID=N8C6LV<!L[F+Z
M7$NG<^&)UMI9DIV]-#SB,RYS3]5BHO-G9NG,+"8G%IB1Y3KE9 9L9>)<L=?M
MSN?S#I)<9ZQG0?\15,_7;%)3W9.^Y"$]6M1,B ];R['W*?8XA5H! 8H<>ABM
M8/=4%^2R\81Y;C73B>.>:ON\N$%_V ;[:;'=]SWV$T?%@3*#F5 E<&C_.^SC
M--?:M'Q(?T8JQ5^?$;O4XR%(/),<*2(7Q82Z -"VO]UOO^N_;?=[[WJ$8L04
MN]RK'>4_>-1AW,%1OR38OR3!(O@ 2A!#@O("2 E<4&E'X! KNM+Y]H>/*8\J
M!9Y'H@N$BYAWO$*8]7%)N8 8$P525A'>_Y!)+,\K)&#KN+G9 %KV YSO@1AL
MVDB;R0!A\7 ^D=2>*O'#+]3:4,$$V7-= GHG1))R/A^5.24G[=5:*PRX]:6$
M?4<R#3<\Q+H#YR$C9%A2C=:^5[\7=WUBE0^.#@?$>YJ->WK&SZY%_@P/X-Z7
M,!N]>FJ54:@J/>,!WDCM1#I1H6'^QTWXQ[7;Z3Y@>RY1X3#8LR$H!_@ * !H
M/Z5."6[PL0<+M;8^ MR3FZE&B2QS89=M.P"0S*]G%PK7CFHG5XHG4FF9K<8E
M.EMTV/)E1( +0"$Z@<E9(0NL0VUO0 !MH&IFRG%-0R _?]OSMN4&@CT\8$ ]
M'!L^]6Q&*(\"?$,(=E1.>BXRG1*?PDG_MLR]M4YZS4RD<V1,/H45&.\?()DJ
M02#":"([GI1IDV<= L@P#K*U5&3(ZLU(* \S"0C""&^(V+-X*=1_2>8[YJ6G
MUV8!(K+D,Y=BS W1>3HUD.JL?:8U45JV'/.2&?]+2 KXB5"VCT%_-'D\FB4=
MC6T78B)W.*V'('PDV(2;Q+,K3;%'84P4(K85B?S%MX17PJ.09J/_[:!JL]08
MZR!U='?[_<Z.)WP<"F1$.2@-Q;D Z,-[IBZ)[DK&V[J,SM+Y[NX0;,2(%::K
M[5K<!G/18EC*D#LGR)QB%%)C:/WX[.,S5WC)0@):R$RQBP64Z3Q8)?H8^T2U
MA3PQ]'<#IMOHJ;>BE1_?)JU)O+=)SV,J#?TH:J&%GE?5B/)J&.%IUVJ3XH%"
M@(D;52;4$DBCGB!5ITS2ZT+;88-U$T?G@V1:SWL+;)YI;ZQ,V-3(!)4";NNT
M\0N3!:SWQ<?X:ZW-# 1\$XZ,7F<;6I;<ID7A=R-<K1^YLF,K2$H)IU/WC<R$
M]8'%86%;YO0^O1#&UQ^BI('^3R2,$Q71J*B>:J! P4+@&(NJRT=M<BJWI;7"
M-^ ]9G]X5Y[#6Q&(<] T[LEL"-H\#;!VB+)KI+[FG2W_@#KUWCUC):4W]P.E
M:*^7@A#"LBNUW6O_"/X>&@7$M<%:<A8^F]@.D>J_(H .&J0#I@H HS;_9S_J
M.,;3Y<: []H_+H$+O*>L?!K)QUCO&M2.S3F] P4J**D7')L".C"SAZW8JLA9
M(?A-Z$YQ6V43_TX;?RQ"2X:RW4H13[H<OQ&D M.(J#&/_66H4621:U%WSOZ>
M=_KNMD!9H'7I&.<TWH@OI8SO64#D2,WPW0(EL.AMI*9"LE]#/*/2E=2"GH4\
M!@V60O\? ,_?VFUV*D6>[;$+)-9]3/]2$J3'M'WVR7?X[1X[X\"T[7;\@N_@
MY.,OE4X;7X&]*]P^H+'!62[O'<&5;MAV9Q?F(**>85O7@Z.S(3L>GIU=#$Y.
M/IY_^'ZKM^6OKRX&Q]5U7"/* _S/>6&A6O77/D(K<Q/:8N_O]R&FZ\M*!IS,
M48:K+.QTL6[R7(S\C)-J1DWTRGK7)_3=XB7]H!W@-VQ1F:5FS"Y9,UCL?]TQ
MGI47;RK;I2]&PR>D]*7I?P!02P,$%     @ Z5A/5&/,Q.25&   %,@   L
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M!SJH8QE< ]8V>^]@]X4MV)@1<?EFFB>#TPN=_7R,XBD*:!J>UZ%]8KPDC(,
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M,9 LLL^_/<.6EX,)EI=ART]C6&7%L$_Q_DO5Y>"!9>+7IO40UK2(8P%MO$2
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MFS=R2?X?4$L! A0#%     @ Z5A/5%.RK PT P  \@L  !$
M ( !     &5N=F(M,C R,C R,3$N>'-D4$L! A0#%     @ Z5A/5'X'8E/_
M"@  ;(<  !4              ( !8P,  &5N=F(M,C R,C R,3%?;&%B+GAM
M;%!+ 0(4 Q0    ( .E83U3,=/@W40<  +]8   5              "  94.
M  !E;G9B+3(P,C(P,C$Q7W!R92YX;6Q02P$"% ,4    " #I6$]4/E!<)*?3
M  !!\P4 "0              @ $9%@  97@Q+3$N:'1M4$L! A0#%     @
MZ5A/5!6B ^IQ1@  2.D!  D              ( !Y^D  &5X-"TQ+FAT;5!+
M 0(4 Q0    ( .E83U2R%)QU'0P  +8]   )              "  7\P 0!E
M>#4M,2YH=&U02P$"% ,4    " #I6$]4;RP0U1 *   ')   "@
M    @ '#/ $ 97@Y.2TQ+FAT;5!+ 0(4 Q0    ( .E83U0UMO?QR H  ' J
M   *              "  ?M& 0!E>#DY+3(N:'1M4$L! A0#%     @ Z5A/
M5&/,Q.25&   %,@   L              ( !ZU$! &9O<FTX+6LN:'1M4$L%
3!@     )  D $P(  *EJ 0    $!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
